☐ Registration Statement Pursuant to Section 12(b) or (g)
of the Securities Exchange Act of 1934,
☐ Transition Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
☐ Shell Company Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of the event requiring this shell company report_________________________
Securities registered or to be registered pursuant to Section
12(b) of the Act:
Securities registered or to be registered pursuant to Section 12(g) of the Act:
None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the
Act:
None
Outstanding shares of each of the issuer’s classes of capital or common stock as
of December 31, 2016: 28,727,616 Ordinary Shares
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined
in Rule 405 of the Securities Act.
If this report is an annual or transition
report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.
Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements
for the past 90 days. Yes
X
No
Indicate by check mark whether the registrant has submitted electronically
and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter ) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes
X
No
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer”
in Rule 12b-2 of the Exchange Act. (Check one):
Indicate by check mark which basis of accounting the registrant has used to prepare the
financial statements included in this filing:
U.S. GAAP
X
International Financial Reporting
Standards as issued by the International Accounting Standards Board
Other
If this is an annual report, indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Unless the context otherwise requires, references
herein to “we,” “us,” “our” or “group” are to EDAP TMS S.A. and its consolidated
subsidiaries and references herein to the “Company,” “EDAP” or “EDAP TMS” are to EDAP TMS S.A.
We prepare our consolidated financial statements
in conformity with United States generally accepted accounting principles (‘‘U.S. GAAP’’). In this annual
report, references to ‘‘euro’’ or ‘‘€’’ are to the legal currency of the countries
of the European Monetary Union, including the Republic of France, and references to ‘‘dollars,’’ ‘‘U.S.
dollars’’ or ‘‘$’’ are to the legal currency of the United States of America. Solely for the
convenience of the reader, this annual report contains translations of certain euro amounts into dollars at specified rates. These
translations should not be construed as representations that the euro amounts actually represent such dollar amounts or could be
converted into dollars at those rates. See Item 3, ‘‘Key Information—Exchange Rates’’ for information
regarding certain currency exchange rates and Item 11, ‘‘Quantitative and Qualitative Disclosures about Market Risk’’
for a discussion of the effects of fluctuations in currency exchange rates on the Company.
The following are registered trademarks of the
Company in the United States: EDAP TMS
®
& associated logo, EDAP
®
, Technomed
®
,
Ablatherm
®
, Ablasonic
®
, Ablapak
®
, Sonolith
®
, Sonolith i-sys
®
,
Sonolith i-move
®
, @-REGISTRY
®
, Focal.One
®
. This annual report also makes references
to trade names and trademarks of companies other than the Company.
This annual report includes certain forward-looking
statements within the meaning of Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E
of the U.S. Securities Exchange Act of 1934 (the “Exchange Act”), which may be identified by words such as ‘‘believe,’’
‘‘plan,’’ ‘‘intend,’’ “should,” ‘‘estimate,’’
‘‘expect’’ and ‘‘anticipate’’ or similar expressions, which reflect our views about
future events and financial performance. Forward-looking statements involve inherent known and unknown risks and uncertainties
including matters not yet known to us or not currently considered material by us. Actual events or results may differ materially
from those expressed or implied in such forward-looking statements as a result of various factors that may be beyond our control.
Factors that could affect future results or cause actual events or results to differ materially from those expressed or implied
in forward-looking statements include, but are not limited to:
You should also consider the information contained
in Item 3, ‘‘Key Information—Risk Factors’’ and Item 5, ‘‘Operating and Financial Review
and Prospects,’’ as well as the information contained in our periodic filings with the Securities and Exchange Commission
(the “SEC”) (including our reports on Form 6-K) for further discussion of the risks and uncertainties that may cause
such differences to occur. Forward-looking statements speak only as of the date they are made. Other than required by law, we do
not undertake any obligation to update them in light of new information or future developments.
PART I
Item 1. Identity of Directors, Senior Management and Advisors
Not applicable.
Item 2. Offer Statistics and Expected Timetable
Not applicable.
Item 3. Key Information
Selected Financial Data
The following table sets forth selected consolidated
financial data for the periods indicated. This information is qualified by and should be read in conjunction with the consolidated
financial statements and the Notes thereto included in Part III of this annual report, as well as Item 5, ‘‘Operating
and Financial Review and Prospects.’’ The selected balance sheet data as of December 31, 2016 and 2015 and the selected
income statement data for the years ended December 31, 2016, 2015 and 2014 set forth below have been derived from our consolidated
financial statements included in this annual report. These financial statements, together with our consolidated financial statements
have been prepared in accordance with U.S. GAAP. To date, we have not been required, and presently are not required under French
law, to prepare consolidated financial statements under French GAAP or IFRS, nor have we done so.
|
|
Year Ended and at December 31,
|
In thousands of euro, except
per share data in euro
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INCOME STATEMENT DATA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
35,611
|
|
|
|
32,253
|
|
|
|
26,785
|
|
|
|
24,080
|
|
|
|
26,065
|
|
Total sales
|
|
|
35,579
|
|
|
|
32,218
|
|
|
|
26,252
|
|
|
|
24,065
|
|
|
|
26,018
|
|
Gross profit
|
|
|
16,411
|
|
|
|
13,785
|
|
|
|
11,201
|
|
|
|
9,319
|
|
|
|
10,433
|
|
Operating expenses
|
|
|
(16,019
|
)
|
|
|
(13,298
|
)
|
|
|
(12,937
|
)
|
|
|
(12,074
|
)
|
|
|
(12,463
|
)
|
Income (loss) from operations
|
|
|
392
|
|
|
|
488
|
|
|
|
(1,736
|
)
|
|
|
(2,755
|
)
|
|
|
(2,030
|
)
|
Income (loss) before income taxes
|
|
|
4,444
|
|
|
|
(907
|
)
|
|
|
(396
|
)
|
|
|
(4,886
|
)
|
|
|
(7,358
|
)
|
Income tax (expense) benefit
|
|
|
(602
|
)
|
|
|
(759
|
)
|
|
|
(116
|
)
|
|
|
(135
|
)
|
|
|
(118
|
)
|
Net income (loss)
|
|
|
3,842
|
|
|
|
(1,667
|
)
|
|
|
(512
|
)
|
|
|
(5,021
|
)
|
|
|
(7,475
|
)
|
Basic earnings (loss) per share
|
|
|
0.14
|
|
|
|
(0.07
|
)
|
|
|
(0.02
|
)
|
|
|
(0.24
|
)
|
|
|
(0.43
|
)
|
Diluted earnings (loss) per share
|
|
|
0.13
|
|
|
|
(0.07
|
)
|
|
|
(0.02
|
)
|
|
|
(0.24
|
)
|
|
|
(0.43
|
)
|
Dividends per share
(1)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Basic weighted average shares outstanding
|
|
|
27,823,313
|
|
|
|
25,021,966
|
|
|
|
23,601,428
|
|
|
|
20,593,720
|
|
|
|
17,556,395
|
|
Diluted weighted average shares outstanding
|
|
|
29,365,583
|
|
|
|
25,021,966
|
|
|
|
23,601,428
|
|
|
|
20,593,720
|
|
|
|
17,556,395
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE SHEET DATA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
40,514
|
|
|
|
33,039
|
|
|
|
26,615
|
|
|
|
22,125
|
|
|
|
24,729
|
|
Property and equipment, net
|
|
|
2,770
|
|
|
|
2,123
|
|
|
|
2,122
|
|
|
|
1,655
|
|
|
|
2,035
|
|
Total current liabilities
|
|
|
15,010
|
|
|
|
16,271
|
|
|
|
12,158
|
|
|
|
11,589
|
|
|
|
13,124
|
|
Total assets
|
|
|
46,591
|
|
|
|
38,581
|
|
|
|
32,154
|
|
|
|
26,874
|
|
|
|
30,444
|
|
Long-term debt, less current portion
|
|
|
3,665
|
|
|
|
4,798
|
|
|
|
2,434
|
|
|
|
3,678
|
|
|
|
6,585
|
|
Total shareholders’ equity
|
|
|
24,451
|
|
|
|
14,430
|
|
|
|
15,141
|
|
|
|
9,284
|
|
|
|
8,161
|
|
(1)
|
|
No
dividends were paid with respect to fiscal years 2012 through 2015 and subject to approval
of the annual shareholders’ meeting to be held in 2017 the Company does not anticipate
paying any dividend with respect to fiscal year 2016. See Item 8, ‘‘Financial
Information — Dividends and Dividend Policy.’’
|
EXCHANGE RATES
Fluctuations in the exchange rate between
the euro and the dollar will affect the dollar amounts received by owners of American Depositary Shares (‘‘ADSs’’)
representing ordinary shares of the Company (‘‘Shares’’) on conversion by the Depositary of dividends,
if any, paid on the Shares in the form of ADSs. Moreover, such fluctuations may affect the dollar price of our ADSs on
NASDAQ
.
The following table sets forth, for each of
the years indicated, the high, low, average and year-end Noon Buying Rates expressed in euro per $1.00. The rate is derived from
the noon buying rate in The City of New York for cable transfers in euro as certified for customs purposes by the Federal Reserve
Bank of New York (the ‘‘Noon Buying Rate’’).
Year ended December 31,
|
|
High
|
|
Low
|
|
Average
(1)
|
|
End of
Year
|
|
|
€
|
|
€
|
|
€
|
|
€
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2012
|
|
|
0.83
|
|
|
|
0.74
|
|
|
|
0.78
|
|
|
|
0.76
|
|
2013
|
|
|
0.78
|
|
|
|
0.72
|
|
|
|
0.75
|
|
|
|
0.73
|
|
2014
|
|
|
0.83
|
|
|
|
0.72
|
|
|
|
0.75
|
|
|
|
0.83
|
|
2015
|
|
|
0.95
|
|
|
|
0.83
|
|
|
|
0.90
|
|
|
|
0.92
|
|
2016
|
|
|
0.96
|
|
|
|
0.87
|
|
|
|
0.90
|
|
|
|
0.95
|
|
(1)
|
|
The
average of the Noon Buying Rates on the last business day of each month during the year
indicated. See ‘‘Presentation of Financial and Other Information’’
elsewhere in this annual report.
|
The following table sets forth, for each of
the previous six months, the high and low Noon Buying Rates expressed in euro per $1.00.
|
|
High
|
|
Low
|
|
Average
(1)
|
|
End of
Month
|
|
|
€
|
|
€
|
|
€
|
|
€
|
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
|
|
|
0.90
|
|
|
|
0.89
|
|
|
|
0.89
|
|
|
|
0.89
|
|
October
|
|
|
0.92
|
|
|
|
0.89
|
|
|
|
0.91
|
|
|
|
0.91
|
|
November
|
|
|
0.95
|
|
|
|
0.90
|
|
|
|
0.93
|
|
|
|
0.95
|
|
December
|
|
|
0.96
|
|
|
|
0.93
|
|
|
|
0.95
|
|
|
|
0.95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January
|
|
|
0.96
|
|
|
|
0.93
|
|
|
|
0.94
|
|
|
|
0.93
|
|
February
|
|
|
0.95
|
|
|
|
0.93
|
|
|
|
0.94
|
|
|
|
0.94
|
|
March, through March 17, 2017
|
|
|
0.95
|
|
|
|
0.93
|
|
|
|
0.94
|
|
|
|
-
|
|
(1)
|
|
The
average of the Noon Buying Rate on each business day of the month.
|
On March 17, 2017, the Noon Buying Rate was U.S.$1.00 = €0.93.
RISK FACTORS
In addition to the other information contained
in this annual report, the following risk factors should be carefully considered in evaluating us and our business. These statements
are intended to highlight the material risk factors that may cause actual financial, business, research or operating results to
differ materially from expectations disclosed in this annual report. See also factors disclosed under “Cautionary statement
on forward-looking information”.
Risks Relating to Our Business
We have a history of operating losses and it is uncertain
whether we can maintain profitability.
Although we achieved operational profitability
in 2015 and 2016, we have incurred operating losses in each previous fiscal year since 1998. We expect that our marketing, selling
and research and development expenses will increase as we attempt to develop and commercialize our lithotripsy and particularly
our High Intensity Focused Ultrasound (“HIFU”) devices in the United States. We may not, however, generate a sufficient
level of revenue to offset these expenses and may not be able to adjust spending in a timely manner to respond to any unanticipated
decline in revenue. We cannot guarantee that we will realize sufficient revenue to remain profitable in the future. See Item 5,
‘‘Operating and Financial Review and Prospects.’’
Our future revenue growth and income depend, among other things,
on the success of our HIFU technology.
Our Extracorporeal Shockwave Lithotripsy (“ESWL”)
line of products competes in a mature market that has experienced overall declining unit sales prices in recent years. We depend
on the success of our HIFU technology for future revenue growth and net income. In particular, we are dependent on the successful
development and commercialization of other product lines, such as medical devices based on HIFU, particularly the Ablatherm and
the Focal One, to generate significant additional revenues and achieve and sustain profitability in the future. The Ablatherm is
commercialized in the European Union, Canada, United States and other countries; the Focal One is commercialized in the European
Union, Saudi Arabia, Canada, South Korea, Malaysia, Brazil, Venezuela, Peru and Chile but is not approved for commercial distribution
in the United States.
Further, even if we do receive the required
approvals, we may not receive them on a timely basis and we may not be able to satisfy the conditions of such approval, if any.
The failure to receive product approval by the FDA for our Focal One device, or any significant delay in receipt thereof, will
have a material adverse effect on our business, financial condition or results of operations. See “—Our clinical trials
for products using HIFU technology may not be successful” and Item 4, “Information on the Company—HIFU Division—HIFU
Division Clinical and Regulatory Status.”
Our clinical trials for products using HIFU technology may
not be successful and we may not be able to obtain regulatory approvals necessary for commercialization of all of our HIFU products.
Before obtaining regulatory approvals for
the commercial sale of any of our devices under development, we must demonstrate through preclinical testing and clinical trials
that the device is safe and effective for use in each indication. Product development, including pre-clinical studies and clinical
trials is a long, expensive and uncertain process, and is subject to delays and failures at any stage. The results from preclinical
testing and early clinical trials may not predict the results that will be obtained in large scale clinical trials. Companies can
suffer significant setbacks in advanced clinical trials, even after promising results in earlier trials. Furthermore, data obtained
from a trial can be insufficient to demonstrate that our products are safe, effective, and marketable. The commencement, continuation
or completion of any of our clinical trials may be delayed or halted, or inadequate to support approval of an application to regulatory
authorities for numerous reasons including, but not limited to:
|
·
|
that regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place
a clinical trial on hold; See Item 4, ‘‘Information on the Company—HIFU Division Clinical and Regulatory Status.’’
|
|
·
|
slower than expected rates of patient recruitment and enrolment;
|
|
·
|
inability to adequately monitor patient during or after treatment;
|
|
·
|
failure of patients to complete the clinical trial;
|
|
|
|
|
|
·
|
prevalence and severity of adverse events and other unforeseen safety issues;
|
|
·
|
third-party organizations not performing data collection and analysis in a timely and accurate
manner;
|
|
·
|
governmental and regulatory delays or changes in regulatory requirements, policies or guidelines;
|
|
·
|
the interim or final results of a clinical trial are inconclusive or unfavorable as to safety or
efficacy; and
|
|
·
|
that regulatory authorities conclude that our trial design is inadequate to demonstrate safety
and efficacy.
|
Additionally, certain regulatory authorities
may disagree with our interpretation of the data from our pre-clinical studies and clinical trials, or may find the clinical trial
design, conduct or results inadequate to prove safety or efficacy, and may require us to pursue additional pre-clinical studies
or clinical trials, which would increase costs and could further delay the approval of our products. If we are unable to demonstrate
the safety and efficacy of our products in our clinical trials, we will be unable to obtain regulatory approval to market our products.
The data we collect from our current clinical trials, our pre-clinical studies and other clinical trials may not be sufficient
to support requested regulatory approval. Discussions with regulatory authorities to improve our clinical protocols may prove difficult
and lengthy. We or the relevant regulatory authorities may suspend or terminate clinical trials at any time and regulating agencies
may even refuse to grant exemptions to pursue clinical trials.
We may also be required to abandon previous
strategies for regulatory approval, despite having made significant financial and time investments, or refocus our efforts on alternative
regulatory strategies, resulting in increased costs and efforts of management, without any guarantee of success, which could materially
adversely affect our business, financial condition and results of operations.
Our HIFU devices that have not received regulatory
approval may not prove to be effective or safe in clinical trials or may not be approved by the appropriate regulatory authorities.
If our HIFU devices do not prove to be effective and safe in clinical trials to the satisfaction of the relevant regulatory authorities,
our business, financial condition and results of operations could be materially adversely affected.
We operate in a highly regulated industry and our future success
depends on obtaining and maintaining government regulatory approval of our products, which we may not receive or be able to maintain
or which may be delayed for a significant period of time.
Government regulation significantly impacts
the development and marketing of our products, particularly in the United States, EU and Japan. We are regulated in each of our
major markets with respect to preclinical and clinical testing, manufacturing, labeling, distribution, sale, marketing, advertising
and promotion of our products. To market and sell products, we are required to obtain approval or clearance from the relevant regulatory
agencies, including the FDA with respect to the United States. The process of applying for regulatory approval is unpredictable,
often lengthy and requires the expenditure of substantial resources.
Further, there can be no assurance that we
will receive the required approvals for our products from the required regulatory authorities or, if we do receive the required
approvals, that we will receive them on a timely basis, on the conditions and for the indications we seek, or that we will otherwise
be able to satisfy the conditions of such approval, if any.
Even if regulatory approval to market a product
is granted, it may include limitations on the indicated uses for which the product may be marketed. Failure to comply with regulatory
requirements can result in fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating
restrictions and criminal prosecutions. Regulatory policy may change and additional government regulations may be established that
could prevent or delay regulatory approval of our products. Any delay, failure to receive regulatory approval or the loss of previously
received approvals could have a material adverse effect on our business, financial condition and results of operations. For more
information on the regulation of our business, see Item 4, ‘‘Information on the Company—Government Regulation’’
and “Information on the Company—HIFU Division—HIFU Division Clinical and Regulatory Status.”
Furthermore, changes to regulatory policy or
the adoption of additional statutes or regulations that affect our business could impose substantial additional costs or otherwise
have a material adverse effect on our business, financial condition and results of operations.
HIFU technology may not be accepted and adopted by the medical
community.
Our HIFU devices represent new therapies for
the conditions that they are designed to treat. Notwithstanding any positive clinical results that our HIFU devices may have achieved
or may achieve in the future in terms of safety and efficacy and any marketing approvals that we have obtained or may obtain in
the future, there can be no assurance that such products will gain acceptance in the medical community. Physician acceptance depends,
among other things, on evidence of the cost effectiveness of a therapy as compared to existing therapies and on adequate reimbursement
from healthcare payers, which has not been provided for our HIFU products in any country, except for full public reimbursement
in Germany and Italy, in France, under certain conditions and partial reimbursement from private insurers in the United Kingdom.
On April 18, 2014, the French healthcare government authorities announced the reimbursement of prostate cancer treatment procedures
using HIFU as part of an innovative process to further validate breakthrough therapies and to accelerate their related reimbursement
process based on clinical trials and data registries. Under this innovative process, French healthcare government authorities will
review the clinical data gathered within the next three years in view of granting definitive reimbursement for HIFU. However, we
cannot guarantee that a definitive reimbursement code will be granted. Furthermore, acceptance by patients depends in part on physician
recommendations, as well as other factors, including the degree of invasiveness, the rate and severity of complications and other
side effects associated with the therapy as compared to other therapies.
If our HIFU devices do not achieve an adequate
level of acceptance by physicians, patients, health care payers and the medical community, we may not generate or maintain positive
cash flows and we may not become profitable or be able to sustain profitability. If we do achieve market acceptance of our products,
we may not be able to sustain it or otherwise achieve it to a degree which would support the ongoing viability of our operations.
Our cash flow is highly dependent on demand for our products.
Our cash flow has historically been subject
to significant fluctuations over the course of any given financial year due to cyclical demand for medical devices, and the resulting
annual and quarterly fluctuations in trade and other receivables and inventories. This has in the past resulted in significant
variations in working capital requirements and operating cash flows. Although in 2015 and 2016, our operating cash flow was positive,
in 2014 our operating cash flow was negative due to the cash requirements of operating activities, working-capital cash requirements,
cash requirements of investing activity to expand our mobile treatment model and to expand the leasing of our products as part
of our revenue-per-procedure (“RPP”) model, and sponsoring of the clinical trials in support of our PMA submission
to the FDA of our Ablatherm solution for the treatment of prostate cancer in the United States and to expand our commercial lithotripsy
activities in the United States, which we financed using cash and cash equivalents on hand. Since we anticipate relying on cash
flow from operating activities to meet our liquidity requirements, a decrease in the demand for our products, or the inability
of our customers to meet their financial obligations to us, would reduce the funds available to us. Our future cash flow may also
be affected by the expected continued expansion of the leasing of our products, or the continued expansion of our mobile treatment
model (which is invoiced on a RPP basis), since each of these activities generates smaller immediate revenues than device sales.
In the future, our liquidity may be constrained and our cash flows may be uncertain, negative or significantly different from period
to period. Our future cash flow will be affected by increased expenses in sales efforts as well as marketing campaigns and promotional
tools, particularly to implement our expanded U.S. and global strategy following the FDA clearance of Ablatherm, and Focal One
when or if approved, while there is no assurance that this will result in the increase in the demand for our products and services.
Competition in the markets in which we operate is intense
and is expected to increase in the future.
Competition in the markets in which we operate
is intense and is expected to increase in the future. In each of our main businesses, we face competition both directly from other
manufacturers of medical devices that apply the same technologies that we use, as well as indirectly from existing or emerging
therapies for the treatment of urological disorders.
We believe that because ESWL has long been the
standard treatment for urinary tract calculus disease, competition in that market comes principally from current manufacturers
of lithotripters, including Wolf, Storz and Dornier. In the markets that we target for our HIFU products, competition comes from
new market entrants and alternative therapies, as well as from current manufacturers of medical devices. In the HIFU market, our
devices, in particular the Ablatherm and the Focal One, compete with all current treatments for localized tumors, including surgery,
external beam radiotherapy, brachytherapy and cryotherapy. Other companies working with HIFU technology for the minimally invasive
treatment of tumors include SonaCare Medical, a U.S. company that markets a device called the Sonablate for the ablation of prostatic
tissue. Sonablate was approved by the FDA for commercialization in the U.S. in October 2015. Insightec, an Israeli company owned
mainly by General Electric and Elbit Medical Imaging, has developed a device using HIFU technology to treat uterine fibroids, painful
bone tumors and brain disorders. Theraclion, a French company licensed by EDAP to use of some of our HIFU patents, is currently
marketing the Echopulse HIFU device to treat thyroid tumors and benign breast tumors. Haifu, a Chinese company, is developing HIFU
products addressing various types of cancers. Philips Healthcare, a Dutch company, is also developing HIFU devices addressing uterine
fibroids, breast tumors and drug delivery activated by HIFU. See Item 4, ‘‘Information on the Company—HIFU Division—
HIFU Competition’’ and Item 4, ‘‘Information on the Company—UDS Division.’’
Many of our competitors have significantly
greater financial, technical, research, marketing, sales, distribution and other resources than we have and may have more experience
in developing, manufacturing, marketing and supporting new medical devices. In addition, our future success will depend in large
part on our ability to maintain a leading position in technological innovation, and we cannot assure investors that we will be
able to develop new products or enhance our current ones to compete successfully with new or existing technologies. Rapid technological
development by competitors may result in our products becoming obsolete before we recover a significant portion of the research,
development and commercialization expenses incurred with respect to those products.
We also face competition for our maintenance
and service contracts. Larger hospitals often utilize their in-house maintenance departments instead of contracting with equipment
manufacturers like us to maintain and repair their medical equipment. In addition, third-party medical equipment maintenance companies
increasingly compete with equipment manufacturers by offering broad repair and maintenance service contracts to hospitals and clinics.
This increased competition for medical devices and maintenance and service contracts could have a material adverse effect on our
business, financial condition and results of operations.
The success of our products depends on whether procedures
performed by those products are eligible for reimbursement which depends on the decisions of national health authorities and third-party
payers.
Our success depends, among other things, on
the extent to which reimbursement can be obtained from healthcare payers for procedures performed with our products. In the United
States, we are dependent upon favorable decisions by the Centers for Medicare & Medicaid Services (‘‘CMS’’)
for Medicare reimbursement, individual managed care organizations, private insurers and other payers. These decisions may be revised
from time to time, which could affect reimbursement for procedures performed using our devices. We are currently in discussion
with CMS and private insurers to advance on the reimbursement of HIFU procedures for prostate tissue ablation. Outside the United
States, and in particular in the European Union and Japan, third-party reimbursement is generally conditioned upon decisions by
national health authorities. In the European Union, there is no harmonized procedure for obtaining reimbursement and, consequently,
we must seek regulatory approval in each Member State. If we fail to establish reimbursement from healthcare payers or government
and private healthcare payers’ policies change, it could have a material adverse effect on our business, financial condition
and results of operations.
Lithotripsy procedures currently are reimbursed
by public healthcare systems in the European Union, in Japan and in the United States. However, a decision in any of those countries
to modify reimbursement policies for these procedures could have a material adverse effect on our business, financial conditions
and results of operations. For example, in April 2016, the Japanese authorities decided to stop reimbursing lithotripters’
disposables (electrodes) necessary to perform a lithotripsy procedure. This decision had and will have a material effect on our
current and future sales of lithotripsy disposables in Japan. In contrast, procedures performed with our HIFU devices are not reimbursed
in the European Union with the exception of Italy, Germany, in France under certain conditions, and in the UK where procedures
are partially reimbursed by either public healthcare systems or private insurers. We cannot assure investors that additional reimbursement
approvals will be obtained in the near future. If reimbursement for our products is unavailable, limited in scope or amount or
if pricing is set at unsatisfactory levels, our business could be materially harmed.
Our manufacturing operations are highly regulated and failure
to comply with those regulations would harm our business.
Our manufacturing operations must comply with
regulations established by regulatory agencies in the United States, the European Union and other countries, and in particular
with the Current Good Manufacturing Practices (‘‘CGMP’’) mandated by the FDA and European Union standards
for quality assurance and manufacturing process control. Since such standards may change, we
may
not, at all times, comply with all applicable standards and, as a result would be unable to manufacture our products for commercial
sale. Our manufacturing facilities are subject to inspection by regulatory authorities at any time. If any inspection by the regulatory
authorities reveals deficiencies in manufacturing, we could be required to take immediate remedial actions, suspend production
or close the current and future production facilities, which would disrupt our manufacturing processes. Accordingly, failure to
comply with these regulations could have a material adverse effect on our business, financial condition and results of operations.
We depend on a single site to manufacture our products, and
any interruption of operations could have a material adverse effect on our business.
Most of our manufacturing currently takes
place in a single facility located in Vaulx-en-Velin, on the outskirts of Lyon, France. In the event of a significant interruption
in the operations of our sole facility for any reason, such as fire, flood or other natural disaster or a failure to obtain or
maintain required regulatory approvals, we would have no other means of manufacturing our products until we were able to restore
the manufacturing capabilities at our facility or develop alternative facilities, which could take considerable time and resources
and have a material adverse effect on our business, financial condition and results of operations. If we are unable to manufacture
a sufficient or consistent supply of our products or products we are developing, or if we cannot do so efficiently, our revenue,
business and financial prospects would be adversely affected.
For certain components or services, we depend on a single
supplier who, due to events beyond our control may fail to deliver sufficient supplies to us or increase the cost of items supplied,
which would interrupt our production processes or negatively impact our results of operations.
We purchase the majority of the components
used in our products from a number of suppliers, but rely on a single supplier for some key components. In addition, we rely on
single suppliers for certain services. If the supply of these components or services were interrupted for any reason, our manufacturing
and marketing of the affected products would be delayed. These delays could be extensive, especially in situations where a component
substitution would require regulatory approval. In addition, such suppliers could decide unilaterally to increase the price of
supplied items and therefore cause additional charges for the Company. We expect to continue to depend upon our suppliers for the
foreseeable future. Failure to obtain adequate supplies of components or services in a timely manner and at the agreed price could
have a material adverse effect on our business, financial condition and results of operations.
Intellectual property rights are essential to protect our
medical devices, and any dispute with respect to these rights could be costly and have an uncertain outcome.
Our success depends in large part on our ability
to develop proprietary products and technologies and to establish and protect the related intellectual property rights, without
infringing the intellectual property rights of third parties. The validity and scope of claims covered in medical technology patents
involve complex legal and factual questions and, therefore, the outcome of such claims may be highly uncertain. The medical device
industry has been characterized by extensive patents and other intellectual property rights litigation. From time to time we receive
letters from third parties drawing our attention to their patent rights. Our products, including our HIFU devices, may be subject
to litigation involving claims of patent infringement or violation of other intellectual property rights of third parties. The
defense and prosecution of intellectual property suits, patent opposition proceedings and related legal and administrative proceedings
are both costly and time consuming and may result in a significant diversion of effort and resources by our technical and management
personnel. An adverse determination in any such litigation or proceeding to which we become a party could subject us to significant
liability to third parties, require us to seek licenses from third parties and pay ongoing royalties, require us to redesign certain
products or subject us to injunctions preventing the manufacture, use or sale of the affected products. In addition to being costly,
drawn-out litigation to defend or prosecute intellectual property rights could cause our customers or potential customers to defer
or limit their purchase or use of our products until the litigation is resolved. See Item 4, ‘‘Information on the Company—HIFU
Division—HIFU Division Patents and Intellectual Property’’ and Item 4, ‘‘Information on the Company—UDS
Division—UDS Division Patents and Intellectual Property.’’
We own patents covering several of our technologies
and have additional patent applications pending in the United States, the European Union, Japan and elsewhere. The process of seeking
patent protection can be long and expensive and there can be no assurance that our patent applications will result in the issuance
of patents. We also cannot assure investors that our current or future patents are or will be sufficient to provide meaningful
protection or commercial advantage to us. Our patents or patent applications could be challenged, invalidated or circumvented in
the future. The failure to maintain or obtain necessary patents, licenses or other intellectual property rights from third parties
on acceptable terms or the invalidation or cancellation of material patents could have a material adverse effect on our business,
financial condition or results of operations. Litigation may be necessary to enforce patents issued to us or to determine the enforceability,
scope and validity of the proprietary rights of others. Our competitors, many of which have substantial resources and have made
substantial investments in competing technologies, may apply for and obtain patents that will interfere with our ability to make,
use or sell certain products, including our HIFU devices, either in the United States or in foreign markets.
We also rely on trade secrets and proprietary
know-how, which we seek to protect through non-disclosure agreements with employees, consultants and other parties. It is possible,
however, that those non-disclosure agreements will be breached, that we will not have adequate remedies for any such breach, or
that our trade secrets will become known to, or independently developed by, competitors. Litigation may be necessary to protect
trade secrets or know-how owned by us. In addition, effective copyright and trade secret protection may be unavailable or limited
in certain countries.
The occurrence of any of the foregoing could
have a material adverse effect on our business, financial condition and result of operations.
We face a significant risk of exposure to product liability
claims in the event that the use of our products results in personal injury or death.
Our products are designed to be used in the
treatment of severe affections and conditions. Despite the use of our products, patients may suffer personal injury or death, and
we may, as a result, face significant product liability claims. We maintain separate product liability insurance policies for the
United States and Canada and for the other markets in which we sell our products. Product liability insurance is expensive and
there can be no assurance that it will continue to be available on commercially reasonable terms or at all. In addition, our insurance
may not cover certain product liability claims or our liability for any claims may exceed our coverage limits. A product liability
claim or series of claims brought against us with respect to uninsured liabilities or in excess of our insurance coverage, or any
claim or product recall that results in significant cost to or adverse publicity against us could have a material adverse effect
on our business, financial condition and results of operations. Also, if any of our products prove to be defective, we may be required
to recall or redesign the product which could result in costly corrective actions and harm to our business reputation, which could
materially affect our business, financial condition and results of operations.
We are exposed to risks related to cybersecurity threats and incidents.
In the conduct of our business, we collect,
use, transmit and store data on information technology systems. This data includes confidential information belonging to us, our
customers and other business partners, as well as personally identifiable information of individuals. We also store data related
to our clinical trials on our information technology systems. We have experienced no significant nor material cybersecurity threats
and incidents. We also rely in part on the reliability of certain tested third parties' cybersecurity measures, including firewalls,
virus solutions and backup solutions. Cybersecurity incidents may result in business disruption, the misappropriation, corruption
or loss of confidential information and critical data (ours or that of third parties), reputational damage, litigation with third
parties, diminution in the value of our investment in research and development, data privacy issues and increased cybersecurity
protection and remediation costs. Moreover, we devote significant resources to network security, data encryption and other measures
to protect our systems and data from unauthorized access or misuse, including meeting certain information security standards that
may be required by our customers, all of which increases cybersecurity protection costs. As these threats, and government and regulatory
oversight of associated risks, continue to evolve, we may be required to expend additional resources to enhance or expand upon
the security measures we currently maintain. Future cybersecurity breaches or incidents or further increases in cybersecurity protection
costs may have a material adverse effect on our business, financial condition or results of operations.
Our international operations expose us to additional costs
and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial
condition.
We have significant international operations. We have direct distribution channels in over fifty countries outside of France, our
country of incorporation, and through our foreign subsidiaries. Compliance with complex foreign and French laws and regulations
that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws
and regulations include, among others, data privacy requirements (particularly with respect to the recent invalidation of the U.S.-European
Union safe harbor by the European Court of Justice), labor relations laws, tax laws, anti-competition regulations, import and trade
restrictions, export requirements, U.S. laws such as the FCPA and other U.S. federal laws and regulations established by the Office
of Foreign Asset Control, laws such as the UK Bribery Act 2010 or other local laws which prohibit corrupt payments to governmental
officials or certain payments or remunerations to customers.
Given the high level of complexity of these laws, there is a risk that we may inadvertently breach some provisions, for example,
through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements,
or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges. We have a dispersed
international sales organization, and this structure makes it more difficult for us to ensure that our international selling operations
comply with our global policies and procedures.
Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements
to obtain export licenses, cessation of business activities in sanctioned countries and prohibitions on the conduct of our business.
Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries
and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees,
or our business, results of operations and financial condition.
We have been and we may in the future be the target of securities
class action or other litigation, which could be costly and time consuming to defend.
In the past, securities class action litigation
has often been brought against companies following a decline in the market price of its securities. This risk is especially relevant
for us because innovative life sciences and medical device companies have experienced significant stock price volatility in recent
years.
On August 4, 2014, a purported class action
lawsuit was filed in the United States District Court for the Southern District of New York asserting that the Company, Marc Oczachowski,
and Eric Soyer (our former Chief Financial Officer) violated federal securities laws by issuing materially false and misleading
statements that caused the price of our ADSs to be artificially inflated. An amended complaint alleges that the Company and Mr.
Oczachowski breached their obligations under the Exchange Act in various ways, including by misrepresenting and failing to disclose
allegedly material information about the safety and efficacy of treatment with Ablatherm-HIFU, and the Company’s interactions
with the FDA. The complaint sought unspecified damages, interest, costs, and fees, including attorneys’ and experts’
fees. In February 2015, the defendants, including the Company, filed a motion to dismiss and on November 11, 2015, we announced
the dismissal of the class action lawsuit and that no notice of appeal was subsequently filed by the plaintiffs.
Any additional litigation, if instituted, could
cause us to incur substantial costs and our management resources may be diverted to defending such litigation, which could adversely
affect our financial condition or results of operations.
We sell our products in many parts of the world and, as a
result, our business is affected by fluctuations in currency exchange rates.
We are exposed to foreign currency exchange
rate risk because the mix of currencies in which our costs are denominated is different from the mix of currencies in which we
earn our revenue. In 2016, approximately 78% of our total costs of sales and operating expenses were denominated in euro, while
approximately 42% of our sales were denominated in currencies other than euro (primarily the U.S. dollar and the Japanese yen).
Our operating profitability could be materially adversely affected by large fluctuations in the rate of exchange between the euro
and other currencies. For instance, a decrease in the value of the U.S. dollar or the Japanese yen against the euro would have
a negative effect on our revenues, which may not be offset by an equal reduction in operating expenses and would therefore negatively
impact operating profitability. From time to time we enter into foreign exchange forward sale contracts to hedge against fluctuations
in the exchange rates of the principal foreign currencies in which our receivables are denominated (in particular, the U.S. dollar
and the Japanese yen), but there can be no assurance that such hedging activities will limit the effect of movements in exchange
rates on our results of operations. As of December 31, 2016, we had no outstanding hedging instruments. In addition, since any
dividends that we may declare will be denominated in euro, exchange rate fluctuations will affect the U.S. dollar equivalent of
any dividends received by holders of ADSs. For more information concerning our exchange rate exposure, see Item 11. “Quantitative
and Qualitative Disclosures about Market Risk.”
Our results of operations have fluctuated significantly from
quarter to quarter in the past and may continue to do so in the future.
Our results of operations have fluctuated in
the past and are expected to continue to fluctuate significantly from quarter to quarter depending upon numerous factors, including,
but not limited to, the timing and results of clinical trials, changes in healthcare reimbursement policies, cyclicality of demand
for our products, changes in pricing policies by us or our competitors, new product announcements by us or our competitors, customer
order deferrals in anticipation of new or enhanced products offered by us or our competitors, product quality problems and exchange
rate fluctuations. Furthermore, because our main products have relatively high unit prices, the amount and timing of individual
orders can have a substantial effect on our results of operations in any given quarter.
Our results of operations and financial condition could be
adversely affected by the adverse economic, geo-political and financial developments.
The current geo-political, economic and financial
environment has affected the level of public and private spending in the
healthcare
sector
generally. A cautious or negative outlook may cause our customers to further delay or cancel investment in medical equipment, which
would adversely affect our revenues.
In addition, we rely on the credit market to
secure dedicated lease financings to fund the development of our RPP
business model
related to the sale of treatments’ procedures.
Due to the limited availability of lending
in the
current
market
environment
, we may be
unable to
access
sufficient
lease financing. Without lease financing, we may be
unable to continue the development of our RPP model or we may need to fund such activity out of
our
existing working capital. Similarly, some of our clients rely on lease financing to finance their purchases of equipment.
Limited
availability of
lease financing facilities may
also
affect their purchasing decisions
and may adversely impact our equipment sales.
The issuance of ADSs upon exercise of outstanding warrants
will cause immediate and substantial dilution to our existing shareholders.
The issuance
of ADSs upon exercise of the warrants issued in May 2013 (the “May 2013 Warrants”) and in April 2016 (the “April
2016 Warrants”) will result in dilution of other shareholders since the selling shareholders may ultimately sell the full
amount of ADSs issuable on exercise. Based on the total number of outstanding warrants as of April 3, 2017, and on the total number
outstanding options to subscribe to new shares, up to 5,973,622 ADSs are issuable upon exercise, representing approximately 20.6%
of our issued and outstanding share capital. Although no single warrant holder may exercise its Warrants if such exercise would
cause it to own more than 9.99% of our outstanding ordinary shares, this restriction does not prevent each holder from exercising
a portion of its holdings and selling those securities. In this way, each holder could sell more than this limit while never holding
more than such limit.
On April
22, 2014, we filed a Form F-3 registration statement with the SEC to register ordinary shares and warrants for a maximum amount
of $50 million, hence providing for registration of any future new ordinary shares issued for the purpose of raising capital. This
registration statement was declared effective by the SEC on May 5, 2014. We issued and registered shares under this registration
statement on June 2, 2014 and on April 14, 2016, although we did not offer the maximum amount registered under this registration
statement.
The sale of ADSs issued upon exercise of outstanding warrants
could encourage short sales by third parties which could further depress the price of our ADSs.
Any downward pressure on the price of ADSs
caused by the sale of ADS issued upon the exercise of the outstanding warrants could encourage short sales by third parties. In
a short sale, a prospective seller borrows shares from a shareholder or broker and sells the borrowed shares. The prospective seller
hopes that the share price will decline, at which time the seller can purchase shares at a lower price for delivery back to the
lender. The seller profits when the share price declines because it is purchasing shares at a price lower than the sale price of
the borrowed shares. Such sales could place downward pressure on the price of our ADSs by increasing the number of ADSs being sold,
which could further contribute to any decline in the market price of our ADSs.
Risks Relating to Ownership of Securities
Our securities may be affected by volume fluctuations, and may fluctuate significantly
in price, causing you to lose some or all of your investment.
Our ADSs
are currently traded on the NASDAQ Global Market. The average daily trading volume of our ADSs in 2016 was 77,782, the high and
low bid price of our ADSs for the last two financial years ended on December 31, 2016 and December 31, 2015, was $4.80 and $2.43,
and $6.57 and $2.26, respectively. Our ADSs have experienced, and are likely to experience in the future, significant price and
volume fluctuations, which could adversely affect the market price of our ADSs without regard to our operating performance. For
example, average daily trading volume of our ADSs in December 2015 was 131,317 as opposed to 40,560 for the same period of 2016.
The price of our securities and our ADSs in particular, may fluctuate as a result of a variety of factors, including changes in
our business, operations and prospects, and factors beyond our control, including regulatory considerations, results of clinical
trials of our products or those of our competitors, developments in patents and other proprietary rights, and general market and
economic conditions.
These broad market and industry factors may
adversely affect the market price of our ADSs, regardless of our operating performance. If you invest in our ADSs, you could lose
some or all of your investment.
In addition, following periods of volatility
in the market price of a company's securities, securities class action litigation has often been instituted. We are currently the
subject of such litigation, and such litigation, regardless of its outcome, and any additional litigation, if instituted, causes
and could cause us to incur substantial costs and our management resources are and could be diverted to defending such litigation,
which could adversely affect our financial condition or results of operations.
We may issue additional securities that may be dilutive to our existing shareholders.
On February 18, 2016, our shareholders adopted
a resolution allowing the Board of Directors to issue 1 million new shares under the form of subscription options to motivate and
reward teams dedicated to successfully implement our U.S. and worldwide expansion plans. As of April 3, 2017, the maximum number
of shares available to be issued was 425,000.
The issuance
of additional ordinary shares, including any additional ordinary shares issuable pursuant to the exercise of preferential subscription
rights that may not be available to all of our shareholders, would reduce the proportionate ownership and voting power of the then-existing
shareholders.
We are subject to different corporate disclosure standards
that may limit the information available to holders of our ADSs.
As a foreign
private issuer, we are not required to comply with the notice and disclosure requirements under the Exchange Act relating to the
solicitation of proxies for shareholder meetings. Although we are subject to the periodic reporting requirements of the Exchange
Act, the periodic disclosure required of foreign private issuers under the Exchange Act is more limited than the periodic disclosure
required of U.S. issuers. Therefore, there may be less publicly available information about us than is regularly published by or
about other public companies in the United States.
We currently do not intend to pay dividends, and cannot assure shareholders that
we will make dividend payments in the future.
We have
never paid any dividend on our shares and do not anticipate paying any dividends for the foreseeable future. Thereafter, declaration
of dividends on our shares will depend upon, among other things, future earnings, if any, the operating and financial condition
of our business, our capital requirements, general business conditions and such other factors as our Board of Directors deems relevant.
See Item 8, “Financial Information—Dividends and Dividend Policy.”
Judgments of U.S. courts, including those predicated on the
civil liability provisions of the federal securities laws of the United States, may not be enforceable in French courts.
An investor in the United States
may find it difficult to:
|
•
|
effect service of process upon or obtain jurisdiction over us or our non-U.S. resident directors and officers in the United States;
|
|
•
|
enforce U.S. court judgments based upon the civil liability provisions of the U.S. federal securities laws against us and our non-U.S. resident directors and officers in France
;
or the United States; or
|
|
•
|
bring an original action
in a French court to enforce liabilities based upon the U.S. federal securities laws against us and our non-U.S. resident directors
and officers.
|
Holders of ADSs have fewer rights than shareholders and must act through the Depositary
to exercise those rights.
Holders
of ADSs do not have the same rights as shareholders and accordingly, cannot exercise rights of shareholders against us. The Bank
of New York Mellon, as Depositary (the “Depositary”), is the registered shareholder of the deposited shares underlying
the ADSs, and therefore holders of ADSs will generally have to exercise the rights attached to those shares through the Depositary.
We have used and will continue to use reasonable efforts to request that the Depositary notify the holders of ADSs of upcoming
votes and ask for voting instructions from them. If a holder fails to return a voting instruction card to the Depositary by the
date established by it for receipt of such voting instructions, or if the Depositary receives an improperly completed or blank
voting instruction card, or if the voting instructions included in the voting instruction card are illegible or unclear, then such
holder will be deemed to have instructed the Depositary to vote its shares and the Depositary shall vote such shares in favor of
any resolution proposed or approved by our Board of Directors and against any resolution not so proposed or approved.
Preferential subscription rights may not be available for
U.S. persons.
Under French
law, shareholders have preferential rights to subscribe for cash issuances of new shares or other securities giving rights to acquire
additional shares on a
pro rata
basis. U.S. holders of our securities may not be able to exercise preferential subscription
rights for their shares unless a registration statement under the Securities Act is effective with respect to such rights or an
exemption from the registration requirements imposed by the Securities Act is available. We may, from time to time, issue new shares
or other securities giving rights to acquire additional shares (such as warrants) at a time when no registration statement is in
effect and no Securities Act exemption is available. If so, U.S. holders of our securities will be unable to exercise their preferential
rights and their interests will be diluted. We are under no obligation to file any registration statement in connection with any
issuance of new shares or other securities.
For holders
of ADSs, the Depositary may make these rights or other distributions available to holders after we instruct it to do so and provide
it with evidence that it is legal to do so. If we fail to do this and the Depositary determines that it is impractical to sell
the rights, it may allow these rights to lapse. In that case, the holders of ADSs will receive no value for them.
Holders of our ADSs may be exposed to increased transaction
costs as a result of proposed European financial transaction taxes.
On February 14, 2013, the EU Commission
adopted a proposal for a Council Directive (the "Draft Directive") on a common financial transaction tax (the "FTT").
According to the Draft Directive, the FTT should have been implemented and should have entered into effect in 10 EU Member States
(Austria, Belgium, Estonia, France, Germany, Greece, Italy, Portugal, Spain, Slovakia, and Slovenia, each a “Participating
Member State”). In March of 2016, Estonia indicated its withdrawal from enhanced cooperation. Pursuant to the Draft Directive,
the FTT was to be payable on financial transactions provided at least one party to the financial transaction was established or
deemed established in a Participating Member State and there was a financial institution established or deemed established in a
Participating Member State which was a party to the financial transaction, or was acting in the name of a party to the transaction.
Under the Draft Directive, the FTT should not have applied, however, to (inter alia) primary
market transactions referred to in Article 5(c) of Regulation (EC) No 1287/2006, including the activity of underwriting and subsequent
allocation of financial instruments in the framework of their issue.
The rates of the FTT were to be fixed by each Participating
Member State but for transactions involving financial instruments other than derivatives would have amounted to at least 0.1 per
cent of the taxable amount. The taxable amount for such transactions would have been generally determined by reference to the consideration
paid or owed in return for the transfer.
The FTT would have been payable by each financial institution
established or deemed established in a Participating Member State which was either a party to the financial transaction, or acting
in the name of a party to the transaction or where the transaction had been carried out on its account. Where the FTT due had not
been paid within the applicable time limits, each party to a financial transaction, including persons other than financial institutions,
would have become jointly and severally liable for the payment of the FTT due.
The Draft
Directive has not been adopted. Following Estonia's withdrawal, a proposal combining a broader scope and lower rates, as well as
several specific rules, are currently being discussed between the ten other Participating Member States, with the objective to
adopt a new proposal in 2017.
Prospective holders should therefore note, in
particular, that any sale, purchase, or exchange of the Shares or ADSs could become subject to the FTT at a minimum rate of 0.1
per cent. The holder may be liable to itself pay this charge or reimburse a financial institution for the charge, and / or may
affect the value of the Shares or ADSs.
The FTT proposal is still subject to negotiation
between the Participating Member States and therefore may be changed at any time. Moreover, once a final agreement on such FTT
proposal will be reached (the "FTT Directive"), it will need to be implemented into the respective domestic laws of the
Participating Member States and the domestic provisions implementing the FTT Directive might deviate from the FTT Directive itself.
See Item 10, "Certain Income Tax Considerations."
In any case,
prospective holders should consult their own advisers in relation to the consequences of the FTT associated with subscribing for,
purchasing, holding and disposing of ADSs.
Item 4. Information on the Company
We develop and market the Ablatherm and Focal
One devices, advanced choices for HIFU treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option for localized prostate cancer with a low occurrence of side effects. Ablatherm is generally recommended
for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option.
It is also used for patients who failed a radiotherapy treatment. Focal One is a robot assisted HIFU device dedicated to the focal
treatment of prostate cancer. In addition, we are developing HIFU technology for the treatment of certain other types of tumors.
We also produce and commercialize medical equipment for treatment of urinary tract stones using ESWL and distribute other types
of urology devices in certain countries.
History and Development of the Company
Our legal name is EDAP TMS S.A. and our commercial
name is EDAP TMS. EDAP TMS S.A. was incorporated on December 3, 1979 as a
société anonyme
organized under
the laws of the Republic of France for a duration of 60 years from the date of incorporation. Our principal executive offices are
located at Parc d’Activités la Poudrette- Lamartine, 4/6, rue du Dauphiné, 69120 Vaulx-en-Velin, France and
our telephone number is +33 (0) 4 72 15 31 50. Corporation Service Company, 1090 Vermont Avenue, Suite 430, Washington, D.C. 20005,
United States, is our agent for service of process in the United States.
Founded in 1979, we originally specialized
in the manufacturing and distribution of lithotripters (devices which use shockwaves to disintegrate urinary calculi) and produced
the first piezoelectric lithotripter (using electric shocks produced by a piezo-component) in 1985. In 1994, we acquired most of
the assets of Technomed International S.A. (‘‘Technomed’’) out of liquidation, including the ownership
of, and full distribution rights to, the Prostatron, the Sonolith series of lithotripters (Sonolith Praktis, Sonolith Vision) and
the Ablatherm device.
In August 2011, we received marketing
clearance from the U.S. Food and Drug Administration, or the FDA, for our Sonolith i-move device, a technologically advanced compact
mobile lithotripter. The FDA has cleared our Sonolith i-move device for fragmentation of kidney stones, ESWL procedures and endourology
applications.
On January 19, 2012, we entered into an Exchange
Agreement with all of the holders of our outstanding 9% Senior Convertible Debentures due October 29, 2012 (the “October
2007 Convertible Debentures”) and warrants, whereby all October 2007 Convertible Debentures and warrants were exchanged for
New Debentures, 1,948,871 newly issued ordinary shares, new warrants (the “January 2012 Warrants”) and $500,000 in
cash, or a combination thereof.
On May 31, 2012, we aligned our management
team to focus on the U.S. opportunities both in the lithotripsy market and the HIFU regulatory program and our CEO consequently
relocated to the United States.
On January 31, 2013, we submitted our PMA application
to the FDA for our Ablatherm HIFU device for treatment of low risk, localized prostate cancer. Our submission included data from
the ENLIGHT U.S. Phase II/III clinical trial, as well as data from our extensive worldwide database of treatment information and
follow-up data from patients who have undergone HIFU therapy for prostate cancer. On June 3, 2013 we held our 100-day meeting with
the FDA to discuss our PMA file and address questions and requests from the FDA reviewing team.
On May 28, 2013, we issued 3,000,000 ordinary
shares in the form of ADSs to certain institutional investors in a registered direct placement (the “May 2013 Placement”),
at a price of $4.00 per share, with warrants attached that allow investors to purchase up to 1,500,000 shares in the form of ADSs,
at an exercise price of $4.25 per share. We also issued warrants to purchase up to 180,000 shares to the placement agent, HC Wainwright
and Co. LLC, at an exercise price of $5.00 per share. Following our May 2013 Placement, on June 14, 2013, we fully redeemed our
$8.0 million outstanding long-term debt by using a portion of the net proceeds from the $12.0 million May 2013 Placement.
On June 2, 2014, we issued 3,000,000 ordinary
shares in the form of ADSs to certain institutional investors in a registered direct placement (the “June 2014 Placement”),
at a price of $3.11 per share.
On October 15, 2015, we announced the withdrawal
of our de novo application and the submission of a 510(k) notice, in accordance with the FDA guidelines, following the FDA clearance
of the Sonablate 450 for prostatic tissue ablation using HIFU.
On November 9, 2015, we announced the receipt
of 510(k) clearance from the FDA to market Ablatherm Integrated Imaging HIFU in the U.S. for the ablation of prostate tissue.
On April 6, 2016, we submitted a 510(k) application
for FDA clearance of our Focal One HIFU device.
On April 14, 2016, we issued 3,283,284 ordinary
shares in the form of ADSs to certain institutional investors in a registered direct placement (the “April 2016 Placement”),
at a price of $3.50 per share, with warrants attached that allow investors to purchase up to 3,283,284 shares in the form of ADSs,
at an exercise price of $4.50 per share.
Business Overview & Strategy
EDAP TMS S.A. is a holding company and is responsible
for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the
group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities
and, in conjunction with its Board of Directors, directing the overall strategy of our group.
Our activity is organized in two divisions:
HIFU and UDS (including lithotripsy activities). Through these two divisions, we develop, produce and market minimally invasive
medical devices, mainly for urological diseases. We believe that the creation of these two divisions has allowed us to expand our
market share by optimizing worldwide distribution capabilities, all of which is coordinated through our subsidiaries.
Our HIFU and UDS divisions operate in Europe,
the Americas, Asia and the rest of the world. Total net sales for the HIFU division (in net contributions to total consolidated
sales) were €13.8 million, €8.4 million and €8.2 million for 2016, 2015 and 2014, respectively. Those sales are
generated in Europe, in the United States and the rest of the world, excluding certain countries in Asia (including Japan) where
our HIFU devices are not approved yet. Total net sales for the UDS division were €21.8 million (including €10.3 million
in Asia and €11.5 million in Europe and the rest of the world), €23.8 million (including €10.7 million in Asia and
€13.0 million in Europe and the rest of the world) and €18.1 million (including €7.5 million in Asia and €10.6
million in Europe and the rest of the world), each for 2016, 2015 and 2014, respectively.
See Note 26 to our consolidated financial statements
for a breakdown of total sales and revenue during the past three fiscal years by operating division and Item 5, “Operating
and Financial Review and Prospects.”
HIFU Division
The HIFU division is engaged in the development,
manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and
other clinical indications. Our HIFU business is quite cyclical and generally linked to lengthy hospital decision and investment
processes. Hence our quarterly revenues are often impacted and fluctuate according to these parameters, generally resulting in
a higher purchasing activity in the last quarter of the year. The HIFU division
contributed €13.8
million
to our consolidated net sales during the fiscal year ended December 31, 2016.
HIFU Division Business Overview
The HIFU division currently develops, manufactures
and markets devices for the minimally invasive destruction of certain types of localized tumors using HIFU technology. HIFU technology
uses a high-intensity convergent ultrasound beam generated by high power transducers to produce heat. HIFU technology is intended
to allow the surgeon to destroy a well-defined area of diseased tissue without damaging surrounding tissue and organs, thereby
eliminating the need for incisions, transfusions and general anesthesia and associated complications. The HIFU Division markets
two HIFU devices: the Ablatherm and the Focal One. The Ablatherm is dedicated to the treatment of organ-confined prostate cancer,
referred to as T1-T2 stage. Ablatherm can be used for patients who are not candidates for surgery or who have failed a radiotherapy
treatment.
HIFU Division also produces and markets the
Focal One device, a HIFU robotic device fully dedicated to the focal therapy of localized prostate cancer, thereby destroying targeted
cancer cells only. As of December 31, 2016, the HIFU division had an installed base of 106 Ablatherm machines, 22 Focal One
and 350 certified trained clinical sites worldwide were having access to this technology.
In addition to developing, manufacturing and
marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables,
spare parts and maintenance services. Our HIFU mobile treatment option provides access to the HIFU devices without requiring hospitals
and clinics to make an up-front investment in the equipment. Instead, hospitals and clinics perform treatments using these devices
and remunerate us on a RPP basis (i.e., on the basis of the number of individual treatments provided). With this model, once the
treatment is established in the medical community, a permanent installation may become more attractive, leading to the sale of
the device in some of the larger locations.
HIFU Division Business Strategy
The HIFU division’s business strategy
is to capitalize on its expertise in HIFU and its position in urology to achieve long-term growth as a leader in the development,
manufacturing, marketing and distribution of minimally invasive medical devices for urological and other indications, using HIFU
technology, while preserving patient quality of life. The HIFU division believes that minimally invasive treatments using HIFU
could provide an alternative to current invasive therapies on the basis of reduced cost and reduced morbidity for a number of different
indications. The key elements of the HIFU division’s strategy to achieve that objective are:
|
·
|
Provide Minimally Invasive Solutions to Treat Localized Prostate Cancer using HIFU
. Building
upon our established position in the ESWL market, our HIFU division is striving to become the leading provider of our minimally
invasive treatment option for prostate cancer. We believe that there is a large market opportunity with an increase in incidence
linked to the aging male population, an increase in screening and recent campaigns to increase awareness. We also believe that
HIFU could represent a credible alternative to surgery, external beam radiotherapy, brachytherapy and cryotherapy for the treatment
of organ-confined prostate cancer without the cost, in-patient hospitalization and adverse side effects associated with those therapies.
With the growing demand for more focused treatments destroying the tumor only (focal therapy) while continuously controlling the
disease, HIFU and its focused approach, is well positioned to address this new clinical approach. The HIFU division intends to
achieve this through a direct sales network in key European countries and the United States and through selected distributors in
other European countries and in Asia. The HIFU division has built a strong clinical credibility based on clinical articles published
in peer-reviewed journals. We ensure effective patient and physician education through a focused communication program.
|
|
|
|
|
·
|
Achieve Long-Term Growth by Expanding HIFU Applications Beyond Prostate Cancer
. The HIFU
division’s long-term growth strategy is to apply our HIFU technology toward the minimally invasive treatment of
other
medical conditions
beyond prostate cancer. We believe that HIFU could represent an alternative to surgery and radiotherapy
for the treatment of many tumors without the cost, in-patient hospitalization and adverse side effects associated with those therapies.
The HIFU division is working on various other applications where HIFU could provide an alternative to current invasive therapies.
We entered into a multi-partner liver cancer development project organized by the HECAM (HEpatocellular CArcinoma Multi-technological)
consortium. This project aims at developing innovative diagnostic, imaging and therapeutic technologies to address liver cancer.
EDAP’s focus within the HECAM consortium is on developing a novel HIFU treatment for liver cancer in cooperation with its
long-term academic partner INSERM and leading cancer centers. To fund this development program, EDAP will receive a maximum of
€2.4 million in non-dilutive financing from Bpifrance over the 5-year project period. In June 2015, EDAP received €736,000
from Bpifrance (€237,000 as a conditional subsidy and €499,000 as a grant) to advance on the HECAM project. In 2016,
the HIFU division maintained expenses
at
levels similar to 2015 on research and development
(“R&D”) projects to develop HIFU applications beyond prostate cancer. The division is considering maintaining similar
levels of R&D spending in 2017 and future years to strengthen its technological leadership in HIFU and expand its application
beyond urology.
|
HIFU Products
Currently, the Company commercializes two products
utilizing the HIFU technology. For both HIFU products, cell destruction by HIFU is accomplished by a combination of thermal and
cavitation effects caused by focused application of piezoelectric-generated high-intensity ultrasound; HIFU procedures are performed
under general or spinal anesthesia.
|
·
|
The Ablatherm is an ultrasound guided HIFU device for the treatment of organ-confined prostate
cancer. It consists of a treatment module, including a HIFU endorectal probe, a control table with a computer and a computer screen,
and a diagnostic ultrasound device connected to the treatment module. After insertion of an endorectal probe, the physician visualizes
the prostate using ultrasound imaging and defines the area to be treated. The computer automatically calculates the optimum treatment
distribution of lesions. During the treatment, the probe automatically moves and fires HIFU beams at each predefined lesion until
the entire targeted area has been treated. At the same time, the physician is able to control and visualize the treatment in real
time due to the integrated imaging system.
|
The Ablatherm is cleared for distribution in the European
Union, the United States, South Korea, Canada, Australia, South Africa, New Zealand, the Philippines Taiwan, Mexico, Argentina,
Brazil, Russia, Venezuela, Peru, Costa Rica and Ecuador.
|
·
|
The Focal One is a HIFU robotic device fully dedicated to the focal therapy of prostate cancer.
Focal One combines the three essential components to efficiently perform a focal treatment of localized prostate cancer: (i) high-quality
imaging to localize tumors with the use of magnetic resonance imaging (MRI) combined with real-time ultrasound, (ii) high precision
of HIFU treatment focused on identified targeted cancer areas and (iii) immediate feedback on treatment efficacy utilizing Contrast-Enhanced
Ultrasound Imaging. Focal One provides an effective and accurate ablative treatment of localized tumors with the capacities of
being flexible and repeatable, while preserving patient quality of life. The Focal One device received CE Marking for European
market clearance in June 2013 and is also approved in Canada, Russia, Saudi Arabia, South Korea, Malaysia, Brazil, Venezuela, Peru
and Chile. We are also working to obtain clearance in other parts of the world.
|
HIFU Division Patents and Intellectual
Property
As of December 31, 2016, the HIFU division’s patent portfolio
contained 34 patents consisting of 11 patents in the United States, 19 patents in the European Union and Japan and four patents
in both Israel and the rest of the world. They belong to 18 groups of patents covering key technologies related to therapeutic
ultrasound principles, systems and associated software.
During 2016, one U.S. patent, two European and
Japanese patents and one Canadian patent exclusively licensed by INSERM to EDAP to address renal tumors using HIFU were abandoned
for non-use and the related license terminated. One key patent covering transducer design allowing fast and large volume of lesion
necrosis for liver applications has been granted in Japan and China. One additional patent also covering transducer design has
been granted in China. Seven additional patents covering certain other aspects of our HIFU technology in the European Union and
Japan (three), the United States (three), and the rest of the world (one) are currently under review. Our ongoing research and
development objectives are to maintain our leadership position in the treatment of prostate cancer and to extend the HIFU technology
to new applications and minimally invasive systems. These research projects are conducted in cooperation with the French National
Institute for Health and Medical Research (“INSERM”) which give rise in some cases to the filing, followed by the grant
of co-owned patents. We have entered into various license agreements with INSERM whereby we commit to pay a fixed amount of royalties
to INSERM based on the net revenues generated from the sales of HIFU devices using co-owned patents. Under these agreements, which
last for the life of each co-owned patents we have the exclusive right to the commercial use of the co-owned patents, including
the right to out-license such commercial rights.
In August 2004, we licensed our HIFU technology
for the specific treatment of the ‘‘cervicofacial’’ lesions, including the thyroid, to Theraclion, a French
company created by our former director of research and development. On January 11, 2011, we extended the above license by granting
Theraclion exclusivity for the treatment of benign breast tumors and by granting a non-exclusive license for the treatment of malignant
breast tumors. This license agreement provides for the payment of certain royalties calculated on the basis of Theraclion’s
future sales of devices. We determined that we could not invest in these specific applications at that time and this license agreement
therefore allows Theraclion to pursue the development of HIFU for these applications. We own no interest in Theraclion. In December
2012, Theraclion obtained CE Marking for their HIFU device dedicated to the treatment of benign breast tumors.
Although we believe that our HIFU patents are
valid and should be enforceable against third parties and that our patent applications should, if successfully pursued, result
in the issuance of additional enforceable patents, there can be no assurance that any or all of these patents or patent applications
will provide effective protection for the HIFU division’s proprietary rights in such technology. HIFU devices, as they are
currently or may in the future be designed, may also be subject to claims of infringement of patents owned by third parties, which
could result in an adverse effect on our ability to market HIFU systems. See Item 3, “Risk Factors – Risks relating
to Intellectual Property Rights.”
HIFU Division Clinical and Regulatory
Status
Clinical and Regulatory Status in Europe
The HIFU division has conducted an extensive
clinical trial for the Ablatherm in the European Union. This trial, the European Multicentric Study, involved a total of 652 patients
diagnosed with localized prostate cancer and included six sites in France, Germany and The Netherlands. The primary goals of the
trial were to assess the safety and effectiveness of the Ablatherm. An interim analysis performed on the first 559 patients included
402 patients treated with the Ablatherm device as a first-line therapy. Of these patients, 81.4% had a normal PSA and 87.2% had
negative biopsies at the last follow-up and were considered cancer free. The trials also included 157 patients who underwent an
Ablatherm treatment as a salvage therapy after a previous failed therapy (hormone therapy, radiation or prostatectomy). Of these
patients, 80.7% and 67.9% had negative biopsies and normal PSA after treatment, respectively.
Based on these results, in May 1999
,
we obtained a CE Marking that allows us to market the Ablatherm in the European Union.
Clinical and Regulatory Status in France
In 2001, the French Urology Association (‘‘AFU’’)
conducted an independent clinical trial to confirm the efficacy and safety results observed in the European Multicentric Study,
and to evaluate the therapy-related costs. Patient recruitment was successfully performed at eight investigational sites. Patient
enrollment was completed in an 11-month period with 117 patients included. Follow-up with these patients will continue to evaluate
the long-term efficacy of the treatment.
In March 2004, we obtained CE Marking, which
currently allows us to market Ablatherm for the treatment of patients who failed radiotherapy.
In 2005, a clinical trial was started in France
to validate the efficacy and safety of Ablatherm as salvage treatment for patients who did not respond to brachytherapy. This clinical
study was successfully completed in 2011 with satisfactory safety and efficacy results. Following the study, in January 2012, we
submitted to the European certification body an application for an extension of Ablatherm CE marking addressing brachytherapy failures.
Extension was granted in February 2012.
In 2007, a new clinical trial using Ablatherm
and dedicated to the treatment of patients with high risk disease who are not candidates for radical surgery because of their age
and/or co-morbidities was started in France. This clinical trial was terminated in March 2012 due to low patient enrollment.
Also in 2007, a clinical trial to evaluate
the utility of Contrast-Enhanced UltraSound (“CEUS”) for the early diagnosis of local cancer recurrence after HIFU
treatment was started in France. The preliminary results assessed that contrast-enhanced ultrasound is efficient in distinguishing
residual viable prostate tissue from ablated tissue after HIFU prostate ablation. This study provides evidence that contrast ultrasound
can diagnose early cancer recurrences. In May 2011, preliminary results related to good detection potential of CEUS after HIFU
treatment were published by Edouard Herriot Hospital, Lyon, France, in the journal
Radiology
. Patient follow-up was completed
in February 2012. CEUS technology was adopted for use in the new Focal One HIFU device.
In 2009, a new clinical trial was started in
France to validate a new strategy of minimally invasive treatment of prostatic adenocarcinomas localized in a single lobe with
HIFU. This concept of partial treatment is proposed as an intermediate option between active surveillance and whole prostate treatment.
Partial treatment for this trial is hemiablation of the prostate in which a single prostatic lobe (or hemisphere) is ablated using
HIFU in patients with prostate cancer that has a low risk of recurrence and for which the imaging and biopsy assessments show a
unilateral cancer. The goal of hemiablation is to reduce the complications associated with standard treatments, notably the risks
of incontinence and impotence. Final results were presented at the 109th Annual Meeting of the French Association of Urology in
Paris France which was held in November 2015. A total of 110 patients were included at 10 centers. The survival rate without additional
definitive treatment at 24 months was 89%. Urinary continence was preserved in 97% of patients and sexual function was preserved
in 78%.
In September 2010, a new clinical trial commenced
in France and Norway to validate the new strategy of hemi-ablation treatment in radio-recurrent prostate cancer localized in a
single lobe. This objective of focal treatment in patients with prostate cancer recurrence after radiotherapy is to reduce the
risks of side effects in a very fragile population of patients. This clinical trial had been expanded to include a cohort of 100
patients and to confirm the published preliminary outcomes. Results from this study were published in the British Journal of Urology
International in 2014. A total of 48 patients were enrolled. The study concluded that hemispherical salvage HIFU is a feasible
therapeutic option in patients with unilateral radio-recurrent prostate cancer, which offers limited urinary and rectal morbidity,
and preserves health-related quality of life.
In June 2011, a new clinical trial began in
France and then extended to Belgium in 2012 to evaluate the new technical improvements in HIFU technology: the Dynamic Focusing
technology. This technology gives the ability to target a more precise area within the prostate making the dynamic focusing technology
the perfect tool for focal therapy. It also allows for the treatment of bigger prostates and for a more precise contouring of the
gland providing a better control over sensitive areas responsible for continence and sexual functions. As a result, the Dynamic
Focusing technology has been incorporated into the new Focal One HIFU device.
In January 2014, a new clinical trial on multifocal
HIFU treatments with the Focal One device began in France in six investigational centers. The aim of this study is to evaluate
the efficacy and safety results of different focal HIFU treatment strategies. Thanks to Focal One technical capacities (Dynamic
Focusing technology, elastic fusion of MRI and ultrasound images and Contrast Enhanced Ultrasound treatment validation) many focal
treatments approaches are possible allowing for treatment that is individually tailored to the patient’s disease. In January
2015, the last patient was included in the above study, clinical results will be analyzed after 12 months’ follow-up.
In February 2015, the reimbursement evaluation
study of HIFU was initiated under the “Forfait Innovation”. This process, piloted by French Association of Urology
(AFU), compares primary whole-gland or sub-total HIFU and salvage whole-gland and focal HIFU results with those of radical prostatectomy
in 42 French urological centers. The primary outcome is the salvage treatment free rate at two years.
Clinical and Regulatory Status in the United
States
In 2005 EDAP started an Investigational Device
Exemption (“IDE”) study (G050103) to assess the safety and effectiveness of Ablatherm HIFU in the U.S. for the treatment
of low risk, localized prostate cancer. This study was designed as a pivotal study to support PMA approval. This study was planned
as a multicentric, prospective, non-randomized, concurrently controlled clinical trial comparing Ablatherm HIFU to cryotherapy
in patients with low risk, localized prostate cancer.
Due to accrual difficulties, particularly
in the cryosurgery arm, this planned study was not completed. Of the planned 205 patients per arm, 136 and five patients were recruited
to the Ablatherm HIFU and cryosurgery arms, respectively.
We completed the treatment of 134 patients in
June 2010, the required two years’ follow-up phase was completed in June 2012. Clinical outcomes from these patients combined
with our strong European long-term database formed the foundation of our PMA submission to the FDA on January 31, 2013.
On March 9, 2015, we announced that based on
our collaborative discussions with the FDA, we planned to seek clearance of Ablatherm HIFU by way of a direct de novo 510(k) application
as opposed to the PMA application amendment we had been considering. The FDA indicated that while PMA approval would be required
for specific claims regarding treatment of prostate cancer, a prostate tissue ablation claim could be cleared via a direct de novo
510(k) application.
On October 15, 2015, we announced the withdrawal
of our de novo application and the submission of a 510(k) notice, in accordance with the FDA guidelines, following the FDA clearance
of the Sonablate 450 for prostatic tissue ablation using HIFU.
On November 9, 2015, we announced the receipt
of 510(k) clearance from the FDA to market Ablatherm
®
Integrated Imaging HIFU in the U.S. for the ablation of prostate
tissue.
In April 2016 EDAP submitted to FDA a 510k application
for the clearance of the Focal One HIFU Device. This application is currently under review.
Clinical and Regulatory Status in Japan
In June 2000, the HIFU division applied for
approval by the Japanese Ministry of Health for the Ablatherm to be marketed in Japan. We retrieved the application in 2005 to
update it and review the process. In December 2016, based on FDA clearance of our Ablatherm HIFU system, we initiated discussions
with the Japanese authorities (“PMDA”) on the best process to apply for obtain Japanese approval for our Focal One
device. The process of requesting approval to market the Focal One in Japan may be long and may never result in the approval to
market the Focal Onein Japan. See Item 3, ‘‘Key Information—Risk Factors—Our future revenue growth and
income depend, among other things, on the success of our HIFU technology.’’
Clinical and Regulatory Status in China
On August 2, 2010, we entered into an exclusive
distribution agreement with Shaw Han Biomedical Co. Ltd to distribute Ablatherm throughout China, once approved by Chinese authorities.
This agreement involves a two-stage process: Shaw Han will first be responsible for processing the marketing clearance application
with China’s Food and Drug Administration for Ablatherm, then they will lead the marketing and distribution of the device
in China for four years post approval. As of the date of this annual report on Form 20-F, the marketing clearance application was
still is progress with the Chinese authorities.
See Item 3, “Risk Factors” –
“We operate in a highly regulated industry and our future success depends on government regulatory approval of our products,
which we may not receive or which may be delayed for a significant period of time.”
HIFU Clinical Data
To date, our clinical Ablatherm results have
been published in more than 85 renowned peer-reviewed journals. In 2010, the results of a major multicentric study on 803 patients
were published showing a local control of the disease in 77.9% of the patients. In 2013, three long-term studies presenting results
obtained over a period of more than 14 years on 538 patients, 704 patients and 1,002 patients were published, showing excellent
cancer-specific and metastasis-free survival in primary patients (Ganzer et al. BJU 2013, Thuroff et al. Journal of Urology 2013
and Crouzet et al. European Urology 2013).
In 2014, the first clinical results of focal
treatments with Ablatherm were published by Baco et al. in the British Journal of Urology International (“BJUInt”)
and Van Velthoven et al. in
Prostate Cancer
magazine. Baco et al. published promising results of hemi-salvage HIFU (treatment
of one lobe of the prostate) after External Beam Radiation Therapy (“EBRT”) and brachytherapy recurrences. In this
fragile population of patients, the treatment of the infected lobe is reported to provide better functional outcomes and preserves
quality of life. A similar approach of HIFU prostate hemi-ablation was presented by Van Velthoven et al. for primary care patients.
With a maximum follow-up of 61 months the study showed a rate of 100% full continence and 75% erectile function preservation combined
with only 11% of salvage treatment (re-HIFU in the contralateral lobe). Authors concluded primary zonal HIFU is a valid focal therapy
strategy which is safe and feasible in a day-to-day practice showing good promising results. This study was updated in 2015 in
Prostate Cancer and Prostatic Diseases journal with 50 patients treated with Hemi-HIFU strategy and provided 100% five-year cancer
specific survival rate. The functional results included 94% pad free patients and 80% erectile function preservation at the end
of follow-ups.
We
have
set up
an extensive
worldwide
patient database called "@-registry." This on-line database is designed to
compile
treatment
information
and
follow-up data for patients who have undergone HIFU for prostate cancer. The goal of the @-registry is to further demonstrate the
safety, effectiveness and durability of Ablatherm.
Information
from
the registry will be submitted to medical conferences for presentation and to peer-reviewed medical journals for publication. Based
on more than 10,000 patients included into our @-registry database, we presented at the European Association of Urology (EAU) held
in Paris in February 2012, an abstract presentation covering 5,662 primary patients, and an abstract covering 929 patients treated
with Ablatherm after radiorecurrence with seven years follow-up that was elected "best poster" by the scientific committee
.
Thüroff et al presented a poster at the American Urology Association (AUA) 2014 on the long
term HIFU retreatment rate, evaluating 2,632 patients. Thüroff et al concluded that technical development and adjuvant transurethral
radical prostatectomy (“TURP”) before HIFU resulted in higher local efficacy and lower HIFU retreatment rates.
In January 2016, Professor Ronald van Velthoven,
Head of Urology Department at Institut Bordet Oncology Center, Brussels, Belgium published outcomes of hemiablation HIFU in the
journal Prostate Cancer and Prostatic Diseases. With the initial patient treated in early 2007 it is the first prospective study
of focal HIFU to enroll patients and had a follow-up of extending to 8 years. The publication reports a 100% cancer specific survival
at 5 years, a 97% rate of continence preservation and 80% rate of potency preservation.
The results of the French hemiablation study
were electronically published in the peer-reviewed journal European Urology in October 2016. The study included a total of 110
patients at 10 centers whose prostates were treated with Ablatherm HIFU in which half the prostate was ablated. The follow-up of
the study was 2 years at which time all patients were required to undergo follow-up biopsy. In the treated side, 5% of subjects
had residual or recurrent clinically significant cancer. The survival rate without additional definitive treatment at 24 months
was 89%. Urinary continence was preserved in 97% of patients and erectile function was preserved in 78%.
In December 2016, Professor Roland van Velthoven
from Institut Bordet Oncology Center, Brussels, Belgium published a matched pair analysis of HIFU hemiablation vs robotic assisted
laparoscopic prostatectomy. In this study, 55 patients with unilateral localized prostate cancer were treated using Ablatherm-HIFU
and their outcomes were compared 1:1 with patients having similar clinical criteria but underwent robotic assisted laparoscopic
prostatectomy. The matched pair analysis concluded that HIFU was comparable to robotic-assisted radical prostatectomy in the management
of prostate cancer and showed HIFU to have significantly better functional outcomes.
HIFU Division Market Potential
Prostate cancer is currently the first or
second most common form of cancer among men in many populations. In the United States, the American Cancer Society estimates the
number of new prostate cancers diagnosed every year to be approximately 161,360, of which approximately 70% are diagnosed with
localized stage prostate cancer. Additionally, the HIFU division believes, based on figures provided by the World Health Organization
that the worldwide incidence of localized prostate cancer is approximately twice this U.S. figure. A more effective diagnostic
method for prostate cancer, the PSA test, has increased public awareness of the disease in developed countries since its introduction.
PSA levels jump sharply when cancer is present. Prostate cancer is an age-related disease, and its incidence in developed countries
is expected to increase as the population ages.
The HIFU division believes that HIFU therapy
could be expanded to other
medical conditions
, such as certain localized thyroid, breast,
gynecological, bladder, kidney, liver, brain, pancreatic and retroperitoneal tumors. For example, late 2016, we initiated a clinical
Phase I study to address certain types of deep endometriosis situated in the low rectum, using Focal One HIFU. We also entered
into a multi-partner liver cancer development project organized by the HECAM (HEpatocellular CArcinoma Multi-technological) consortium.
This project aims at developing innovative diagnostic, imaging and therapeutic technologies to address liver cancer. EDAP’s
focus within the HECAM consortium is on developing a novel HIFU treatment for liver cancer in cooperation with its long-term academic
partner INSERM and leading cancer centers. To fund this development program, EDAP will receive a maximum of €2.4 million in
non-dilutive financing from Bpifrance over the five-year project period of which we received the first instalment of €736,000
in June 2015. However, the expansion of the use of HIFU to other areas of treatment will require a significant investment in research
and development, an investment we will undertake gradually while focusing on the acceptance of HIFU as a treatment for localized
prostate cancer. For example, our licensee, Theraclion, obtained CE Marking for their HIFU device dedicated to the treatment of
benign breast tumors and thyroid tumors. See Item 4, “Information on the Company—HIFU Division Patents and Intellectual
Property.”
HIFU Competition
The principal current therapies for prostate
cancer carry side effects that can seriously affect a patient’s quality of life. One of the current therapies is radical
prostatectomy (surgery), which involves the ablation of the entire prostate gland. Radical prostatectomy requires several days
of hospital stay and several weeks of recovery, usually with catheterization, and may result in partial and/or total urinary incontinence.
In addition, it almost invariably renders patients impotent. A new surgical technique, nerve-sparing prostatectomy, has been developed
to address that problem. However, the procedure can only be applied when the tumor is not located close to the surface of the prostate
and requires a very skilled surgeon. Other therapies for localized prostate cancer include brachytherapy, a therapy that involves
the implantation of radioisotopes into the prostate gland, EBRT and cryotherapy.
Our HIFU devices compete with all current treatments
for localized tumors, which include surgery, brachytherapy, radiotherapy, cryotherapy and hormonotherapy. We believe that HIFU
competes against those treatments on the basis of efficacy, limited side effects and cost-effectiveness.
We also believe that Focal One will be well
positioned to address the growing demand for a “focal” approach of localized prostate cancer which cannot be answered
by surgery or radiation therapy. “Focal” treatment (also known as “partial” or “zonal” treatment,
as opposed to “radical” treatment) provides an effective and accurate ablative treatment of localized tumors with the
capacities of being flexible and repeatable, while preserving patient quality of life.
Other companies are working with HIFU for the
minimally invasive treatment of tumors. See Item 3, “Risk Factors – Risks Relating to Competition.”
Certain existing and potential competitors of
our HIFU division may have substantially greater financial, research and development, sales and marketing and personnel resources
than us and may have more experience in developing, manufacturing, marketing and supporting new products. We believe that an important
factor in the potential future market for HIFU treatments will be the ability to make the substantial investments in research and
development in advancing the technology beyond the treatment of prostate cancer. This future investment is wholly dependent on
the successful acceptance of the device for the treatment of prostate cancer.
HIFU Division Sales and Distribution of Products
The HIFU division markets and sells its products
through our own direct marketing and sales organization as well as through selected third-party distributors and agents in several
countries. Using our direct subsidiaries or representative offices network, the HIFU division maintains direct marketing and sales
forces in France, United States, Germany, Russia and Italy, which currently represent its largest HIFU markets. Additionally, the
HIFU division markets and sells its products through our distribution platform in the Middle East, South Korea and South East Asia.
The HIFU division’s customers are located
worldwide and have historically been principally public and private hospitals and urology clinics. The HIFU division believes that
as it increases its customer base it will gain further access to the urological community, which will enable it to monitor the
urological market, introduce new products and conduct trials under satisfactory conditions. No single customer of the HIFU division
represents a significant portion of the division’s installed base.
The HIFU division’s marketing efforts
include the organization of information and training programs for urologists, mainly in key European countries and in the United
States where HIFU awareness is growing, comprehensive media and web programs to educate patients on the availability of HIFU technology
to treat localized prostate cancer and strong participation in focused dedicated urological events. Our dedicated web site www.hifu-planet.com
for patients and physicians is visited regularly. The information contained on that website is not incorporated by reference herein.
UDS Division
The UDS division is engaged in the development,
marketing, manufacturing and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders,
mainly urinary stones, and other clinical indications. The UDS division
contributed €21.8
million
to our consolidated net sales during the fiscal year ended December 31, 2016.
Our UDS business is quite cyclical and generally
linked to lengthy hospital decision and investment processes and their activities. Hence our quarterly revenues are often impacted
and fluctuate according to these parameters, generally resulting in a higher selling activity in the last quarter of the year.
UDS Division Business Overview
The UDS division’s primary business
is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology.
ESWL uses extracorporeal shockwaves, which can be focused at urinary stones within the human body to fragment the stones, thereby
permitting their natural elimination and preventing the need for incisions, transfusions, general anesthesia, and the resulting
complications. The UDS division currently manufactures two models of lithotripters: the Sonolith i-move and the Sonolith i-sys.
As of December 31, 2016, the UDS division
has sold
863 ESWL lithotripters worldwide
to this date and
actively
maintained or otherwise serviced
694 installed lithotripters
.
In addition to its manufacturing and selling
of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables,
spare parts and maintenance services. It also derives revenues from the distribution of urodynamics products as urology lasers.
UDS Division Business Strategy
The business strategy for the UDS division
is to capitalize on its expertise in ESWL and its position in urology to achieve long-term growth as a leader in the development,
production, marketing and distribution of minimally invasive medical devices for urological and other clinical indications. The
UDS division manufactures its own products as part of EDAP TMS France SAS (“EDAP TMS France”), our wholly owned subsidiary.
The key elements of the UDS division’s strategy are:
|
·
|
Capitalize on the Current ESWL Installed Base
. The UDS division’s long-term growth
strategy relies on its ability to capitalize on its extensive installed base of ESWL lithotripters to recognize ongoing revenue
from sales of disposables, accessories, services and replacement machines. We believe that a combination of continued investment
in lowering end-user costs and offering innovative units that are easily adaptable to various treatment environments, as well as
a commitment to quality and service will allow the UDS division to achieve this goal. See ‘‘Information on the Company—UDS
Division Products’’.
|
|
|
|
|
|
·
|
Capitalize on an Established Distribution Platform in Urology by Expanding Distribution Possibilities
.
We believe that we can achieve additional long-term growth by offering our established distribution platform in urology to other
developers of medical technologies and acting as a distributor for their devices. Our distribution platform in urology consists
of a series of well-established subsidiaries in Europe, United States, Middle East and Asia as well as a network of third-party
distributors worldwide.
|
|
|
|
|
·
|
Provide Manufacturing Solutions to Other Developers of Medical Technologies
. Building upon
its established position in the high-tech medical devices market, we believe that the UDS division can become a provider of manufacturing
alternatives to other developers of medical technologies that do not have or do not wish to invest in their own manufacturing facilities.
We believe that our FDA-inspected, ISO 9001 (V:2008) certified and ISO 13485 (V:2003) certified facilities allow us to offer manufacturing
services to a wide range of potential medical equipment developers.
|
UDS Division Products
The UDS division offers the Sonolith i-move
(replacing Sonolith Praktis) to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals that can
afford a fully dedicated and integrated lithotripter. The UDS division also sells disposable parts for lithotripters, including
the piezoelectric elements of the LT02, (a machine we discontinued manufacturing in 2002) and the electrodes of the Sonolith line,
which need to be replaced approximately every ten treatments. These parts incorporate key proprietary technologies, and the UDS
division has retained sole marketing rights for these parts.
The Sonolith i-move and the Sonolith i-sys rely
on the electroconductive technology for shockwave generation. The electroconductive technology, which is derived from the electrohydraulic
technology on which the first ESWL lithotripters were based, permits improved focusing of the shockwave, reduces the variability
in the shockwave pressure and allows a better transfer of energy to the calculus. These features result in a faster, more effective
treatment as compared to electrohydraulic lithotripters.
The UDS division’s ESWL customers are
located worldwide and have historically been principally large hospitals, urology clinics and research institutions. To increase
its penetration of the market segment of smaller hospitals and outpatient clinics, the UDS division developed the Sonolith i-move,
an electroconductive lithotripter designed for smaller clinics. It is more compact than the Sonolith i-sys, which is more fully
integrated and dedicated to larger hospitals and can be used as a urological workstation to perform endourological procedures.
The Sonolith i-move, launched in 2010, brings a novel approach to the market by offering a wide range of configurations to suit
various budgets and various local market needs. The Sonolith i-move has also been very successful thanks to its innovative
Visio-Track
ultrasound stone localization: a unique three dimensional virtual system that uses infrared stereovision technology to guide the
treatment robotically.
UDS Division Patents and Intellectual
Property
As of December 31, 2016, the UDS division’s
patent portfolio contained eleven patents consisting of one patent in the United States, eight patents in the European Union and
Japan and two patents in both Israel and the rest of the world. One additional patent covering localization system using ultrasound
imaging on Sonolith i-sys and Sonolith i-move lithotripters has been delivered in Japan. They belong to five groups of patents
covering key technologies relating to ESWL systems and associated software capabilities. The patent covering the ultrasound localization
system is also in the examination process in the United States.
The UDS division’s patents cover both
piezoelectric and electroconductive technologies associated to ESWL generator, localization systems and device design. The UDS
division’s ongoing R&D objectives in ESWL are to further increase the clinical efficacy, the cost-effectiveness and the
ease of use of its products to make them accessible to wider patient and user populations.
As with the development of our HIFU technology,
we cooperate with INSERM to develop our ESWL technology. This cooperation gave rise to co-owned patents in some cases. We have
entered in the past into various license agreements with INSERM whereby we committed to pay a fixed amount of royalties to INSERM
based on the net revenues generated from the sales of ESWL devices using co-owned patents. Under these agreements, we had the exclusive
right to the commercial use of the co-owned patents, including the right to out-license such commercial rights. These license agreements
expired in 2016, allowing EDAP to freely use the related patents.
UDS Division Regulatory Status
The Sonolith i-move is available for commercial
distribution in the European Union, South Korea, Malaysia, Peru, Venezuela, Colombia, Costa Rica, Japan, United States, Taiwan,
Singapore, Saudi Arabia, Mexico and Brazil.
The Sonolith i-sys is available in the European
Union, South Korea, Canada, United States, Peru, Colombia, Argentina, Venezuela, Mexico, Costa Rica, Japan, Australia, Malaysia,
Singapore, Saudi Arabia and Taiwan.
The UDS division continues to provide disposables,
replacement parts and services for the current installed base of LT02 machines and Sonolith Praktis, even though we discontinued
the manufacture of these machines.
UDS Division Market Potential
We estimate that roughly, 2% to 3% of the
world population suffers from kidney or ureteric stones during their lifetime and that urinary calculi are responsible for 10%
of urological hospital admissions worldwide. Although urinary calculi may be eliminated naturally by the body, natural elimination
is frequently accompanied by considerable pain and very often by serious complications, such as obstruction and infection of the
urinary tract.
Since its introduction in clinical practice
35 years ago, ESWL has become the standard treatment for urinary calculi. ESWL consists of fragmenting calculi within the body
using extracorporeal shockwaves without any surgery. We believe that the market for lithotripters includes both buyers looking
for a sophisticated, higher-priced machine (generally hospitals and larger urology clinics) but also buyers looking for simpler
and less expensive machines (typically smaller clinics). We also believe that after a period of fast growth in the mid-1980s and
early 1990s, the market for lithotripters is now mature and has become primarily a replacement and service and maintenance market
in most of the world. Several geographical opportunities remain in under-equipped countries or in some countries where the national
health system strategy is being reviewed for hospitals and clinics equipment. ESWL is today in competition with less costly stone
laser devices. Consequently, in order to remain competitive, EDAP integrated stone laser products into its ESWL product range.
We believe that companies with a large installed
base of ESWL lithotripters will be most successful in the replacement market. Consequently, we intend to capitalize on our share
of the installed base of ESWL lithotripters to gain a significant position in the replacement market for those machines. We expect
the ESWL business to continue to contribute, at historically consistent levels, to the UDS division’s financial results despite
the mature nature of the market, due to revenues from maintenance contracts and demand for replacement machines. See Item 5, ‘‘Operating
and Financial Review and Prospects’’.
UDS Division Competition
The ESWL market is characterized by severe
price competition among manufacturers, with the result that, in recent years, the average unit price of ESWL lithotripters has
declined. The UDS division expects this trend to continue. See Item 5, ‘‘Operating and Financial Review and Prospects.’’
The UDS division’s major competitors in developed countries are Wolf, Storz and Dornier.
UDS Division Sales and Distribution of
Products
The UDS division markets, sells and services
its products through our direct sales and service platform in France, Italy, Germany, United States, Japan, South Korea, Malaysia
and, most recently, in the United Arab Emirates through our representative office in Dubai. The UDS division also markets its products
through agents and third-party distributors in several other countries.
The UDS division’s customers are located
worldwide and have historically been mainly public and private hospitals and urology clinics. We believe that the division’s
customer base provides it with excellent access to the urological community and enables it to introduce new products and conduct
trials under satisfactory conditions.
No single customer of the UDS division represents
a significant portion of the division’s installed base. The UDS division’s marketing efforts include the organization
of training programs for urologists worldwide.
UDS Division Services and Distribution
The UDS division is also pursuing various distribution
options that use its strong network of worldwide subsidiaries and agents. The UDS division distributes urodynamics products on
behalf of Laborie Company, including MMS (Medical Measurement Systems) products, and Andromeda in Japan. The UDS division also
distributes laser urology solutions from Lumenis in France and from Quanta System in Asia. We believe that the laser use in endo-urology
will increase in the coming years, for both the treatment of urinary stones and for other urological procedures such as HoLEP (Holmium
Laser Enucleation of Prostate). We believe that the UDS division can successfully market its worldwide distribution platform to
a wide range of medical equipment development companies, thus allowing for quick, easy and economically sound entry for these companies
into markets covering most of the world.
Manufacturing
Our current manufacturing operations consist
of manufacturing medical products in our FDA-approved facility, which is certified under international standards ISO 9001 and ISO
13485. We believe that this facility can extend its outsourced services to provide device and disposable development and manufacturing
services to a wide range of medical equipment development companies. Each division manufactures its own products through EDAP TMS
France.
We manufacture the critical components for
our devices and accessories, unless a subcontractor can manufacture the component more cost-effectively, we also perform final
assembly and quality control processes and maintain our own set of production standards. We purchase the majority of the raw materials
used in our products from a number of suppliers, but for several components of our products, rely on a single source. Furthermore,
we conduct regular quality audits of suppliers’ manufacturing facilities. Our principal suppliers are located in France,
Germany, Denmark, South Korea and the United States. Management believes that the relationships with our suppliers are good.
Quality and Design Control
The manufacturing operations of EDAP TMS France
must comply with the GMP regulations enacted by the FDA, which establish requirements for assuring quality by controlling components,
processes and document traceability and retention, among other things. EDAP TMS France’s facilities are also subject to inspections
performed by the FDA. The FDA last visited our manufacturing site in June 2014 with no findings nor issuance of Form 483 observations.
EDAP TMS France has obtained the ISO 9001 (V:2008) and ISO 13485 (V:2003) certifications, which indicate compliance by EDAP TMS
France’s manufacturing facilities with international standards for quality assurance, design and manufacturing process control.
EDAP TMS France also complies with the applicable requirements that will allow it to affix the CE Marking to certain of its products.
Our manufacturing site also complies with Taiwanese, Japanese and Canadian regulations, as well as with the U.S. Quality System
Regulation. See ‘‘Information on the Company—Government Regulation—Healthcare Regulation in the United
States’’ and ‘‘—Government Regulation—Healthcare Regulation in the European Union.’’
Property and Equipment
We have one principal facility, which is located
in Vaulx-en-Velin, on the outskirts of Lyon, France. The premises comprise 4,150 square meters and are leased to us under a renewable
ten-year commercial lease agreement signed on July 1, 2015. We use this facility to manufacture our device portofolio. We believe
the terms of the lease reflect commercial practice and market rates. The manufacturing facility, and principal offices, which we
utilize to manufacture and/or assemble all of our products, have ISO 9001 and ISO 13485 certifications. We are not aware of any
environmental issues that could affect utilization of the facility.
In addition, we lease office and/or warehouse
facilities in Kuala Lumpur (Malaysia), Rome (Italy), Flensburg (Germany), Austin (U.S.), Moscow (Russia), Seoul (South Korea),
Fukuoka, Osaka, Sapporo and Tokyo (Japan), Dubai (United Arab Emirates).
Organizational Structure
The following table sets forth the fully consolidated
subsidiaries of the Company as of the date of this annual report:
Name of the Company
|
|
Jurisdiction of
Establishment
|
|
Percentage Owned
(1)
|
|
|
|
|
|
EDAP TMS France SAS
|
|
|
France
|
|
|
|
100
|
%
|
EDAP Technomed Inc.
|
|
|
United States
|
|
|
|
100
|
%
|
EDAP Technomed Co. Ltd
|
|
|
Japan
|
|
|
|
100
|
%
|
EDAP Technomed Sdn Bhd
|
|
|
Malaysia
|
|
|
|
100
|
%
|
EDAP Technomed Srl
|
|
|
Italy
|
|
|
|
100
|
%
|
EDAP TMS GmbH
|
|
|
Germany
|
|
|
|
100
|
%
|
(1)
|
|
Percentage
of equity capital owned by EDAP TMS S.A. directly or indirectly through subsidiaries
(percentage of capital owned and voting rights are the same).
|
Government Regulation
Government regulation in our major markets,
in particular the United States, the European Union and Japan, is a significant factor in the development and marketing of our
products and in our ongoing research and development activities. See Item 3, “Risk Factors –Risks Related to Government
Regulations.”
Regulation in the United States
We and our products are regulated in the United
States by the FDA under a number of statutes including the Federal Food, Drug and Cosmetic Act (‘‘FDC Act’’).
Pursuant to the FDC Act, the FDA regulates the preclinical and clinical testing, manufacturing, labeling, distribution, sale, marketing,
advertising and promotion of medical devices in the United States. Medical devices are classified in the United States into one
of three classes - Class I, II or III - on the basis of the controls reasonably necessary to ensure their safety and effectiveness.
Class I devices are those whose safety and effectiveness can be ensured through general controls, such as establishment and registration,
medical device listing, FDA-mandated CGMP, labeling. Most Class I devices are exempt from premarket notification. Class II devices
are those whose safety and effectiveness can reasonably be ensured through the use of general controls and ‘‘special
controls,’’ such as special labeling requirements, mandatory performance standards, and post-market surveillance. Class
II medical devices require a 510(k) clearance. The FDA may require the submission of clinical data as part of pre-market notifications
for Class II devices. The FDA introduced the de novo 510(k) process for Class II devices for instances where a device is novel
and there is therefore no suitable predicate device to support a standard 510(k) submission. To qualify for the de novo pathway,
the new device must also present no more than moderate risk. Class III devices are those that must receive PMA by the FDA
to ensure their safety and effectiveness. Before a new Class III device may be introduced on the market, the manufacturer generally
must obtain FDA approval of a PMA. The PMA process is expensive and often lengthy, typically requiring several years, and may never
result in approval. The manufacturer or the distributor of the device must obtain an IDE from the FDA before commencing human clinical
trials in the United States in support of the PMA. Our lithotripsy range of products has been reclassified by the FDA as a Class
II device. As far as our Ablatherm
or Focal One HIFU
devices are concerned, they also
have been reclassified as Class II devices. Ablatherm has been cleared by FDA in November 2015, via a 510(k) application, based
on a prostate tissue ablation claim, following the approval of another HIFU device via a de novo 510(k) process. In April 2016,
we submitted a 510(k) application for our Focal One device, which is still under FDA review. Advertising and promotional activities
in the United States are subject to regulation by the FDA and, in certain instances, by the U.S. Federal Trade Commission. The
FDC Act also regulates our quality control and manufacturing procedures by requiring us to demonstrate and maintain compliance
with current GMP regulations. Our manufacturing facilities are in compliance with GMP regulations. No major deficiencies have been
observed during inspections carried out by FDA auditors (or its representative, the GMED, in France) in the past few years. In
June 2014, the FDA conducted an inspection of our manufacturing processes and facility with no findings nor issuance of Form 483
observations.
Regulation in the European Union
In the European Union, we annually perform
ISO 9001 (V:2008) and ISO 13485 (V:2003) certification audits, showing that we comply with standards for quality assurance, manufacturing
and design control. In the European Union, our products are also subject to legislation implementing the European Union Council
Directive 93/42/EEC concerning medical devices (the ‘‘Medical Device Directive’’). The Medical Device Directive
provides that medical devices that meet certain safety standards must bear a certification of conformity, the European Community
approval ‘‘CE Marking.’’ Except in limited circumstances,
member states
of the European Union
may not prohibit or restrict the sale, free movement or use for its intended purpose of a medical
device bearing the CE Marking. Medical devices marketed throughout the European Union must comply with the requirement of the Medical
Device Directive to bear a CE Marking (subject to certain exceptions). All of our products bear the CE Marking.
Pursuant to the Medical Device Directive, medical
devices are classified into four classes, Class I, Class IIa, Class IIb and Class III, on the basis of their invasiveness and the
duration of their use. The classification serves as a basis for determining the conformity assessment procedures that apply to
medical devices to be eligible to receive a CE Marking. The conformity assessment procedures for Class I devices can be carried
out, as a general rule, under the sole responsibility of the manufacturer, while for devices of other classes, the involvement
of an authorized supervisory body is required. The extent of the involvement of such body in the development and manufacturing
of a device varies according to the class under which it falls, with Class III devices being subject to the greatest degree of
supervision. All of the devices currently marketed by us are Class IIb devices.
Regulation in Japan
The import and sales of medical devices in
Japan is regulated by the Japanese Ministry of Health, Labor and Welfare (‘the “MHLW’’) under the license
“Marketing Authorization Holder.” Our Japanese subsidiary has obtained a general license as well as specific approvals
to import our products that have been approved in Japan. The MHLW also administers various national health insurance programs to
which each Japanese citizen is required to subscribe. These programs cover, among other things, the cost of medical devices used
in operations. The MHLW establishes a price list of reimbursable prices applicable to certain medical devices under the national
health insurance programs and until a new device is included in this list its costs are not covered by the programs. The LT02,
the Sonolith Praktis, the Sonolith Vision, the Sonolith i-sys and the Sonolith i-move are all included on the MHLW’s list
for reimbursement.
Item 4A. Unresolved Staff Comments
None.
Item 5. Operating and Financial Review and Prospects
The following discussion of our results of
operations and liquidity and capital resources for the fiscal years ended December 31, 2016, 2015 and 2014 is based on, and should
be read in conjunction with our consolidated financial statements and the notes thereto included in Item 18 of this annual report.
The consolidated financial statements have been prepared in accordance with U.S. GAAP and refer to the new topic-based FASB Accounting
Standards Codification (‘ASC’).
The following discussion contains certain forward-looking
statements that involve risks and uncertainties. Actual results may differ materially from those contained in such forward-looking
statements. See ‘‘Cautionary Statement on Forward-Looking Information’’ at the beginning of this annual
report.
Critical Accounting Policies
The discussion and analysis of our financial
condition and results of operations are based upon the consolidated financial statements, which have been prepared in accordance
with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to
make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure
of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to revenue recognition,
accounts receivable, bad debts, inventories, warranty obligations, litigation and deferred tax assets. We base our estimates on
historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates
and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions.
We believe our more significant judgments and
estimates used in the preparation of our consolidated financial statements are made in connection with the following critical accounting
policies.
Revenue Recognition
Sales of goods:
For medical device sales with no significant
remaining vendor obligation, payments contingent upon customer financing or acceptance criteria that can be subjectively interpreted
by the customer or tied to the use of the device, revenue is recognized when evidence of an arrangement exists, title to the device
passes (depending on terms, either upon shipment or delivery), and the customer has the intent and ability to pay in accordance
with contract payment terms that are fixed or determinable. For sales in which payment is contingent upon customer financing, acceptance
criteria that can be subjectively interpreted by the customer, or payment depends on use of the device, revenue is recognized when
the contingency is resolved. We provide training and a minimum of one-year warranty upon installation with a maximum of two-year
warranty. We accrue the estimated warranty costs at the time of sale. Revenues related to disposables are recognized when goods
are delivered.
Sales of RPP treatments and leases:
Revenues related to the sale of HIFU treatments
invoiced on a RPP basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers
under operating leases are recognized on a straight-line basis.
Sales of spare parts and services:
Revenues related to spare parts are recognized
when goods are delivered. Maintenance contracts rarely exceed one year and are recognized on a straight-line basis. Billings or
cash receipts in advance of services due under maintenance contracts are recorded as deferred revenue.
Warrants
On May 28, 2013, pursuant to a securities purchase
agreement dated May 20, 2013, as amended, the Company issued new ordinary shares in the form of ADSs to selected institutional
investors in a registered direct placement (the “May 2013 Placement”) with warrants attached (the “May 2013 Investor
Warrants”). The Company also issued warrants to the placement agent, H.C. Wainwright & Co., LLC (the “May 2013
Placement Agent Warrants” and together with the May 2013 Investor Warrants, the “May 2013 Warrants”). As the
May 2013 Warrants included an exercise price determined in U.S. dollars while the functional currency of the Company is the euro,
the Company determined that the May 2013 Warrants should be accounted for as a liability.
The Company used the Black-Scholes pricing
model to value the May 2013 Warrants at inception, with changes in fair value recorded as a financial expense or income.
On April 14, 2016, pursuant to a securities
purchase agreement dated April 7, 2016, the Company issued new ordinary shares in the form of ADSs to selected institutional investors
in a registered direct placement (the “April 2016 Placement”) with warrants attached (the “April 2016 Investor
Warrants”). As the April 2016 Warrants comprised the same structure and provisions than the May 2013 Warrants, including
an exercise price determined in U.S. dollars while the functional currency of the Company is the Euro, the Company determined that
the April 2016 Warrants should be accounted for as a liability.
The Company used the Black-Scholes pricing
model to value the April 2016 Warrants at inception, with changes in fair value recorded as a financial expense or income.
Accounts Receivable
We generate most of our revenues and corresponding
accounts receivable from sales of medical equipment, spare parts, maintenance and service to distributors, public and private hospitals
and physicians worldwide. We perform initial credit evaluations of our customers and adjust credit terms based upon customers’
creditworthiness as determined by such things as their payment history, credit ratings and our historical experiences.
Allowance for Doubtful Accounts
We evaluate the collectability of our accounts
receivable based on the individual circumstances of each customer on a quarterly basis. In circumstances where we are aware of
a specific customer’s inability to meet its financial obligations to us (e.g., bankrupcy filings, substantial downgrading
of credit scores), we record a specific reserve for bad debts against amounts due to reduce the net recognized receivable to the
amount we reasonably believe we will collect. If circumstances change (i.e. higher than expected defaults or an unexpected material
adverse change in a major customer’s ability to meet its financial obligations to us), our estimates of the recoverability
of amounts due to us could be reduced by a material amount.
Operating Results
Overview
Total revenues include sales of our medical
devices and sales of disposables (“sales of goods”), sales of RPPs and leases, and sales of spare parts and services,
all net of commissions, as well as other revenues.
Sales of goods have historically been comprised
of net sales of medical devices (ESWL lithotripters and HIFU devices) and net sales of disposables (mostly Ablapaks and Focalpaks
in the HIFU division and electrodes in the UDS division). Sales of goods also included products such as urology laser and urodynamics
devices distributed through our agents and third-party distributors. The sale price of our medical devices is subject to variation
based on a number of factors, including market competition, warranties and payment terms. Consequently, a particular sale of a
medical device may, depending on its terms, result in significant fluctuations in the average unit sale price of the product for
a given period, which may not be indicative of a market trend.
Sales of RPP and leases include the revenues
from the sale of Ablatherm and Focal One treatment procedures and from the leasing of Ablatherm and Focal One machines. We provide
Ablatherm and Focal One machines to clinics and hospitals for free for a limited period, rather than selling the devices. These
hospitals and clinics perform treatments using the devices and usually pay us based on the number of individual treatments provided.
With this business model, the hospital or clinic does not make an initial investment until the increase in patient demand justifies
the purchase of a HIFU machine. Consequently, we are able to make Ablatherm or Focal One treatments available to a larger number
of hospitals and clinics, which we believe should serve to create more long-term interest in the product. Compared to the sale
of devices, this business model initially generates a smaller, although more predictable stream of revenue and, if successful,
should lead to more purchases of Ablatherm and Focal One machines by hospitals and clinics in the long term.
Sales of spare parts and services include revenues
arising from maintenance services furnished by us for the installed base of ESWL lithotripters and HIFU devices.
We derive a significant portion of both net
sales of medical devices and consumables and net sales of spare parts and services from our operations in Asia, through our wholly
-
owned
subsidiaries or representative offices in Japan (Edap Technomed Co. Ltd), Malaysia (Edap Technomed Sdh Bhd) and South Korea (Edap
Technomed Korea). Net sales derived from our operations in Asia represented approximately 29% of our total consolidated net sales
in 2016. Net sales of goods in Asia represented approximately 31% of such sales in 2016 and consisted mainly of sales of ESWL lithotripters
and consumables. Net sales of spare parts, supplies and services in Asia represented approximately 43% of such sales in 2016 and
related primarily to ESWL lithotripters, reflecting the fact that approximately 46% of the installed base of our ESWL lithotripters
that we actively maintain or otherwise serve
is located in Asia.
We sell our products in many parts of the world
and, as a result, our business is affected by fluctuations in currency exchange rates. We are exposed to foreign currency exchange
rate risk because the mix of currencies in which our costs are denominated is different from the mix of currencies in which we
earn revenues. In 2016, approximately 78% of our costs of sales and research and development, selling, marketing and general and
administrative expenses were denominated in euro, while approximately 42% of our sales were denominated in currencies other than
euro (primarily the U.S. Dollar and Japanese yen). Our operating profitability could be materially affected by large fluctuations
in the rate of exchange between the euro and such other currencies. To minimize our exposure to exchange rate risks, we sometimes
use certain financial instruments for hedging purposes. See Item 3, ‘‘Key Information—Risk Factors—We sell
our products in many parts of the world and, as a result, our business is affected by fluctuations in currency exchange rates’’
and Item 11, ‘‘Quantitative and Qualitative Disclosures About Market Risk’’ for a description of the impact
of foreign currency fluctuations on our business and results of operations.
Reserves for slow-moving and obsolete inventory
are determined based upon quarterly reviews of all inventory items. Items which are not expected to be sold or used in production,
based on management’s analysis, are written down to their net realizable value, which is their fair market value or zero
in the case of spare parts or disposable parts for devices that are no longer in commercial production.
Consolidated research and development expenses
include all costs related to the development of new technologies and products and the enhancement of existing products, including
the costs of organizing clinical trials and of obtaining patents and regulatory approvals. We do not capitalize any of our research
and development expenses, except for the expenses relating to the production of machines to be used in clinical trials and that
have alternative future uses as equipment or components for future research projects.
Consolidated research and development expenses,
as described above, amounted to €3.9 million, €2.7 million and €2.9 million in 2016, 2015 and 2014, respectively,
representing approximately 10.9%, 8.4% and 10.9% of total revenues in 2016, 2015 and 2014, respectively. Consolidated research
and development expenses included research and development government grants and tax credits of €0.7 million, €0.6 million
and €0.8 million in 2016, 2015 and 2014, respectively. Research and development costs in 2014 included clinical expenses for
the Phase II/III PMA trials in the United States to expand our leadership in HIFU for prostate cancer. Beginning in 2017, management
expects the budget for research and development expenses in Europe to level off at approximately 13% of total revenues, which we
expect will allow us to maintain our strategy to launch new clinical studies (thus strengthening our clinical credibility), to
continue to focus our efforts on obtaining regulatory approvals in the U.S. and in Japan in particular, and reimbursement in key
countries, to continue to develop our HIFU and ESWL product range and to fund projects to expand the use of HIFU beyond the treatment
of prostate cancer, particularly through HECAM program.
Consolidated selling and marketing expenses
amounted to €8.9 million in 2016, €7.4 million in 2015 and €6.7 million in 2014. Selling and marketing expenses
included net impact of allowances for doubtful accounts of €0.02 million in 2016, and allowances for doubtful accounts €0.02
million in 2015 and €0.4 million in 2014. The €1.4 million or 20% increase in selling and marketing expenses from 2014
to 2016 was primarily a result of the increase in sales and marketing activity. Management expects marketing and sales efforts
to stay at significant levels in the future to consolidate the Ablatherm and Focal One HIFU technology’s status as a standard
of care for prostate pathologies in Europe, and to sustain the Company’s worldwide market position in lithotripsy, including
in the United States where the Company’s full range of lithotripsy products and Ablatherm HIFU device are now approved. Beginning
in 2017, management expects selling and marketing expenses to continue to increase significantly in view of the Company’s
expansion in the U.S.
In 2016, 2015 and 2014
,
our UDS sales activity benefited from continued product innovation and the success of our Sonolith i-sys device launched in 2007
and our Sonolith i-move device launched in 2010, together with
a
sustained commercial
effort in distributing additional urology devices which allowed us to capture market share
in
both
the
European, Asian and U.S. markets. We believe that the market for ESWL lithotripters
is now mature and has become primarily a replacement and maintenance market, with intense competition. As a result, we expect total
market volumes for our UDS Division to remain stable in the foreseeable future.
We believe that our results of operations in
the near future will be affected by our ability to grow our sales volumes both in the prostate cancer and the lithotripsy markets,
along with our ability to control expenses in connection with the development, marketing and commercial launch of HIFU applications,
particularly in the United States, and the continuation of the regulatory process for Focal One in the United States. See ‘‘—Liquidity
and Capital Resources.’’
Fiscal Year Ended December 31, 2016 Compared to
Fiscal Year Ended December 31, 2015
We report our segment information on a “net
contribution” basis, so that each segment’s results comprise the elimination of our intra-group revenues and expenses
and thus reflect the true contribution to consolidated results of the segment. See Note 26 to our consolidated financial statements.
(in millions of euros)
|
|
2016
|
|
2015
|
|
|
|
|
|
Total revenues
|
|
|
35.6
|
|
|
|
32.3
|
|
Total net sales
|
|
|
35.6
|
|
|
|
32.2
|
|
Of which HIFU
|
|
|
13.8
|
|
|
|
8.5
|
|
Of which UDS
|
|
|
21.8
|
|
|
|
23.8
|
|
Total cost of sales
|
|
|
(19.2
|
)
|
|
|
(18.5
|
)
|
Gross profit
|
|
|
16.4
|
|
|
|
13.8
|
|
Gross profit as a percentage of total net sales
|
|
|
46.1
|
%
|
|
|
42.8
|
%
|
Total operating expenses
|
|
|
(16.0
|
)
|
|
|
(13.3
|
)
|
Income (loss) from operations
|
|
|
0.4
|
|
|
|
0.5
|
|
Net income (loss)
|
|
|
3.8
|
|
|
|
(1.7
|
)
|
Total revenues
Our total revenues increased 10.4% from €32.3
million in 2015 to €35.6 million in 2016, principally due to the increase in HIFU machine sales.
HIFU division
. The HIFU division’s
total revenues
increased 63.0% to €13.8 million in 2016 as compared to €8.5 million
in 2015.
The HIFU division’s net sales of medical
devices increased 110.9% to €7.8 million in 2016, with six Ablatherm units and eight Focal One units sold
,
as
compared to
€3.7 million, with two Ablatherm and five Focal One units sold in
2015.
Treatment-driven revenue, which includes net
sales of RPP & leases and net sales of consumables, increased 25.8% to €5.2 million in 2016.
Net sales of HIFU-related spare parts, and services
increased from €0.7 million in 2015 to €0.9 million in 2016.
Other HIFU-related revenues were €28 thousand
from €32 thousand in 2015 and were comprised of license-based revenues from Theraclion.
UDS division
. The UDS division’s
total revenues decreased 8.3 % from €23.8 million in 2015 to €21.8 million in 2016, mostly due to the decrease in machine
sales.
The UDS division’s net sales of medical
devices decreased 15.5% from €14.5 million in 2015 to €12.2 million in 2016 with 36 devices sold in 2016 compared to
52 units sold in 2015.
Net sales of UDS-related spare parts, supplies,
RPP, leasing and services increased 2.8% from €9.3million in 2015 to €9.6 million in 2016, as a result of the larger
installed base of UDS machines and despite the Japanese authorities’ decision to stop reimbursing lithotripters’ disposables.
Cost of sales
.
Cost of sales increased 4.0% from €18.5
million in 2015 to €19.2 million in 2016, and represented 54.0% as a percentage of net sales in 2016, down from 57.3% as a
percentage of net sales in 2015, thanks primarily to the strong growth in HIFU sales.
Operating expenses
.
Operating expenses increased 20.5%, or €2.7
million, from €13.3 million in 2015 to €16.0 million in 2016. This increase in operating expenses included an adverse
exchange rate impact of €0.3 million.
Marketing and sales expenses increased €1.5
million, or 19.6%, reflecting the sales and marketing efforts on expanding the HIFU business
.
Research and development expenses increased
43.8% at €3.9 million in 2016 from €2.7 million in 2015, mainly driven by HIFU development projects and comprised R&D
grants and tax credits of €0.7 million and €0.6 million in 2016 and 2015, respectively, including costs of the FDA approval
of €0.3 million in 2015. Following the Ablatherm FDA clearance received on November 9, 2015, there is no more cost recorded
on this segment activity in 2016 compared to €0.3 million recorded in 2015.
General and administrative expenses increased
2.9% to €3.3 million in 2016.
Operating profit
.
As a result of the factors discussed above,
we recorded a consolidated operating profit of €0.4 million in
2016,
as compared
to a consolidated operating profit of €0.5 million in 2015
.
We realized an operating profit in the HIFU
division of €1.0 million in 2016, as compared with an operating profit of €0.5 million in 2015, and an operating profit
in the UDS division of €0.7 million in 2016, as compared to an operating profit of €1.6 million in 2015.
Financial (expense) income, net
. Net
financial income was €3.9 million in 2016, including a €3.8 million income for fair value adjustments on the outstanding
warrants, compared with a
net financial expense
of €2.1 million in 2015, including
a €2.4 million expense income due to fair value adjustments.
Foreign currency exchange gains (loss), net
.
In 2016, we recorded a net foreign currency exchange income of €0.1 million, mainly due to the variation of the Euro against
the U.S. Dollar and the Japanese Yen, compared to an income of €0.7 million in 2015.
Income taxes
. Income tax was an expense
of €0.6 million in 2016 and €0.8 million in 2015.
Net
income
/ (
loss)
As a result of the above, we realized a consolidated
net income of €3.8 million in 2016 compared with a consolidated net loss of €1.7 million in 2015.
Fiscal Year Ended December 31, 2015 Compared to
Fiscal Year Ended December 31, 2014
We report our segment information on a “net
contribution” basis, so that each segment’s results comprise the elimination of our intra-group revenues and expenses
and thus reflect the true contribution to consolidated results of the segment. See Note 26 to our consolidated financial statements.
(in millions of euros)
|
|
2015
|
|
2014
|
|
|
|
|
|
Total revenues
|
|
|
32.3
|
|
|
|
26.8
|
|
Total net sales
|
|
|
32.2
|
|
|
|
26.3
|
|
Of which HIFU
|
|
|
8.5
|
|
|
|
8.2
|
|
Of which UDS
|
|
|
23.8
|
|
|
|
18.1
|
|
Total cost of sales
|
|
|
(18.5
|
)
|
|
|
(15.6
|
)
|
Gross profit
|
|
|
13.8
|
|
|
|
11.2
|
|
Gross profit as a percentage of total net sales
|
|
|
42.8
|
%
|
|
|
42.7
|
%
|
Total operating expenses
|
|
|
(13.3
|
)
|
|
|
(12.9
|
)
|
Income (loss) from operations
|
|
|
0.5
|
|
|
|
(1.7
|
)
|
Net income (loss)
|
|
|
(1.7
|
)
|
|
|
(0.5
|
)
|
Total revenues
Our total revenues increased 20.4% from €26.8
million in 2014 to €32.3 million in 2015, principally due to the increase in UDS machine sales.
HIFU division
. The HIFU division’s
total revenues
decreased 2.8% to €8.5 million in 2015 as compared to €8.7 million in
2014.
The HIFU division’s net sales of medical
devices decreased 18.6% to €3.7 million in 2015, with two Ablatherm units and five Focal One units sold
,
as
compared to
€4.5 million, with four Ablatherm and six Focal One units sold in
2014.
Net sales of RPP treatments increased 15% to
€2.1 million in 2015.
Net sales of consumables and net sales of HIFU-related
spare parts, supplies, leasing and services increased from €1.9 million in 2014 to €2.7 million in 2015.
Other HIFU-related revenues were €32 thousand
from €518 thousand in 2014 and were comprised of license-based revenues from Theraclion.
UDS division
. The UDS division’s
total revenues increased 31.6 % from €18.1 million in 2014 to €23.8 million in 2015, mostly due to the increase in machine
sales.
The UDS division’s net sales of medical
devices increased 54.4% from €9.4 million in 2014 to €14.5 million in 2015 with 52 devices sold in 2015 compared to 42
units sold in 2014.
Net sales of UDS-related spare parts, supplies,
RPP, leasing and services increased 7.2% from €8.7million in 2014 to €9.3 million in 2015, as a result of the larger
installed base of lithotripsy machines.
Cost of sales
.
Cost of sales increased 18.5% from €15.6
million in 2014 to €18.5 million in 2015, and represented 57.3% as a percentage of net sales in 2015, down from 59.4% as a
percentage of net sales in 2014.
Operating expenses
.
Operating expenses increased 2.8%, or €0.4
million, from €12.9 million in 2014 to €13.3 million in 2015. Operating expenses included R&D grants and tax credits
of €618 thousand and €797 million in 2015 and 2014, respectively. The increase in operating expenses included an adverse
exchange rate impact of €0.6 million. The costs associated with the FDA approval decreased 75% to €0.3 million in 2015.
Marketing and sales expenses increased €0.7
million, or 10.9%, mostly due to the increase in sales-related bonuses.
Research and development expenses decreased
8.3% at €2.7 million in 2015 from €2.9 million in 2014, and comprised R&D grants and tax credits of €0.6 million
and €0.8 million in 2015 and 2014, respectively, and costs of the FDA approval of €0.3 million and €1.2 million
in 2015 and 2014, respectively.
General and administrative expenses decreased
3.8% to €3.2 million in 2015.
Operating loss
.
As a result of the factors discussed above,
we recorded a consolidated operating profit of €0.5 million in
2015,
as compared
to a consolidated operating loss of €1.7million in 2014.
We realized an operating profit in the HIFU
division of €0.5 million in 2015, as compared with an operating profit of €1.2 million in 2014, and an operating profit
in the UDS division of €1.6 million in 2015, as compared to an operating loss of €.0.2 million in 2014.
Financial (expense) income, net
. Net
financial expense was €2.1 million in 2015, including a €2.4 million expenses for fair value adjustments on the outstanding
warrants, compared with a
net financial income
of €1.8 million in 2014, including
a €1.7 million income due to fair value adjustments.
Foreign currency exchange gains (loss), net
.
In 2015, we recorded a net foreign currency exchange income of €0.7 million, mainly due to the variation of the Euro against
the U.S. Dollar and the Japanese Yen, compared to a loss of €0.4 million in 2014.
Income taxes
. Income tax was an expense
of €0.8 million in 2015 and €0.1 million in 2014.
Net
income
/ (
loss)
As a result of the above, we realized a consolidated
net loss of €1.7 million in 2015 compared with a consolidated net loss of €0.5 million in 2014.
Effect of Inflation
Management believes that the impact of inflation
was not material to our net sales or loss from operations in the three years ended December 31, 2016.
Liquidity and Capital Resources
Our cash flow has historically been subject
to significant fluctuations over the course of any given financial year due to cyclical demand for medical devices. Cyclical demand
has historically resulted in significant annual and quarterly fluctuations in trade and other receivables and inventories, and
therefore led to significant variations in working capital requirements and operating cash flows that were not necessarily indicative
of changes in our business. We believe our working capital is sufficient for our present working capital requirements although
we have in the past experienced negative cash flows and associated risks to liquidity, and may in the future experience the same.
Our cash flow situation
is
described in more detail below.
We anticipate that cash flow in future periods
will be derived mainly from ongoing operations. As of the date of this annual report we do not employ any off-balance sheet financing.
Because we anticipate relying principally on cash and cash equivalent balances to meet our liquidity requirements, a decrease in
the demand for our products, or the inability of our customers to meet their financial obligations to us due to operating difficulties
or adverse market conditions, would reduce the availability of funds to us.
(in thousands of euros)
|
|
2016
|
|
2015
|
|
2014
|
|
|
|
|
|
|
|
Net cash generated/(used) in operating activities
|
|
|
1,119
|
|
|
|
1,338
|
|
|
|
(1,014
|
)
|
Net cash generated/(used) in investing activities
|
|
|
(384
|
)
|
|
|
(541
|
)
|
|
|
(1,034
|
)
|
Net cash generated/(used) in financing activities
|
|
|
7,694
|
|
|
|
1,987
|
|
|
|
6,039
|
|
Net effect of exchange rate changes
|
|
|
(19
|
)
|
|
|
(347
|
)
|
|
|
469
|
|
Net increase/(decrease) in cash and cash equivalents
|
|
|
8,410
|
|
|
|
2,436
|
|
|
|
4,461
|
|
Cash and cash equivalents at the beginning of the year
|
|
|
13,578
|
|
|
|
11,142
|
|
|
|
6,681
|
|
Cash and cash equivalents at the end of the year
|
|
|
21,989
|
|
|
|
13,578
|
|
|
|
11,142
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cash and cash equivalents, and short-term investments at the end of the year
|
|
|
21,989
|
|
|
|
14,578
|
|
|
|
12,142
|
|
Our cash position as of December 31, 2016, 2015
and 2014, was €22.0 million (with no short-term treasury investments), €14.6 million (including €1.0 million of
short-term treasury investments) and €12.1 million (including €1.0 million of short-term treasury investments), respectively.
We experienced positive cash flows of €8.4 million in 2016, €2.4 million in 2015, and €4.5 million in 2014.
In 2016, our positive net cash flow was due
to the April 2016 Placement and our positive cash flow from operations. In 2015, our positive net cash flow was due to a positive
cash flow from operations and to warrant exercises for €1.1 million. In 2014, our positive cash flow was due to the June 2014
Placement, while cash flow from operations remained negative.
In 2016, net cash generated by operating activities
was €1.1 million compared with net cash generation by operating activities of €1.3 million in 2015 and compared with
net cash used in operating activities of €1.0 million in 2014.
In 2016, net cash generated in operating activities
reflected principally:
-
|
|
a net income of €3.8 million;
|
-
|
|
elimination of €2.4 million of net gain without effects on cash, including a
gain of €4.0 million due to fair value variations of financial instruments, €1.0 million of depreciation and amortization,
and €0.4 million of non-cash compensation linked to stock-options plans.
|
-
|
|
a decrease in trade accounts receivables of €1.8 million;
|
-
|
|
an increase in inventories of €2.0 million;
|
-
|
|
a decrease in payables of €0.2 million;
|
-
|
|
a increase in accrued expenses and other current liabilities
of €0.1 million.
|
In 2015, net cash generated in operating activities
reflected principally:
-
|
|
a net loss of €1.7 million;
|
-
|
|
elimination of €3.1 million of net loss without effects on cash, including €1.0
million of depreciation and amortization and a loss of €2.0 million due to fair value variations of financial instruments;
|
-
|
|
a increase in trade accounts receivables of €1.8 million;
|
-
|
|
a decrease in other receivables of €0.2 million;
|
-
|
|
an increase in inventories of €0.4 million;
|
-
|
|
an increase in payables of €0.5 million;
|
-
|
|
an increase in prepaid expenses of €0.1 million; and
|
-
|
|
an increase in accrued expenses and other current liabilities
of €1.5 million.
|
In 2014, net cash used in operating activities
reflected principally:
-
|
|
a net loss of €0.5 million;
|
-
|
|
elimination of €0.4 million of net gains without effects on cash, including €0.9
million of depreciation and amortization and a gain of €1.8 million due to fair value variations of financial instruments;
|
-
|
|
a decrease in trade accounts receivables of €0.9 million;
|
-
|
|
a decrease in other receivables of €0.2 million;
|
-
|
|
an increase in inventories of €1.3 million;
|
-
|
|
an increase in payables of €26 thousand;
|
-
|
|
an increase in prepaid expenses of €47 thousand; and
|
-
|
|
an increase in accrued expenses of €34 thousand.
|
In 2016, net cash used in investing activities
was €0.4 million compared with net cash used of €0.5 million in investing activities in 2015 and net cash used of €1.0
thousand in 2014.
Net cash used in investing activities of €0.4
million in 2016 reflected investments of €0.9 million in capitalized assets produced by the Company, mostly for commercial
demonstrations, training and RPP activity and investment of €0.5 million in property, equipment and software, and net proceeds
from sales of short term investments of €1,0 million.
Net cash used in investing activities of €0.5
million in 2015 reflected investments of €0.5 million in capitalized assets produced by the Company, mostly for commercial
demonstrations, training and RPP activity and investment of €0.2 million in property, equipment and software, net proceeds
from sales of leased-back assets of €0.1 million and net proceeds from sales of assets of €26 thousand.
Net cash used in investing activities of €1.0
million in 2014 reflected investments of €0.9 million in capitalized assets produced by the Company, mostly for commercial
demonstrations, training and RPP activity and investment of €0.1 million in property, equipment and software.
In 2016, net cash generated in financing activities
was €7.7 million compared with net cash generated in financing activities of €2.0 million in 2015 and net cash generated
in financing activities of €6.0 million in 2014.
Net cash generated in financing activities of
€7.7 million in 2016 reflected principally the €9.2 million net proceeds from the April 2016 Placement and the net proceeds
of €0.1 million from the exercise of stock options and warrants, repayment of short-term and long-term borrowings and lease
financing for €1.7 million.
Net cash generated in financing activities of
€2.0 million in 2015 reflected principally the net proceeds of €0.2 million from the exercise of stock options and warrants,
but also new long-term borrowings of €0.5 million, repayment of short-term and long-term borrowings and lease financing for
€0.4 million and an increase of short-term borrowings of €0.7 million.
Net cash generated in financing activities of
€6.0 million in 2014 reflected principally the €6.1 million net proceeds from the June 2014 Placement and net proceeds
of €0.2 million from the exercise of stock options and warrants, but also new long term borrowings of €0.2 million, repayment
of short-term and long-term borrowings and lease financing for €0.4 million.
Our policy is that our treasury department should
maintain liquidity with the use of short-term borrowings and the minimal use of long-term borrowings. The treasury department currently
adheres to this objective by using fixed-rate debt, which normally consists of long-term borrowing from a Japanese bank and with
certain long-term borrowings consisting of sale and leaseback equipment financing. Currently the short-term debt consists of account
receivables factored and for which the Company is supporting the collection risk. We maintain bank accounts for each of our subsidiaries
in the local currencies of each subsidiary. The primary currencies in which we maintain balances are the euro, the U.S. dollar
and the Japanese yen. To minimize our exposure to exchange rate risks, we may use certain financial instruments for hedging purposes
from time to time. As of December 31, 2016, there were no outstanding hedging instruments. See Notes 13 and 14 to the consolidated
financial statements for further information on our borrowings.
Contractual Obligations and Commercial Commitments as of December 31, 2016 (in thousands
of euro)
|
|
Payments Due by Period
|
|
|
Total
|
|
Less than
1 year
|
|
1-3 years
|
|
4-5 years
|
|
More than
5 years
|
Short-Term Debt
|
|
|
1,629
|
|
|
|
1,629
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Long-Term Debt
|
|
|
4,520
|
|
|
|
855
|
|
|
|
3,583
|
|
|
|
82
|
|
|
|
-
|
|
Capital Lease Obligations
|
|
|
535
|
|
|
|
222
|
|
|
|
233
|
|
|
|
66
|
|
|
|
15
|
|
Operating Leases
|
|
|
3,390
|
|
|
|
671
|
|
|
|
875
|
|
|
|
729
|
|
|
|
1,115
|
|
Interest
|
|
|
33
|
|
|
|
19
|
|
|
|
14
|
|
|
|
1
|
|
|
|
-
|
|
New Accounting Pronouncements
In July 2015, the FASB issued ASU 2015-14
Revenue from Contracts with Customers: Deferral of the Effective Date (ASU 2015-14) which deferred the effective date for ASU No.
2014-09, Revenue from Contracts with Customers (ASU 2014-09), by one year. ASU 2014-09 will supersede the revenue recognition requirements
in Revenue Recognition (Topic 605) and requires entities to recognize revenue in a way that depicts the transfer of promised goods
or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for
those goods or services. ASU 2014-09 is now effective for annual reporting periods beginning after December 15, 2017, including
interim periods within that reporting period, which for the Company is January 1, 2018. Early adoption is permitted only as of
annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The new standard
can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change
recognized at the date of the initial application in retained earnings. The Company reviewed the accounting pronouncement with
respect to its current accounting principles and does not expect a significant impact from implementation. The company anticipates
selecting the full retrospective method.
In November 2015, the FASB issued ASU No.
2015-17,
Balance Sheet Classification of Deferred Taxes
(ASU 2015-17), which requires that deferred tax liabilities and
assets be classified as noncurrent in a classified statement of financial position. ASU 2015-17 is effective for the Company in
its first quarter of fiscal 2017, with early application permitted and, upon adoption, may be applied either prospectively or retrospectively.
The Company will adopt the ASU 2015-17 for the year ended December 31, 2017.
In February 2016, the FASB issued ASU No.
2016-02,
Leases
(ASU 2016-02), which supersedes ASC 840 “
Leases
” and creates a new topic, ASC 842 "
Leases
."
This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including
operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures
surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those
fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach
for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements.
The Company is expecting that the impact of this update on its consolidated statements will mainly consist of leases for facilities
situated in France, Japan and in the U.S. as described in Note 12.2.
In August 2014, the FASB issued ASC Update
No. 2014-15, Presentation of Financial Statements—Going Concern: Disclosure of Uncertainties about an Entity’s Ability
to Continue as a Going Concern (Subtopic 205-40). Update 2014-15 requires management to assess an entity’s ability to continue
as a going concern every reporting period, and provide certain disclosures if management has substantial doubt about the entities
ability to operate as a going concern, or an express statement if not, by incorporating and expanding upon certain principles that
are currently in U.S. auditing standards. Update 2014-15 is effective for the annual period ending after December 15, 2016, and
for annual periods and interim periods thereafter. The Company implemented ASU 2014-15 as of January 1, 2016.
Research and Development, Patents and Licenses
See
“—
Operating
Results
—
Overview” and Item 4, ‘‘Information on the Company—HIFU
Division—HIFU Division Patents and Intellectual Property’’ and ‘‘Information on the Company—UDS
Division—UDS Division Patents and Intellectual Property.’’
The French government provides tax credits to
companies for innovative research and development. This tax credit is calculated based on a percentage of eligible research and
development costs and it can be refundable in cash.
In 2009, the Company reviewed the presentation
of its research tax credit and elected to change for the preferred classification as permitted under ASC 250-10.
The research tax credit amounted to €511
thousand in 2016, €448 thousand in 2015 and €518 thousand in 2014 and was classified as a reduction of research and development
expenses.
Off-Balance Sheet Arrangements
At December 31, 2016, we had no off-balance
sheet arrangements other than those specified in Notes 2 and 14-1 of our consolidated financial statements.
Item 6. Directors, Senior Management and Employees
Senior Executive Officers
The following table sets forth the name, age
and position of each of our Senior Executive Officers as of April 3, 2017. The Chief Executive Officer and the Chief Financial
Officer listed below have entered into employment contracts with us or our subsidiaries (which permit the employee to resign subject
to varying notice periods). In addition, in case of a change of control of the Company, or of a termination of their employment
contract by the Company without cause, the Senior Executive Officers are entitled to receive severance packages totaling approximately
€ 0.8 million.
Name
|
Position
|
|
|
Marc Oczachowski
|
Chief Executive Officer of EDAP
TMS S.A.
|
Age: 47
|
President of EDAP TMS France SAS and EDAP Technomed,
Inc.
|
|
Marc Oczachowski joined the Company
in May 1997 as Area Sales Manager, based in Lyon, France. From March 2001 to January 2004, he held management positions as General
Manager of EDAP Technomed Malaysia. He was appointed Chief Operating Officer of EDAP TMS in November 2004 and became Chief Executive
Officer of the Company on March 31, 2007. In 2012, he relocated to Austin, Texas to manage EDAP’s U.S. operations. Previously
he worked for Sodem Systems, which manufactures orthopedic power tools, as Area Sales Manager. He is a graduate of Institut Commercial
de Lyon, France.
|
|
|
François Dietsch
|
Chief Financial
Officer of EDAP TMS S.A.
|
Age: 41
|
François
Dietsch joined EDAP in 2005 as Internal Audit and Consolidation Manager, leading the implementation of internal controls for Sarbanes-Oxley
Compliance, consolidation of financial statements from the Company's subsidiaries and preparation of financial statements in accordance
with U.S. GAAP, including EDAP's annual report on Form 20-F. In 2012, he was promoted to Group Financial Control Manager and Finance
Manager of EDAP's French subsidiary where, in addition to his previous responsibilities, he managed accounting firm relationships
at the subsidiary level and was the primary liaison between the Company and its external auditors. He also managed the Finance
department at EDAP France. He was appointed Chief Financial Officer of the Company on July 14, 2015. Prior to joining EDAP he held
finance positions at Valeo, a leading global supplier of components and systems to the automotive industry. He holds Master's Degrees
in Management and Corporate Finance from University of Paris Dauphine.
|
|
|
|
Board of Directors
The following table sets forth the names and
backgrounds of the members of the Board of Directors. None of the directors has service contracts with the Company or any of its
subsidiaries providing for benefits upon termination of employment. All of the Board members are independent within the meaning
of NASDAQ Marketplace Rule 5605(2). All four Board of Directors mandates terminate in June 2020 at the General Meeting of Shareholders
approving the 2019 accounts.
Philippe Chauveau
Age: 81
Mandate: 6 years
Appointment: April. 8, 1997
(renewed)
Expiration: 2020
|
Philippe Chauveau was named chairman of EDAP TMS S.A.'s Supervisory
Board in 1997. In 2002, the Company’s two-tiered board structure was replaced by a single Board of Directors with Philippe
Chauveau serving as Chairman and CEO until 2004 when he was succeeded as CEO. From 2000 to 2007, Philippe Chauveau served as founding
Chairman of the Board of Scynexis Inc., funded by private equity, which is an innovative drug discovery company based in the United
States. He was Vice-President of research and development at AT&T Bell Labs and has also served as Chairman of Apple Computer
Europe, preceded by increasing marketing roles in ITT and in Procter & Gamble. He has an Honours Degree from Trinity College
Dublin with a B.A. and a Bsc.
|
|
|
Pierre Beysson
Age: 75
Mandate: 6 years
Appointment:
September 27, 2002
(renewed)
Expiration: 2020
|
Pierre Beysson was appointed as a member of the Board of Directors
in September 2002. Pierre Beysson was then the Chief Financial Officer of Compagnie des Wagons-Lits ("CWL"), the on-board
train service division of Accor, a French multinational Hotel and Business Services Group. In this capacity, he sat on a number
of boards of companies related to the Accor Group. Before his assignment at CWL, Pierre Beysson held a number of senior financial
positions with Nixdorf Computers, Trane (Air Conditioning), AM International (Office Equipment) and FMC (Petroleum Equipment).
Pierre Beysson was trained as a CPA, has auditing experience and holds an MBA from Harvard Business School.
|
|
|
Argil Wheelock
Age: 69
Mandate: 6 years
Appointment: June 25, 2009
(renewed)
Expiration: 2020
|
Dr. Argil Wheelock was elected as a member of the Company's Board
of Directors in June 2009. Dr. Wheelock, a U.S. board certified urologist, is currently Senior Physician at the University of Tennessee
Department of Urology at Erlanger Medical Center, a tertiary care and teaching hospital in Chattanooga, Tennessee. He is Chief
Medical Advisor to HealthTronics Inc., a privately held company. HealthTronics is a leading U.S. provider of urological services
and products. From 1996 to 2005, Dr. Wheelock served as Chairman and CEO of HealthTronics, a publicly traded NASDAQ company where
he was a founder. He has built a successful track record introducing new medical devices to the U.S. and navigating the FDA approval
process. He is widely known among the U.S. urological community for bringing clinical benefits to patients and economic value to
urology practices. Dr. Wheelock graduated from the University of Tennessee College of Medicine and completed urological training
at Mount Sinai Hospital in New York City.
|
|
|
Rob Michiels
Age: 67
Mandate: 6 years
Appointment: July 16, 2009
(renewed)
Expiration: 2020
|
Rob Michiels was elected as a member of the Company's Board of Directors in July 2009. He is a 30-year U.S. veteran of the medical device industry. He most recently serves as Chief Executive Officer (CEO) of CardiAQ Valve Technologies, a venture funded start-up developing Transcatheter Mitral Valve Implantation which was acquired by Edwards Lifesciences during the second half of 2015. He previously served as Chief Operating Officer (COO) of CoreValve (acquired by Medtronic); and as President and COO of InterVentional Technologies (acquired by Boston Scientific). He helped drive both companies from cardiovascular start-ups to established market leaders, using new and innovative technologies which have strong synergies to the HIFU story. Rob Michiels is a director of Aegis Surgical Ltd, Atrius Ltd, FEops NV and Embolization Prevention Technologies, all privately held companies developing cutting edge cardio-vascular less-invasive Technologies. Rob Michiels is a founding partner of CONSILIUM, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch languages, he holds a bachelor's degree in economics from Antwerp University in Belgium and a Master’s in business administration (MBA) from Indiana University.
|
Compensation
Aggregate compensation paid or
accrued for services in all capacities by the Company and its subsidiaries to Senior Executive Officers and to the Board of
Directors as a group for the fiscal year 2016 was approximately €756 thousand including performance bonuses of
€ 118 thousand and benefits in kind of €94 thousand (benefits in kind comprise car allowances for senior
management and housing and school allowances for senior management located outside France). No amount was set aside or
accrued by us to provide pension, retirement or similar benefits for Senior Executive Officers and to the Board of Directors
as a group in respect of the year 2016. For information regarding compensation paid in the form of stock options, see
“Directors, Senior Management and Employees - Share Ownership” and “Directors, Senior Management and
Employees - Options to Purchase or Subscribe for Securities.”
Compensation Committee
The Compensation Committee is comprised of
the following members: Mr. Philippe Chauveau, Mr. Pierre Beysson, Dr. Argil Wheelock and Mr. Rob Michiels. The Committee gathers
once a year to review the compensation of our Chief Executive Officer, as per the approved charter of the Compensation Committee,
and to propose to the Board of Directors any changes to the Chief Executive Officer’s compensation. The Chief Executive Officer
is not present when the Compensation Committee reviews his compensation. In August 2014, the Compensation Committee updated its
charter which was subsequently approved by the Board of Directors.
Audit Committee
The Board of Directors’ Audit Committee
comprises all four independent members of the Board: Mr. Pierre Beysson, acting as Head of the Audit Committee and financial expert,
Mr. Philippe Chauveau, Dr. Argil Wheelock and Mr. Rob Michiels. The purpose of the Audit Committee, in accordance with its annually
approved charter, is to:
-
|
|
Provide assistance to the Board of Directors in fulfilling their oversight responsibility
to the shareholders, potential shareholders, the investment community and others relating to: the integrity of our financial statements,
our compliance with legal and regulatory requirements, our accounting practices and financial reporting processes, the effectiveness
of our disclosure controls and procedures and internal control over financial reporting, the independent auditor’s qualifications
and independence, and the performance of our internal audit function and independent auditors.
|
-
|
|
Prepare the Audit Committee report.
|
-
|
|
The Audit Committee may request any officer or employee of the Company or our outside
counsel or independent auditor to attend a meeting of the Audit Committee or to meet with any members of, or consultants to, the
Audit Committee.
|
Nomination Committee
The Company’s Board of Directors, currently
composed of four independent directors: Mr. Philippe Chauveau, Mr. Pierre Beysson, Dr. Argil Wheelock and Mr. Rob Michiels (as
such term is defined in the NASDAQ Listing Rules), recommends for the Board’s selection director nominees to submit to the
vote of the Company’s shareholders. In addition, under specified circumstances and in accordance with French law, shareholders
may also submit resolutions to the general meeting to appoint directors.
The Company’s nominations practice is
formalized in a Board resolution and at its Board meeting in February 2015, the Board resolved that in the event that one or more
directors is or are no longer independent, the Board will create a Nominations Committee (composed exclusively of independent Directors).
A Nominations Committee Charter was approved accordingly, the terms of which apply to the Board of Directors when considering director
nominees.
Employees
As of December 31, 2016, we employed 197 individuals
on a full-time basis, as follows:
|
Sales & Marketing
|
Manufacturing
|
Service
|
Research & Dvpt
|
Regulatory
|
Clinical Affairs
|
Administrative
|
Total
|
France
|
23
|
34
|
23
|
18
|
2
|
8
|
13
|
121
|
Italy
|
4
|
0
|
0
|
0
|
0
|
0
|
2
|
6
|
Germany
|
4
|
0
|
3
|
0
|
0
|
0
|
2
|
9
|
Japan
|
17
|
0
|
14
|
0
|
2
|
0
|
4
|
37
|
Malaysia
|
2
|
0
|
3
|
0
|
0
|
0
|
2
|
7
|
South Korea
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
USA
|
7
|
0
|
3
|
0
|
0
|
1
|
4
|
15
|
Total
|
58
|
34
|
46
|
18
|
4
|
9
|
28
|
197
|
As of December 31, 2015, we employed 165 individuals
on a full-time basis, as follows:
|
Sales & Marketing
|
Manufacturing
|
Service
|
Research & Dvpt
|
Regulatory
|
Clinical Affairs
|
Administrative
|
Total
|
France
|
19
|
28
|
22
|
14
|
3
|
6
|
11
|
103
|
Italy
|
3
|
0
|
0
|
0
|
0
|
0
|
2
|
5
|
Germany
|
4
|
0
|
2
|
0
|
0
|
0
|
2
|
8
|
Japan
|
18
|
0
|
11
|
0
|
1
|
0
|
3
|
33
|
Malaysia
|
2
|
0
|
2
|
0
|
0
|
0
|
2
|
6
|
South Korea
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
USA
|
3
|
0
|
1
|
0
|
0
|
1
|
3
|
8
|
Total
|
50
|
28
|
38
|
14
|
4
|
7
|
24
|
165
|
As of December 31, 2014, we employed 161 individuals
on a full-time basis, as follows:
|
Sales & Marketing
|
Manufacturing
|
Service
|
Research & Dvpt
|
Regulatory
|
Clinical Affairs
|
Administrative
|
Total
|
France
|
14
|
35
|
19
|
12
|
4
|
6
|
13
|
103
|
Italy
|
3
|
0
|
0
|
0
|
0
|
0
|
2
|
5
|
Germany
|
4
|
0
|
2
|
0
|
0
|
0
|
2
|
8
|
Japan
|
14
|
0
|
13
|
0
|
1
|
0
|
3
|
31
|
Malaysia
|
2
|
0
|
2
|
0
|
0
|
0
|
2
|
6
|
South Korea
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
USA
|
1
|
0
|
1
|
0
|
0
|
1
|
3
|
6
|
Total
|
39
|
35
|
37
|
12
|
5
|
7
|
26
|
161
|
Management considers labor relations to be good.
Employee benefits are in line with those specified by applicable government regulations.
Share Ownership
As of April 3, 2017, the total number of shares
issued was 29,368,394 with 370,528 shares held as treasury shares, thus bringing the total number of shares outstanding to 28,997,866.
As of April 3, 2017, the Board of Directors
and the Senior Executive Officers of the Company held a total of 60,623 Shares
.
The Board of Directors and Senior Executive
Officers beneficially own, in the aggregate less than 1% of the Company's shares.
As of April 3, 2017, Senior Executive Officers
held a total of 20,001 Shares and an aggregate of 555,338 options to purchase or to subscribe a total of 555,338 ordinary shares,
with a weighted average exercise price of €2.82 per share. Of these options, 105,338 expire on October 29, 2017, 30,000 expire
on June 25, 2020, 200,000 expire on January 18, 2023 and 220,000 expire on April 26, 2026.
Options to Purchase or Subscribe for Securities
On May 22, 2007, the shareholders authorized
the Board of Directors to grant up to 600,000 options to subscribe to 600,000 new shares at a fixed price to be set by the Board
of Directors.
On June 24, 2010, the shareholders authorized
the Board of Directors to grant up to 229,100 options to purchase pre-existing shares at a fixed price to be set by the Board of
Directors. All of the shares that may be purchased through the exercise of stock options are currently held as treasury stock.
On December 19, 2012, the shareholders authorized
the Board of Directors to grant up to 500,000 options to subscribe to 500,000 new shares at a fixed price to be set by the Board
of Directors.
On February 18, 2016, the shareholders authorized
the Board of Directors to grant up to 1,000,000 options to subscribe to 1,000,000 new shares at a fixed price to be set by the
Board of Directors.
As of April 3, 2017, we had sponsored four
stock purchase and subscription option plans open to employees of EDAP TMS group.
On December 31, 2016, the expiration of our
stock option contracts was as follows:
Date of expiration
|
|
Number of
Options
|
|
|
|
October 29, 2017
|
|
|
377,838
|
|
June 25, 2020
|
|
|
127,100
|
|
January 18, 2023
|
|
|
362,500
|
|
April 26, 2026
|
|
|
560,000
|
|
As of December 31, 2016, a summary of stock
option activity to purchase or to subscribe to shares under these plans is as follows:
|
|
2016
|
|
2015
|
|
2014
|
|
|
Options
|
|
Weighted average exercise
price
(€)
|
|
Options
|
|
Weighted average exercise
price
(€)
|
|
Options
|
|
Weighted average exercise
price
(€)
|
Outstanding on January 1,
|
|
|
917,188
|
|
|
|
2.79
|
|
|
|
1,095,850
|
|
|
|
2.76
|
|
|
|
1,310,850
|
|
|
|
2.70
|
|
Granted
|
|
|
575,000
|
|
|
|
3.22
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
(72,412
|
)
|
|
|
2.13
|
|
|
|
(750
|
)
|
|
|
3.99
|
|
Forfeited
|
|
|
(64,750
|
)
|
|
|
3.30
|
|
|
|
(106,250
|
)
|
|
|
2.88
|
|
|
|
(90,250
|
)
|
|
|
2.07
|
|
Expired
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(124,000
|
)
|
|
|
2.60
|
|
Outstanding on December 31,
|
|
|
1,427,438
|
|
|
|
2.94
|
|
|
|
917,188
|
|
|
|
2.79
|
|
|
|
1,095,850
|
|
|
|
2.76
|
|
Exercisable on December 31,
|
|
|
774,938
|
|
|
|
2.87
|
|
|
|
724,688
|
|
|
|
3.03
|
|
|
|
784,600
|
|
|
|
3.09
|
|
Share purchase options available for grant on December 31
|
|
|
243,428
|
|
|
|
|
|
|
|
232,428
|
|
|
|
|
|
|
|
232,428
|
|
|
|
|
|
The following table summarizes information
about options to purchase existing shares held by the Company, or to subscribe to new Shares, at December 31, 2016:
|
|
Outstanding options
|
|
|
|
Fully vested options
(1)
|
|
|
Exercise price (€)
|
|
Options
|
|
Weighted average remaining contractual life
|
|
Weighted average exercise price
(€)
|
|
Aggregate
Intrinsic
Value
(2)
|
|
Options
|
|
Weighted average exercise price
(€)
|
|
Aggregate
Intrinsic
Value
(2)
|
3.99
|
|
|
327,838
|
|
|
|
0.8
|
|
|
|
3.99
|
|
|
|
-
|
|
|
|
327,838
|
|
|
|
3.99
|
|
|
|
-
|
|
2.38
|
|
|
127,100
|
|
|
|
3.5
|
|
|
|
2.38
|
|
|
|
93,004
|
|
|
|
127,100
|
|
|
|
2.38
|
|
|
|
93,004
|
|
3.22
|
|
|
560,000
|
|
|
|
9.3
|
|
|
|
3.22
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
1.91
|
|
|
362,500
|
|
|
|
6.0
|
|
|
|
1.91
|
|
|
|
435,629
|
|
|
|
270,000
|
|
|
|
1.91
|
|
|
|
324,469
|
|
1.88
|
|
|
50,000
|
|
|
|
3.5
|
|
|
|
1.88
|
|
|
|
61,587
|
|
|
|
50,000
|
|
|
|
1.88
|
|
|
|
61,587
|
|
1.88 to 3.99
|
|
|
1,427,438
|
|
|
|
4.5
|
|
|
|
2.94
|
|
|
|
590,220
|
|
|
|
774,938
|
|
|
|
2.87
|
|
|
|
479,060
|
|
(1)
|
|
Fully
vested options are all exercisable options
|
(2)
|
|
The
aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $3.28
at December 31, 2016, which would have been received by the option holders had all in-the-money option holders exercised their
options as of that date.
|
Item 7. Major Shareholders and Related Party Transactions
Major Shareholders
To our knowledge, we are not directly or indirectly
owned or controlled by another corporation, by any foreign government, or by any other natural or legal person or persons acting
severally or jointly.
To the best of our knowledge and on the basis
of the notifications received or filed with the SEC, shareholders who are beneficial owners of more than 5% of our shares are as
follows.
|
|
# of shares
held on
Dec. 31,
2016
|
|
% of share
capital on
Dec. 31,
2016
|
|
# of shares
held on
Dec. 31,
2015
|
|
% of share
capital on
Dec. 31,
2015
|
|
# of shares
held on
Dec. 31,
2014
|
|
% of share
capital on
Dec. 31,
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bruce & Co. Inc
|
|
|
1,045,494
|
|
|
|
3.64
|
|
|
|
1,045,494
|
|
|
|
4.05
|
|
|
|
1,565,494
|
|
|
|
6.20
|
|
There are no arrangements known to us, the
operation of which may at a later date result in a change of control of the Company. All shares issued by the Company have the
same voting rights, except the treasury shares held by the Company, which have no voting rights.
As of April
3, 2017, 29,368,394 shares were issued, including 28,997,866 outstanding and 370,528 treasury shares. At March 17, 2017, there
were 29,342,294 ADSs, each representing one Share, all of which were held of record by 19 registered holders in the United States
(including The Depository Trust Company).
Related Party Transactions
The General Manager of the Company's Korean
branch "EDAP-TMS Korea" is also Chairman of a Korean company named Dae You. EDAP-TMS Korea subcontracts to Dae You the
service contract maintenance of our medical devices installed in Korea. The amounts invoiced by Dae You under this contract were
€62 thousand, €78 thousand and €68 thousand, for 2016, 2015 and 2014 respectively. As of December 31, 2016, payables
to Dae You amounted to €9 thousand. As of December 31, 2015, payables to Dae You amounted to €53 thousand.
Dae You has purchased medical devices from
us, which it operates in partnership with hospitals or clinics. These purchases (‘Sales of goods’) amounted to€483
thousand, €408 thousand and €308 thousand, in 2016, 2015 and 2014, respectively. As of December 31, 2016, receivables
(‘Net trade accounts and notes receivable’) amounted to €325 thousand As of December 31, 2015, receivables (‘Net
trade accounts and notes receivable’) amounted to €380 thousand.
Interests of Experts and Counsel
Not applicable.
Item 8. Financial Information
Consolidated Financial Statements
See Item 18, ‘‘Financial Statements.’’
Export Sales
As of December 31, 2016, total consolidated
export net sales, which we define as sales made outside of mainland France, were €25.9 million, which represented 73% of total
net sales.
As part
of our business, we are engaged in sales and marketing activities with hospitals, clinics, distributors or agents in countries
on a worldwide basis where we can provide our minimally invasive therapeutic solutions to patients with prostate cancer or urinary
stones. The following information complies with the sub-section “Disclosure of Certain Activities Relating to Iran”
of the Section 13 of the U.S. Securities Exchange Act of 1934 as amended: in 2015 we honored warranty contracts on previous sales
of lithotripsy devices to three Iranian public hospitals in order to provide the hospitals with the necessary disposables and services
to treat patients with kidney stones using our devices. As part of these warranty commitments, in 2016 we did not invoice any medical
equipment to the hospitals.
Legal Proceedings
From time to time, we may become involved
in legal proceedings or be subject to claims arising in the ordinary course of our business. Regardless of the outcome, litigation
can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
On August 4, 2014, Mark Eaton filed a purported
class action lawsuit in the United States District Court for the Southern District of New York, asserting that the Company, Marc
Oczachowski, and Eric Soyer (our former Chief Financial Officer) violated federal securities laws Section 10(b) and 20(a) of the
Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by issuing materially false and misleading statements about
the Company’s business operations and prospects particularly concerning the Company’s Ablatherm-HIFU PMA file under
review by the FDA that caused the price of the Company’s American Depository Receipts to be artificially inflated during
the period from February 1, 2013 to July 30, 2014. On August 6, 2014, Ronnie Haddad filed a second purported class action lawsuit,
also in the United States District Court for the Southern District of New York, asserting similar claims.
On October 24, 2014, the related cases were
consolidated by the United States District Court for the Southern District of New York and a lead plaintiff and lead counsel were
appointed.
On December 22, 2014, the lead plaintiff filed
an amended complaint that no longer included Mr. Soyer. The amended complaint alleges that the Company and Mr. Oczachowski breached
their obligations under the Exchange Act in various ways, including by misrepresenting and failing to disclose allegedly material
information about the safety and efficacy of treatment with Ablatherm-HIFU, and the Company’s interactions with the FDA.
The complaint seeks unspecified damages, interest, costs, and fees, including attorneys’ and experts’ fees.
On December 31, 2014, we accrued €206
thousand as legal costs to be incurred by the Company in relation to this litigation.
On February 20, 2015, the defendants, including
the Company, filed a motion to dismiss the action.
On September 14, 2015, we received a confirmation
of the dismissal of our class action. On November 11, 2015, we announced the appeals period had concluded with no notice of appeal
had been filed by the plaintiffs. The remaining accrued amount was reversed as of December 31, 2015.
Dividends and Dividend Policy
The payment and amount of dividends depend on
our earnings and financial condition and such other factors that our Board of Directors deems relevant. Dividends are subject to
recommendation by the Board of Directors and a vote by the shareholders at the shareholders’ ordinary general meeting. Dividends,
if any, would be paid in euro and, with respect to ADSs, would be converted at the then-prevailing exchange rate into U.S. dollars.
Holders of ADSs will be entitled to receive payments in respect of dividends on the underlying Shares in accordance with the Deposit
Agreement.
No dividends were paid with respect to fiscal
years 2009 through 2015, and we do not anticipate paying any dividends for the foreseeable future. Thereafter, any declaration
of dividends on our shares as well as the amount and payment will be determined by majority vote of the holders of our shares at
an ordinary general meeting, following the recommendation of our Board of Directors. Such declaration will depend upon, among other
things, future earnings, if any, the operating and financial condition of our business, our capital requirements, general business
conditions and such other factors as our Board of Directors deems relevant in its recommendation to shareholders.
Significant Changes as of April 3, 2017
Since January 1, 2017, we issued a total of 270,250 new ordinary
shares in the form of ADSs following the exercise of subscription options and March 2012 Warrants.
Item 9. The Offer and Listing
Description of Securities
The shares are traded solely in the form of
ADSs, each ADS representing one ordinary share. Each ADS may be evidenced by an American Depositary Receipt issued by The Bank
of New York, our Depositary. The principal United States trading market for the ADSs, which is also the principal trading market
for the ADSs overall, is the NASDAQ Global Market of the NASDAQ Stock Market, Inc. (‘‘NASDAQ”), on which the
ADSs are quoted under the symbol ‘‘EDAP.’’
Trading Market
The following tables set forth, for the years
2011 through 2016, the reported high and low sales prices of the ADSs on NASDAQ.
|
|
NASDAQ
|
|
|
High
|
|
Low
|
|
|
$
|
2016
|
|
|
4.80
|
|
|
|
2.43
|
|
2015
|
|
|
6.57
|
|
|
|
2.26
|
|
2014
|
|
|
6.05
|
|
|
|
1.15
|
|
2013
|
|
|
4.94
|
|
|
|
1.98
|
|
2012
|
|
|
2.85
|
|
|
|
1.43
|
|
The following tables set forth, for the years
2015 and 2016, and through March 17, 2017, the reported high and low sales prices of the ADSs on NASDAQ for each full financial
quarter:
|
|
NASDAQ
|
|
|
High
|
|
Low
|
|
|
$
|
2017:
|
|
|
|
|
|
|
|
|
Through March 17, 2017
|
|
|
3.62
|
|
|
|
2.25
|
|
2016:
|
|
|
|
|
|
|
|
|
First Quarter
|
|
|
4.74
|
|
|
|
2.89
|
|
Second Quarter
|
|
|
4.80
|
|
|
|
3.00
|
|
Third Quarter
|
|
|
3.42
|
|
|
|
2.43
|
|
Fourth Quarter
|
|
|
3.60
|
|
|
|
2.59
|
|
2015:
|
|
|
|
|
|
|
|
|
First Quarter
|
|
|
4.09
|
|
|
|
2.26
|
|
Second Quarter
|
|
|
3.69
|
|
|
|
2.59
|
|
Third Quarter
|
|
|
6.00
|
|
|
|
2.76
|
|
Fourth Quarter
|
|
|
6.57
|
|
|
|
3.05
|
|
The following table sets forth, for the most
recent six months (from September 2016 through March 17, 2017), the reported high and low sale prices of the ADSs on NASDAQ for
each month:
|
|
NASDAQ
|
|
|
High
|
|
Low
|
2017:
|
|
$
|
January
|
|
|
3.62
|
|
|
|
3.10
|
|
February
|
|
|
3.30
|
|
|
|
2.25
|
|
March (through March 17, 2017)
|
|
|
3.16
|
|
|
|
2.50
|
|
2016:
|
|
|
|
|
|
|
|
|
September
|
|
|
3.04
|
|
|
|
2.73
|
|
October
|
|
|
2.93
|
|
|
|
2.60
|
|
November
|
|
|
3.60
|
|
|
|
2.59
|
|
December
|
|
|
3.40
|
|
|
|
2.97
|
|
Item 10. Additional Information
Memorandum and Articles of Association
Set forth below is a brief summary of significant
provisions of our by-laws (or
statuts
) and applicable French laws. This is not a complete description and is qualified in
its entirety by reference to our by-laws, a translation of which is provided in Exhibit 1.1 to this annual report. Each time they
are modified, which can only occur with the approval of a two third majority of the shareholders present or represented at a shareholders’
meeting, we file copies of our
statuts
with, and such by-laws are publicly available from, the Registry of Commerce and
Companies in Lyon, France, under number 316 488 204.
Our corporate affairs are governed by our by-laws
and by Book II of the French Commercial Code, as amended.
Our by-laws were last updated in January 2017
to reflect the increases in share capital related to the issuance of additional shares following the exercise of warrants and options
in the course of 2016
.
Corporate Purposes
Pursuant to Article 2 of the by-laws, the
purpose of the Company is:
-
|
|
the taking of financial interests, under whatever form, in all French or foreign groups,
companies or businesses which currently exist or which may be created in the future, mainly through contribution, subscription
or purchasing of stocks or shares, obligations or other securities, mergers, holding companies, groups, alliances or partnerships;
|
-
|
|
the management of such financial investments;
|
-
|
|
the direction, management, control and coordination of its subsidiaries and interests;
|
-
|
|
the provision of all administrative, financial, technical or other services; and
|
-
|
|
generally, all transactions of whatever nature, whether financial, commercial, industrial,
civil, relating to property and/or real estate, which may be connected directly or indirectly, in whole or in part, to the Company’s
purposes or to any similar or related purposes which may favor the extension or development of such purpose.
|
Board of Directors
The Board of Directors is currently composed
of four members, all of which were appointed by the shareholders for a period of six years expiring on the date of the annual general
shareholders’ meeting approving the financial results for fiscal year 2019. See Item 6, ‘‘Directors, Senior Management
and Employees.’’ A director’s term ends at the end of the ordinary general shareholders” meeting convened
to vote on the accounts of the then-preceding fiscal year and held in the year during which the term of such director comes to
an end. Directors may be re-elected; a director may also be dismissed at any time at the shareholders’ meeting.
Each director must own at least one share during
his/her term of office. If, at the time of his/her appointment, a director does not own the required number of shares or if during
his/her term, he/she no longer owns the required number of shares, he/she will be considered to have automatically resigned if
he/she fails to comply with the shareholding requirement within three months.
An individual person may not be a member of
more than five Boards of Directors or Supervisory Boards in corporations (
société anonyme
) registered in France;
directorships held in controlled companies (as defined by Section L.233-16 of the French Commercial Code) by the Company are not
taken into account.
In the event of the death or resignation of
one or more directors, the Board of Directors may make provisional appointments to fill vacancies before the next general shareholders’
meetings. These provisional appointments must be ratified by the next ordinary shareholders meeting. Even if a provisional appointment
is not ratified, resolutions and acts previously approved by the Board of Directors nonetheless remain valid.
If the number of Directors falls below the compulsory
legal minimum, the remaining directors must immediately convene an ordinary general shareholders’ meeting to reach a full
Board of Directors.
Any director appointed in replacement of another
director whose term has not expired remains in office only for the remaining duration of the term of his predecessor.
One of our employees may be appointed to serve
as a director. His/her employment contract must include actual work obligations. In this case, he/she does not lose the benefit
of his/her employment contract.
The number of directors that have employment
contracts with the Company may not exceed one third of the directors then in office and in any case, a maximum of five members.
Pursuant to our by-laws, a director may not
be older than eighty-five years of age. If a director reaches this limit during his/her term, such director is automatically considered
to have resigned at the next general shareholders meeting.
A director cannot borrow money from the Company.
The Board of Directors determines the direction
of our business and supervises its implementation. Within the limits set out by the corporate purposes and the powers expressly
granted by law to the general shareholders’ meeting, the Board of Directors may deliberate upon our operations and make any
decisions in accordance with our business. A director must abstain from voting on matters in which the director has an interest.
The resolutions passed in a meeting of the Board of Directors are valid only if a quorum of half of the Directors is reached.
French law provides that the functions of Chairman
of the Board and Chief Executive Officer in a French
société anonyme
may be distinct and held by two separate
individuals.
The Chairman of the Board
The Board of Directors must elect one of its
members as Chairman of the Board of Directors, who must be an individual. The Board of Directors determines the duration of the
term of the Chairman, which cannot exceed that of his/her tenure as a director. The Board of Directors may revoke the Chairman
at any time. The Chairman’s compensation is determined by the Board of Directors, upon recommendation of the Compensation
Committee.
The Chairman represents the Board of Directors
and organizes its work. The Chairman reports on the Board’s behalf to the general shareholders’ meeting. The Chairman
is responsible for ensuring the proper functioning of our governing bodies and that the Board members have the means to perform
their duties.
Pursuant to Section 706-43 of the French Criminal
Proceedings Code, the Chairman may validly delegate to any person he/she chooses the power to represent us in any criminal proceedings
that we may face.
As with any other Director, the Chairman may
not be over eighty-five years old. In case the Chairman reaches this limit during his/her tenure, he/she will automatically be
considered to have resigned. However, his/her tenure is extended until the next Board of Directors meeting, during which his/her
successor will be appointed. Subject to the age limit provision, the Chairman of the Board may also be re-elected.
The Chief Executive Officer
We are managed by the Chairman of the Board
of Directors or by an individual elected by the Board of Directors bearing the title of Chief Executive Officer. The choice between
these two methods of management belongs to the Board of Directors and must be made pursuant to our by-laws. On March 31, 2007,
the Board of Directors appointed Mr. Marc Oczachowski as Chief Executive Officer.
The Chief Executive Officer is vested with the
powers to act under all circumstances on behalf of the Company, within the limits set out by the Company’s corporate purposes,
and subject to the powers expressly granted by law to the Board of Directors and the general shareholders’ meeting.
The Chief Executive Officer represents the Company
with respect to third parties. The Company is bound by any acts of the Chief Executive Officer even if they are contrary to corporate
purposes, unless it is proven that the third party knew such act exceeded the Company’s corporate purposes or could not ignore
it in light of the circumstances. Publication of the by-laws alone is not sufficient evidence of such knowledge.
The Chief Executive Officer’s compensation
is set by the Board of Directors, upon recommendation of the Compensation Committee. The Chief Executive Officer can be revoked
at any time by the Board of Directors. If such termination is found to be unjustified, damages may be allocated to the Chief Executive
Officer, except when the Chief Executive Officer is also the Chairman of the Board.
The Chief Executive Officer may not hold another
position as Chief Executive Officer or member of a Supervisory Board in a corporation (
société anonyme
) registered
in France except when (a) such company is controlled (as referred to in Section L.233-16 of the French Commercial Code) by the
Company and (b) when this controlled company’s shares are not traded on a regulated market.
Pursuant to our by-laws, the Chief Executive
Officer may not be over seventy years old. In case the Chief Executive Officer reaches this limit during his/her office, he/she
is automatically considered to have resigned. However, his/her tenure is extended until the next Board of Directors meeting, during
which his/her successor must be appointed.
Dividend and Liquidation Rights (French
Law)
Net income in each fiscal year, increased
or reduced, as the case may be, by any profit or loss of the Company carried forward from prior years, less any contributions to
legal reserves, is available for distribution to our shareholders as dividends, subject to the requirements of French law and our
by-laws.
Under French law and our by-laws, we are required
to allocate 5% of our net profits in each fiscal year to a legal reserve fund until the amount in such reserve fund is equal to
10% of the nominal amount of the registered capital. The legal reserve is distributable only upon the liquidation of the Company.
Our shareholders may, upon recommendation of
the Board of Directors, decide to allocate all or a part of distributable profits, if any, among special or general reserves, to
carry them forward to the next fiscal year as retained earnings, or to allocate them to the shareholders as dividends.
Our by-laws provide that, if so agreed by the
shareholders, reserves that are available for distribution under French law and our by-laws may be distributed as dividends, subject
to certain limitations.
If we have made distributable profits since
the end of the preceding fiscal year (as shown on an interim income statement certified by our statutory auditors), the Board of
Directors has the authority under French law, without the approval of shareholders, to distribute interim dividends to the extent
of such distributable profits. We have never paid interim dividends.
Under French law, dividends are distributed
to shareholders pro rata according to their respective shareholdings. Dividends are payable to holders of shares outstanding on
the date of the annual shareholders' meeting deciding the distribution of dividends, or in the case of interim dividends, on the
date of the Board of Directors meeting approving the distribution of interim dividends. However, holders of newly issued shares
may have their rights to dividends limited with respect to certain fiscal years. The actual dividend payment date is decided by
the shareholders in an ordinary general meeting or by the Board of Directors in the absence of such a decision by the shareholders.
The payment of the dividends must occur within nine months from the end of our fiscal year. Under French law, dividends not claimed
within five years of the date of payment revert to the French State.
If the Company is liquidated, our assets remaining
after payment of our debts, liquidation expenses and all of our remaining obligations will be distributed first to repay in full
the nominal value of the shares, then the surplus, if any, will be distributed pro rata among the shareholders based on the nominal
value of their shareholdings and subject to any special rights granted to holders of priority shares, if any. Shareholders are
liable for corporate liabilities only up to the par value of the shares they hold and are not liable to further capital calls of
the Company.
Changes in Share Capital (French Law)
Our share capital may be increased only with
the approval of two thirds of the shareholders voting or represented at an extraordinary general meeting, following a recommendation
of the Board of Directors. Increases in the share capital may be effected either by the issuance of additional shares (including
the creation of a new class of shares) or by an increase in the nominal value of existing shares. Additional Shares may be issued
for cash or for assets contributed in kind, upon the conversion of debt securities previously issued by the Company, by capitalization
of reserves, or, subject to certain conditions, in satisfaction of indebtedness incurred by the Company. Dividends paid in the
form of shares may be distributed in lieu of payment of cash dividends, as described above under ‘‘—Dividend
and Liquidation Rights (French law).’’ French law permits different classes of shares to have liquidation, voting and
dividend rights different from those of the outstanding ordinary shares, although we only have one class of shares.
Our share capital may be decreased only with
the approval of two thirds of the shareholders voting or represented at an extraordinary general meeting. The share capital may
be reduced either by decreasing the nominal value of the shares or by reducing the number of outstanding shares. The conditions
under which the registered capital may be reduced will vary depending upon whether or not the reduction is attributable to losses
incurred by the Company. The number of outstanding shares may be reduced either by an exchange of shares or by the repurchase and
cancellation by the Company of its shares. Under French law, all the shareholders in each class of shares must be treated equally
unless the inequality in treatment is accepted by the affected shareholder. If the reduction is not attributable to losses incurred
by us, each shareholder will be offered an opportunity to participate in such capital reduction and may decide whether or not to
participate therein.
Repurchase of Shares (French Law)
Pursuant to French law, the Company may not
acquire its own shares except (a) to reduce its share capital under certain circumstances with the approval of the shareholders
at an extraordinary general meeting or (b) to provide shares for distribution to employees under a profit sharing or a stock option
plan. However, the Company may not hold more than 10% of its shares then-issued. A subsidiary of the Company is prohibited by French
law from holding shares of the Company and, in the event it becomes a shareholder of the Company, such shareholder must transfer
all the shares of the Company that it holds.
Attendance and Voting at Shareholders’
Meetings (French Law)
In accordance with French law, there are two
types of general shareholders’ meetings, ordinary and extraordinary. Ordinary general meetings are required for matters such
as the election of directors, the appointment of statutory auditors, the approval of the report prepared by the Board of Directors
and the annual accounts, the declaration of dividends and the issuance of (non-convertible) bonds.
Extraordinary general meetings are required
for approval of matters such as amendments to the Company’s by-laws, modification of shareholders’ rights, approval
of mergers, increases or decreases in share capital (including a waiver of preferential subscription rights), the creation of a
new class of shares, the authorization of the issuance of investment certificates or securities convertible or exchangeable into
shares and for the sale or transfer of substantially all of the Company’s assets.
The Board of Directors is required to convene
an annual ordinary general shareholders’ meeting, which must be held within six months of the end of our fiscal year, for
approval of the annual accounts. Other ordinary or extraordinary meetings may be convened at any time during the year. Shareholders’
meetings may be convened by the Board of Directors or, if the Board of Directors fails to call such a meeting, by our statutory
auditors or by a court-appointed agent. The court may be requested to appoint an agent either by one or more shareholders holding
at least 5% of the our registered capital or by an interested party under certain circumstances, or, in case of an urgent matter,
by the Work Council (
Comité d’entreprise
) representing the employees. The notice calling a meeting must state
the agenda for such meeting.
French law provides that, at least 15 days before
the date set for any general meeting on first notice, and at least ten days before the date set for any general meeting on second
notice, notice of the meeting (
avis de convocation
) must be sent by mail to all holders of properly registered shares who
have held such shares for more than one month before the date of the notice. A preliminary written notice (
avis de réunion
)
must be sent to each shareholder who has requested to be notified in writing. Under French law, one or several shareholders together
holding a specified percentage of shares may propose resolutions to be submitted for approval by the shareholders at the meeting.
Upon our request, The Bank of New York Mellon will send to holders of ADSs notices of shareholders’ meetings and other reports
and communications that are made generally available to shareholders. The Works Council may also require the registration of resolution
proposals on the agenda.
Attendance and exercise of voting rights at
ordinary and extraordinary general shareholders’ meetings are subject to certain conditions. Shareholders deciding to exercise
their voting rights must have their shares registered in their names in the shareholder registry maintained by or on behalf of
the Company before the meeting. An ADS holder must timely and properly return its voting instruction card to the Depositary to
exercise the voting rights relating to the shares represented by its ADSs. The Depositary will use its reasonable efforts to vote
the underlying shares in the manner indicated by the ADS holder. In addition, if an ADS holder does not timely return a voting
instruction card or the voting instruction card received is improperly completed or blank, that holder will be deemed to have given
the Depositary a proxy to vote, and the Depositary will vote in favor of all proposals recommended by the Board of Directors and
against all proposals that are not recommended by the Board of Directors.
All shareholders who have properly registered
their shares have the right to participate in general shareholders’ meetings, either in person, by proxy, or by mail, and
to vote according to the number of shares they hold. Each share confers on the shareholder the right to one vote. Under French
law, an entity we control directly or indirectly is prohibited from holding shares in the Company and, in the event it becomes
a shareholder, shares held by such entity would be deprived of voting rights. A proxy may be granted by a shareholder whose name
is registered on our share registry to his or her spouse, to another shareholder or to a legal representative, in the case of a
legal entity, or by sending a proxy in blank to the Company without nominating any representatives. In the latter case, the Chairman
of the shareholders’ meeting will vote such blank proxy in favor of all resolutions proposed by the Board of Directors and
against all others.
The presence in person or by proxy of shareholders
having not less than 20% (in the case of an ordinary general meeting or an extraordinary general meeting deciding upon any capital
increase by capitalization of reserves) or 25% (in the case of any other extraordinary general meeting) of the shares entitled
to vote is necessary to reach a quorum. If a quorum is not reached at any meeting, the meeting is adjourned. Upon reconvening of
an adjourned meeting, there is no quorum requirement in the case of an ordinary general meeting or an extraordinary general meeting
deciding upon any capital increase by capitalization of reserves. The presence in person or by proxy of shareholders having not
less than 20% of the Shares is necessary to reach a quorum in the case of any other type of extraordinary general meeting.
At an ordinary general meeting or an extraordinary
general meeting deciding upon any capital increase by capitalization of reserves, a simple majority of the votes of the shareholders
present or represented by proxy is required to approve a resolution. At any other extraordinary general meeting, two-thirds of
the votes cast is required. However, a unanimous vote is required to increase liabilities of shareholders. Abstention from voting
by those present or represented by proxy is viewed as a vote against the resolution submitted to a vote.
In addition to his/her rights to certain information
regarding the Company, any shareholder may, during the two-week period preceding a shareholders’ meeting, submit to the Board
of Directors written questions relating to the agenda for the meeting. The Board of Directors must respond to such questions during
the meeting.
Under French law, shareholders can nominate
individuals for election to the Board of Directors at a shareholders’ meeting. When the nomination is part of the agenda
of the shareholders’ meeting, the nomination must contain the name, age, professional references and professional activity
of the nominee for the past five years, as well as the number of shares owned by such candidate, if any. In addition, if the agenda
for the shareholders’ meeting includes the election of members of the Board of Directors, any shareholder may require, during
the meeting, the nomination of a candidate for election at the Board of Directors at the shareholders’ meeting, even if such
shareholder has not followed the nomination procedures. Under French law, shareholders cannot elect a new member of the Board of
Directors at a general shareholders meeting if the agenda for the meeting does not include the election of a member of the Board
of Directors, unless such nomination is necessary to fill a vacancy due to the previous resignation of a member.
As set forth in our by-laws, shareholders’
meetings are held at the registered office of the Company or at any other locations specified in the written notice. We do not
have staggered or cumulative voting arrangements for the election of Directors.
Preferential Subscription Rights (French
Law)
Shareholders have preferential rights to subscribe
for additional shares issued by the Company for cash on a pro rata basis (or any equity securities of the Company or other securities
giving a right, directly or indirectly, to equity securities issued by the Company). Shareholders may waive their preferential
rights, either individually or at an extraordinary general meeting under certain circumstances. Preferential subscription rights,
if not previously waived, are transferable during the subscription period relating to a particular offering of shares. U.S. holders
of ADSs may not be able to exercise preferential rights for Shares underlying their ADSs unless a registration statement under
the Securities Act is effective with respect to such rights or an exemption from the registration requirement thereunder is available.
Form and Holding of Shares (French Law)
Form of Shares
Our by-laws provide that shares can only be held in registered
form.
Holding of Shares
The shares are registered in the name of the
respective owners thereof in the registry maintained by or on behalf of the Company.
Stock certificates evidencing shares, in a manner
comparable to that in the United States, are not issued by French companies, but we may issue or cause to be issued confirmations
of shareholdings registered in such registry to the persons in whose names the shares are registered. Pursuant to French law, such
confirmations do not constitute documents of title and are not negotiable instruments.
Ownership of ADSs or Shares by Non-French
Residents (French Law)
Under French law, there is no limitation on
the right of non-French residents or non-French security holders to own, or where applicable, vote securities of a French company.
A non-resident of France must file a
déclaration administrative
, or administrative notice, with French authorities
in connection with the acquisition of a controlling interest in any French company. Under existing administrative rulings, ownership,
by a non-resident of France or a French corporation which is itself controlled by a foreign national, of 33.33% or more of a company’s
share capital or voting rights is regarded as a controlling interest, but a lower percentage may be held to be a controlling interest
in certain circumstances (depending upon such factors as the acquiring party’s intentions, its ability to elect directors
or financial reliance by the French company on the acquiring party).
Also, certain foreign investments in companies
incorporated under French laws are subject to the prior authorization from the French Minister of the Economy, where all or part
of the target’s business and activity relate to a strategic sector, such as energy, transportation, public health, telecommunications,
etc.
Certain Exemptions (French Law)
Under the U.S. securities laws, as a foreign
private issuer, we are exempt from certain rules that apply to domestic U.S. issuers with equity securities registered under the
U.S. Securities Exchange Act of 1934, including the proxy solicitation rules and the rules requiring disclosure of share ownership
by directors, officers and certain shareholders. We are also exempt from certain of the current NASDAQ corporate governance requirements.
For more information on these exemptions, see Item 16 G, ‘‘Corporate Governance —Exemptions from Certain NASDAQ
Corporate Governance Rules.’’
Enforceability of Civil Liabilities (French
Law)
We are a
société anonyme
,
or limited liability corporation, organized under the laws of the Republic of France. The majority of our directors and executive
officers reside in the Republic of France. All or a substantial portion of our assets and the assets of such persons are located
outside the United States. As a result, it may not be possible for investors to effect service of process within the United States
upon such persons or to enforce, either inside or outside the United States, judgments against such persons obtained in U.S. courts
or to enforce in U.S. court judgments obtained against such persons in courts in jurisdictions outside the United States, in each
case, in any action predicated upon the civil liability provisions of the federal securities laws of the United States. In an original
action brought in France predicated solely upon the U.S. federal securities laws, French courts may not have the requisite jurisdiction
to grant the remedies sought, and actions for enforcement in France of judgments of U.S. courts rendered against French persons
referred to in the second sentence of this paragraph would require such French persons to waive their right under Article 15 of
the French Civil Code to be sued in France only. We believe that no such French persons have waived such right with respect to
actions predicated solely upon U.S. federal securities laws. In addition, actions in the United States under the U.S. federal securities
laws could be affected under certain circumstances by the French law of July 16, 1980, which may preclude or restrict obtaining
evidence in France or from French persons in connection with such actions.
Material Contracts
On May 28, 2013, pursuant to a securities purchase
agreement, we issued Investor Warrants which will expire on November 29, 2018. The Investor Warrants are exercisable, from November
29, 2013, at the option of the holder, upon the surrender of the Investor Warrants to us and the payment in cash of the exercise
price of $4.25 per ordinary share in the form of ADSs. We also issued Placement Agent Warrants with an exercise price of $5.00
per ordinary share in the form of ADSs. The Placement Agent Warrants are exercisable from November 29, 2013 and expire on May 28,
2016. With respect to both the Investor Warrants and the Placement Agent Warrants (together, the “May 2013 Warrants”),
the exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar
events affecting our ordinary shares. The holders of the May 2013 Warrants are entitled to 20 days’ notice before the record
date for certain distributions to holders of our ordinary shares. If certain “fundamental transactions” occur, such
as a merger, consolidation, sale of substantially all of our assets, tender offer or exchange offer with respect to our ordinary
shares or reclassification of our ordinary shares, the holders of the May 2013 Warrants will be entitled to receive thereafter
in lieu of our ordinary shares, the consideration (if different from ordinary shares) that the holders of the May 2013 Warrants
would have been entitled to receive upon the occurrence of the fundamental transaction as if the May 2013 Warrants had been exercised
immediately before the fundamental transaction. If any holder of ordinary shares is given a choice of consideration to be received
in the fundamental transaction, then the holders of the May 2013 Warrants shall be given the same choice upon the exercise of the
May 2013 Warrants following the fundamental transaction. A copy of the form of Investor Warrant was furnished to the SEC on our
report on Form 6-K dated May 28, 2013. The foregoing description is qualified in its entirety by reference to the full text of
the Form 6-K.
On April 14, 2016, pursuant to a securities
purchase agreement dated April 7, 2016, we issued Investor Warrants which will expire on October 14, 2018 (the “April 2016
Warrants”). The April 2016 Warrants are exercisable, from October 14, 2016, at the option of the holder, upon the surrender
of the Investor Warrants to us and the payment in cash of the exercise price of $4.50 per ordinary share in the form of ADSs. With
respect to the April 2016 Warrants, the exercise price is subject to appropriate adjustment in the event of stock dividends, stock
splits, reorganizations or similar events affecting our ordinary shares. The holders of the April 2016 Warrants are entitled to
20 days’ notice before the record date for certain distributions to holders of our ordinary shares. If certain “fundamental
transactions” occur, such as a merger, consolidation, sale of substantially all of our assets, tender offer or exchange offer
with respect to our ordinary shares or reclassification of our ordinary shares, the holders of the April 2016 Warrants will be
entitled to receive thereafter in lieu of our ordinary shares, the consideration (if different from ordinary shares) that the holders
of the April 2016 Warrants would have been entitled to receive upon the occurrence of the fundamental transaction as if the April
2016 Warrants had been exercised immediately before the fundamental transaction. If any holder of ordinary shares is given a choice
of consideration to be received in the fundamental transaction, then the holders of the April 2016 Warrants shall be given the
same choice upon the exercise of the April 2016 Warrants following the fundamental transaction. A copy of the form of Investor
Warrant was furnished to the SEC on our report on Form 6-K dated April 14, 2016. The foregoing description is qualified in its
entirety by reference to the full text of the Form 6-K.
Exchange Controls
Under current French foreign exchange control
regulations, there are no limitations on the amount of cash payments that we may remit to residents of foreign countries. Laws
and regulations concerning foreign exchange controls do require, however, that all payments or transfers of funds made by a French
resident to a non-resident be handled by an accredited intermediary.
Under current French law, there is no limitation
on the right of non-French residents or non-French security holders to own, or where applicable, vote securities of a French company.
A non-resident of France must file a
déclaration administrative
, or administrative notice, with French authorities
in connection with the acquisition of a controlling interest in any French company. Under existing administrative rulings, ownership
by a non-resident of France or a French corporation which is itself controlled by a foreign national, of 33
1
/
3
%
or more of a French company’s share capital or voting rights is regarded as a controlling interest, but a lower percentage
may be held to be a controlling interest in certain circumstances (depending upon such factors as the acquiring party’s intentions,
its ability to elect directors or financial reliance by the French company on the acquiring party).
Certain Income Tax Considerations
The following generally summarizes the material
French and US tax consequences of purchasing, owning and disposing of Shares or ADS (the “Securities”). The statements
set forth below are based on the applicable laws, treaties and administrative interpretations of France and the United States as
of the date hereof, all of which are subject to change.
This discussion is intended only as a descriptive
summary and does not purport to be a complete analysis or listing of all potential tax effects of the purchase, ownership or disposition
of Securities. It does not constitute legal or tax advice.
Investors should consult their own tax advisors
regarding the tax consequences of the purchase, ownership and disposition of Securities in light of their particular circumstances,
including especially the laws of all jurisdictions in which they are resident for tax purposes.
French Taxation
The following summary of the French tax consequences
of purchasing and disposing of Securities does not address the treatment of Securities that are held by a resident of France (except
for purposes of describing related tax consequences for other holders) or in connection with a permanent establishment or fixed
base through which a holder carries on business or performs personal services in France, or by a person that owns, directly or
indirectly, 5% or more of the stock of the Company. Moreover, the following discussion of the tax treatment of dividends only deals
with distributions made on or after January 1, 2016.
There are currently no procedures available
for holders that are not U.S. residents to claim tax treaty benefits in respect of dividends received on Securities registered
in the name of a nominee. Such holders should consult their own tax advisors about the consequences of owning and disposing of
Securities.
French law provides for specific rules relating
to trusts, in particular specific tax and filing requirements as well as modifications to wealth, estate and gift taxes as they
apply to trusts. Given the complex nature of these new rules and the fact that their application varies depending on the status
of the trust, the grantor, the beneficiary and the assets held in the trust, the following summary does not address the tax treatment
of Securities held in a trust.
If Securities are held in trust, the grantor, trustee and beneficiary are urged to consult their
own tax adviser regarding the specific tax consequences of acquiring, owning and disposing of Securities.
Taxation of Dividends on Securities - Withholding
Tax
Dividends paid by a French corporation, such
as EDAP, to non-residents normally are subject to a 30% French withholding tax (reduced to 21% when non-residents are individuals
resident from one of the countries of the European Economic Area and 15% for distributions made to not-for-profit organizations
with a head office in a Member State of the European Economic Area which would be subject to the tax regime set forth under article
206-5 of the French General Tax Code if their head office was located in France and which meet the criteria set forth in the administrative
guidelines BOI-RPPM-RCM-30-30-10-70-20120912, n°130).
Dividends paid by a French corporation transferred
to non-cooperative States or territories (Etat ou territoire non coopératif), within the meaning of Article 238-0 A of the
French General Tax Code (a “Non-Cooperative State”), will be subject to French withholding tax at a rate of 75% irrespective
of the tax residence of the beneficiary of the dividends, if the dividends are received in such States or territories (subject
to certain exceptions and the more favorable provisions of an applicable double tax treaty, provided that the double tax treaty
is found to apply and the relevant conditions are fulfilled). The list of Non-Cooperative States is published by ministerial executive
order, which is updated from time to time. However, non-resident holders that are entitled to and comply with the procedures for
claiming benefits under an applicable tax treaty may be subject to a reduced rate (generally 15%) of French withholding tax. If
a non-resident holder establishes its entitlement to treaty benefits prior to the payment of a dividend, then French tax generally
will be withheld at the reduced rate provided under the treaty.
Taxation on Sale or Disposition of Securities
Generally, holders, who are not residents of
France for tax purposes, will not be subject to any French income tax or capital gains tax upon the sale or the disposal of Securities
unless:
-
|
|
the holders have held more than 25% of EDAP dividend rights, known as (“droits
aux bénéfices sociaux”), at any time during the preceding five years, either directly or indirectly, and,
as relates to individuals, alone or with relatives; or
|
-
|
|
the holders are established or domiciled in a Non-Cooperative State, in which case
they will be subject to a 75% tax on your capital gain.
|
If the holders are resident in a State with
which France has signed a double tax treaty that contains more favorable provisions, the holders may be exempt from any French
income or capital gains tax when they sell or dispose of any Securities even if one of the above statements applies to them.
Transfers of Securities issued by a listed French
company such as EDAP will not be subject to French registration or stamp duty if such transfers are not evidenced by a written
agreement (acte). However, if the transfer is evidenced by a written agreement executed either in France or outside France, the
transfer of Securities will be subject to a registration duty of 0.1% assessed on the sale price.
Pursuant to Article 235 ter ZD of the French
General Tax Code, purchases of shares or ADS are subject to a 0.2% French tax on financial transactions provided that the market
capitalization of the issuer exceeds 1 billion euros as of December 1 of the year preceding the taxation year. The list of issuers
whose securities are subject to the tax as at January 1, 2016, has been published in the official guidelines of the French tax
authorities on December 21, 2015 (BOI-ANNX-000467-20151221). EDAP was not included in such list as its market capitalization did
not exceed 1 billion as at December 1, 2015. Therefore, purchases of EDAP’s securities are not subject to the French tax
on financial transactions.
Estate and Gift Tax
France imposes estate and gift tax on Securities
of a French company that are acquired by inheritance or gift. The tax applies without regard to the tax residence of the transferor.
However, France has entered into estate and gift tax treaties with a number of countries pursuant to which, assuming certain conditions
are met, residents of the treaty country may be exempted from such tax or obtain a tax credit.
Wealth Tax
Individuals who are not residents of France
for purposes of French taxation are not subject to a wealth tax (“impôt de solidarité sur la fortune”)
in France as a result of owning an interest in the share capital of a French corporation, provided that such ownership interest
is, directly and indirectly, less than 10% of the corporation’s share capital and does not enable the shareholder to exercise
influence over the corporation. Double taxation treaties may provide for a more favorable tax treatment.
Taxation of U.S. Holders
Shares
The following is a summary of the material French
and U.S. federal income tax consequences of the purchase, ownership and disposition of Securities by a holder that is a resident
of the United States for purposes of the Convention between the Government of the United States of America and the Government of
the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and
Capital of August 31, 1994, (the “Treaty”), which entered into force on December 30, 1995 (as amended by the protocol
described below and any subsequent protocols), and the tax regulations issued by the French tax authorities, and are fully eligible
for benefits under the Treaty ( a “U.S. holder”).
In particular, the United States and France
signed a protocol on January 13, 2009, that entered into force on December 23, 2009 and make several significant changes to the
Treaty, including changes to the “Limitation of Benefits” provision. U.S. holders are advised to consult their own
tax advisors regarding the effect the protocol may have on their eligibility for Treaty benefits in light of their own particular
circumstances.
A holder generally will be entitled to Treaty
benefits in respect of Securities if he is concurrently:
·
|
|
the beneficial owner of Securities (and the dividends paid with respect thereto);
|
·
|
|
an individual resident of the United States, a U.S. corporation, or a partnership,
estate or trust to the extent its income is subject to taxation in the United States in its hands or in the hands of its partners
or beneficiaries;
|
·
|
|
not also a resident of France for French tax purposes; and
|
·
|
|
not subject to an anti-treaty shopping article that applies in limited circumstances.
|
Special rules apply to pension funds and certain
other tax-exempt investors.
If a partnership holds Securities, the tax treatment
of a partner generally will depend on the status of the partner and the activities of the partnership. If a U.S. holder is a partner
in a partnership that holds Securities, the holder is urged to consult its own tax advisor regarding the specific tax consequences
of owning and disposing of its Securities.
For U.S. federal income tax purposes, a U.S.
holder’s ownership of our ADSs will be treated as ownership of our underlying ordinary shares.
This summary does not deal with Securities that
are not held as capital assets, and does not address the tax treatment of holders of ADSs that acquire them in “pre-release”
transactions or holders that are subject to special rules, such as banks, insurance companies, dealers in securities or currencies,
regulated investment companies, persons that elect mark-to-market treatment, persons holding Securities as a position in a synthetic
security, straddle or conversion transaction, persons that own, directly or indirectly, 5% or more of our voting stock or 5% or
more of our outstanding capital and persons whose functional currency is not the U.S. dollar.
This summary does not discuss the treatment
of Securities that are held in connection with a permanent establishment or fixed base through which a holder carries on business
or performs personal services in France. The summary is based on laws, treaties, regulatory interpretations and judicial decisions
in effect on the date hereof, all of which are subject to change. Such changes could apply retroactively and could affect the consequences
described below.
Holders should consult their own tax advisors
regarding the U.S. tax consequences of the purchase, ownership and disposition of Securities in the light of their particular circumstances,
including the effect of any state or local laws.
Dividends and Paying Agents
Generally, dividend distributions to non-residents
of France are subject to French withholding tax at a 30% rate (reduced to 21% when non-residents are individuals’ residents
from one of the countries of the European Economic Area) or to 75% if paid in non-cooperative States or territories, as defined
in Article 238-0 A of the French General Tax Code, irrespective of the tax residence of the beneficiary of the dividends if the
dividends are received in such States or territories. Eligible U.S. holders providing evidence of the entitlement to Treaty benefits
with respect to the dividend (art.30) under the ‘‘Limitation on Benefits’’ provision contained in the Treaty
who are U.S. residents, as defined pursuant to the provisions of the Treaty and who receive dividends in non-cooperative States
or territories, should not be subject to this 75% withholding tax rate.
Under the Treaty, the rate of French withholding
tax on dividends paid to an eligible U.S. holder as defined pursuant to the provisions of the Treaty and whose ownership of Securities
is not effectively connected with a permanent establishment or fixed base that such U.S. holder has in France is reduced to 15%,
or to 5% if such U.S. holder is a corporation and owns directly or indirectly at least 10% of the share capital of the issuing
company; such U.S. holder may claim a refund from the French tax authorities of the amount withheld in excess of the Treaty rates
of 15% or 5%, if any. For U.S. holders that are not individuals, the requirements for eligibility for Treaty benefits, including
the reduced 5% or 15% withholding tax rate, contained in the “Limitation on Benefits” provision of the Treaty are complicated,
and certain technical changes were made to these requirements the protocol of January 13, 2009. U.S. holders are advised to consult
their own tax advisers regarding their eligibility for Treaty benefits in light of their own particular circumstances.
French withholding tax will be withheld at the
5% or 15% Treaty rate if a U.S. holder has established before the date of payment that the holder is a resident of the United States
under the Treaty by following the simplified procedure described below.
The gross amount of dividends that a U.S. holder
receives (before the deduction of French withholding tax) generally will be subject to U.S. federal income taxation as ordinary
dividend income to the extent paid or deemed paid out of the current or accumulated earnings and profits of the Company (as determined
under U.S. federal income tax principles). Such dividends will not be eligible for the dividends received deduction generally allowed
to U.S. corporations. To the extent that an amount received by a U.S. holder exceeds the allocable share of current and accumulated
earnings and profits of the Company, such excess will be applied first to reduce such U.S. holder’s tax basis in its Securities
and then, to the extent it exceeds the U.S. holder’s tax basis, it will constitute capital gain from a deemed sale or exchange
of such Securities. As the Company does not maintain “earnings and profits” computations, holders should assume that
all distributions constitute dividends.
Subject to certain exceptions for short-term
and hedged positions, the U.S. dollar amount of dividends received by an individual with respect to the Securities is currently
subject to taxation at a maximum rate of 20% if the dividends are “qualified dividends.” Dividends paid on the Securities
will be treated as qualified dividends if (i) the issuer is eligible for the benefits of a comprehensive income tax treaty with
the United States that the IRS has approved for the purposes of the qualified dividend rules and (ii) the Company was not, in the
year prior to the year in which the dividend was paid, and is not, in the year in which the dividend is paid, a passive foreign
investment company, or PFIC. The Treaty has been approved for the purposes of the qualified dividend rules. Based on our audited
financial statements and relevant market and shareholder data, we do not believe we were a PFIC for U.S. federal income tax purposes
with respect to our 2015 taxable year. In addition, we do not anticipate it becoming a PFIC for the 2016 taxable year (as described
under “—Passive Foreign Investment Company Rules” below). Accordingly, dividends, if any, paid by us in 2015
to a U.S. holder would constitute “qualified dividends.”
Holders of Securities should consult their own
tax advisers regarding the availability of the reduced dividend tax rate in light of their own particular circumstances.
Dividends distributed with respect to the Securities
generally will be treated as dividend income from sources outside of the United States, and generally will be treated as “passive
category” (or, in the case of certain U.S. holders, “general category”) income for U.S. foreign tax credit purposes.
Subject to certain limitations, French income tax withheld in connection with any distribution with respect to the Securities may
be claimed as a credit against the U.S. federal income tax liability of a U.S. holder if such U.S. holder elects for that year
to credit all foreign income taxes. Alternatively, such French withholding tax may be taken as a deduction against taxable income.
Foreign tax credits will not be allowed for withholding taxes imposed in respect of certain short-term or hedged positions in securities
and may not be allowed in respect of certain arrangements in which a U.S. holder’s expected economic profit is insubstantial.
U.S. holders should consult their own tax advisors concerning the implications of these rules in light of their particular circumstances.
Dividends paid in euro will be included in the
income of a U.S. holder in a U.S. dollar amount calculated by reference to the exchange rate in effect on the date of receipt by
the holder (or, in the case of the ADSs, by the Depositary), regardless of whether the payment is in fact converted into U.S. dollars.
If such a dividend is converted into U.S. dollars on the date of receipt, a U.S. holder generally should not be required to recognize
foreign currency gain or loss in respect of the dividend income.
Capital Gains
Under the Treaty, a U.S. holder will not be
subject to French tax on any gain derived from the sale or exchange of Securities, unless the gain is effectively connected with
a permanent establishment or fixed base maintained by the holder in France.
For U.S. federal income tax purposes, gain or
loss realized by a U.S. holder on the sale or other disposition of Securities will be capital gain or loss, and will be long-term
capital gain or loss if the Securities were held for more than one year. The net amount of long-term capital gain recognized by
an individual U.S. holder generally is currently subject to taxation at a maximum rate of 20%. U.S. holders’ ability to offset
capital losses against ordinary income is limited.
Additional Issues For U.S. Holders
Procedures for Claiming Treaty Benefits
Pursuant to French official administrative guidelines
(BOFIP BOI-INT-DG-20-20-20-20-20120912), U.S. holders can either claim Treaty benefits under a simplified procedure or under the
normal procedure. The procedure to be followed depends on whether the application for Treaty benefits is filed before or after
the dividend payment.
Under the simplified procedure, in order to
benefit from the lower rate of withholding tax applicable under the Treaty before the payment of the dividend, a U.S. holder must
complete and deliver to the paying agent (through its account holder) a treaty form (Form 5000), to certify in particular that:
|
-
|
the U.S. holder is beneficially entitled to the dividend;
|
|
-
|
the U.S. holder is a U.S. resident within the meaning of the Treaty;
|
|
-
|
the dividend is not derived from a permanent establishment or a fixed base that the U.S. holder
has in France; and
|
|
-
|
the dividend received is or will be reported to the tax authorities in the United States.
|
For partnerships or trusts, claims for Treaty
benefits and related attestations are made by the partners, beneficiaries or grantors who also have to supply certain additional
documentation.
In order to be eligible for Treaty benefits,
pension funds and certain other tax-exempt U.S. holders must comply with the simplified procedure described above, though they
may be required to supply additional documentation evidencing their entitlement to those benefits.
If Form 5000 is not filed prior to the dividend
payment, a withholding tax will be levied at the 30% rate, and a holder would have to claim a refund for the excess under the normal
procedure by filing both Form 5000 and Form 5001 no later than December 31 of the second calendar year following the year in which
the dividend is paid.
Pension funds and certain other tax-exempt entities
are subject to the same general filing requirements as other U.S. holders except that they may have to supply additional documentation
evidencing their entitlement to these benefits.
Copies of Form 5000 and Form 5001 may be downloaded
from the French tax authorities’ website (www.impots.gouv.fr) and are also available from the U.S. Internal Revenue Service
and from the
Centre des Impôts des Non-Résidents
in France (10 rue du Centre 93160, Noisy-le-Grand).
Medicare Tax
Certain U.S. holders that are individuals, estates
or trusts are required to pay an additional 3.8% tax on, among other things, dividends on and capital gains from the sale or other
disposition of stock. U.S. holders that are individuals, estates or trusts should consult their tax advisors regarding the effect
of this legislation on their ownership and disposition of the Securities.
Passive Foreign Investment Company Rules
Unfavorable U.S. tax rules such as the PFIC
rules, apply to companies that are considered PFICs. The Company will be classified as a PFIC in a particular taxable year if either
(a) 75% or more of its gross income is treated as passive income for purposes of the PFIC rules; or (b) the average percentage
of the value of its assets that produce or are held for the production of passive income is at least 50%.
As explained above, the Company believes that
it was not a PFIC for U.S. tax purposes with respect to the year 2015, and also does not anticipate becoming a PFIC with respect
to the year 2016. However, as discussed in Form 20-Fs filed by the Company with respect to certain prior years the Company believes
that it was a PFIC in the past. Moreover, because the PFIC determination is made annually and is dependent upon a number of factors,
some of which are beyond the Company's control (including whether the Company continues to earn substantial amounts of operating
income as well as the market composition and value of the Company's assets), there can be no assurance that the Company will not
become a PFIC in future years.
U.S. holders that held Securities at any time
during the years when the Company was a PFIC and did not make certain U.S. tax elections (a "mark-to-market election"
or a "QEF election") will be subject to adverse tax treatment. For instance, such holders will be subject to a special
tax at ordinary income tax rates on certain dividends that the Company pays and on gains realized on the sale of Securities (“excess
distributions”) in all subsequent years, even though the Company ceased to qualify as a PFIC. The amount of this tax will
be increased by an interest charge to compensate for tax deferral, calculated as if the excess distributions had been earned ratably
over the period the U.S. holder held its Securities. It may be possible, in certain circumstances, for a holder to avoid the application
of the PFIC rules by making a "deemed sale" election for its taxable year that includes the last day of the Company’s
last taxable year during which it qualified as a PFIC. The PFIC rules are extremely complex, and holders should consult their own
tax advisers regarding the possible application of the PFIC rules to their Securities and the desirability and availability of
the above elections.
French Estate and Gift Tax
Under the estate and gift tax convention between
the United States and France dated November 24, 1978 (as amended by the protocol signed on December 8, 2004), a transfer of Securities
by gift or by reason of the death of a U.S. holder entitled to benefits under that convention generally will not be subject to
French gift or inheritance tax, so long as the donor or transferor was not domiciled in France at the time of the transfer, and
Securities were not used or held for use in the conduct of a business or profession through a permanent establishment or fixed
base in France.
French Wealth Tax
The French wealth tax does not generally apply
to Securities of a U.S. holder if the holder is a resident of the United States for purposes of the Treaty and does not own directly
or indirectly a shareholding exceeding 25% of the financial rights of EDAP.
U.S. Information Reporting and Backup Withholding Rules
Payments of dividends and sales proceeds that
are made within the United States or through certain U.S.-related financial intermediaries are subject to information reporting
and may be subject to backup withholding unless the holder (i) is a corporation or other exempt recipient or (ii) provides a taxpayer
identification number and certifies that no loss of exemption from backup withholding has occurred. Holders that are not U.S. persons
generally are not subject to information reporting or backup withholding. However, such a holder may be required to provide a certification
of its non- U.S. status in connection with payments received within the United States or through a U.S.-related financial intermediary.
Information with Respect to Foreign Financial
Assets
In addition, U.S. holders that are individuals
(and, to the extent provided in future regulations, entities) are subject to reporting obligations with respect to the shares,
securities, debt instruments and other obligations of a French corporation if the aggregate value of such assets and certain other
“specified foreign financial assets” exceeds $50,000. Significant penalties can apply if a U.S. holder fails to disclose
its specified foreign financial assets.
U.S. holders should also consider their possible
obligation to file online a FinCEN Form 114 Foreign Bank and Financial Accounts Report as a result of holding the Securities. U.S.
holders are urged to consult their tax advisors regarding these and any other reporting requirements that may apply with respect
to their Securities.
The discussion above is a general summary.
It does not cover all tax matters that may be important to you. You should consult your tax advisors regarding the application
of the U.S. federal tax rules to your particular circumstances, as well as the state, local, non-U.S. and other tax consequences
to you of the purchase, ownership and disposition of the Securities.
Statement by Experts
Not applicable.
Documents on Display
We file annual, periodic, and other reports
and information with the SEC. These materials, including this annual report and the exhibits hereto, may be inspected and copied
at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. The public may obtain information on the
operation of the SEC’s Public Reference Room by calling the SEC in the United States at +1 800 SEC 0330. Certain of our public
filings are also available on the SEC’s website at http://www.sec.gov (such documents are not incorporated by reference in
this annual report).
Subsidiary Information
Not applicable.
Item 11. Quantitative and Qualitative Disclosures about Market
Risk
We are exposed to market risk from changes
in both foreign currency exchange rates and interest rates. We do not hold or issue derivative or other financial instruments.
As of December 31, 2016, we had no outstanding foreign exchange sale or purchase contracts.
Exchange Rate Risk
Revenues and Expenses in Foreign Currencies
We are exposed to foreign currency exchange
rate risk because a significant portion of our costs are denominated in currencies other than those in which we earn revenues.
In 2016, approximately 78% of our total costs of sales and operating expenses were denominated in euro. During the same period,
approximately 58% of our sales were denominated in euro, the rest being denominated primarily in U.S. dollars and Japanese yen.
A uniform 10% strengthening in the value of
the euro as of December 31, 2016 relative to the U.S. dollar and the Japanese yen would have resulted in a decrease in income before
taxes and minority interests of approximately €9,000 for the year ended December 31, 2016, compared to a increase of approximately
€67,000 for the year ended December 31, 2015. A uniform 10% decrease in the value of the euro as of December 31, 2016 relative
to the U.S. dollar and the Japanese yen would have resulted in an increase in income before taxes and minority interests of approximately
€10,000 for the year ended December 31, 2016 as compared to a decrease of approximately €74,000 for the year ended December
31, 2015. This calculation assumes that the U.S. dollar and Japanese yen exchange rates would have changed in the same direction
relative to the euro. In addition to the direct effect of changes in exchange rates quantified above, changes in exchange rates
also affect the volume of sales.
We regularly assess the exposure of our receivables
to fluctuations in the exchange rates of the principal foreign currencies in which our sales are denominated (in particular, the
U.S. dollar and the Japanese yen) and, from time to time, hedge such exposure by entering into forward sale contracts for the amounts
denominated in such currencies that we expect to receive from our local subsidiaries. As of December 31, 2016 we had no outstanding
hedging instruments.
Financial Instruments and Indebtedness
Over the past three years, we also had exchange
rate exposures with respect to indebtedness and assets denominated in Japanese yen and U.S. dollars. Approximately €0.1 million,
€0.2 million and €0.2 million of our outstanding indebtedness at December 31, 2016, 2015 and 2014, respectively, were
denominated in Japanese yen. Approximately €3.9 million, €4.4 million and €2.1 million of our outstanding indebtedness
at December 31, 2016, 2015 and 2014, respectively, were denominated in U.S. dollars. In addition, we had approximately €2.8
million, €2.1 million and €0.746 million of cash denominated in U.S. dollars at December 31, 2016, 2015 and 2014, respectively,
and €1.5million, €0.9 million and €1.8 million of cash denominated in Japanese yen at December 31, 2016, 2015 and
2014, respectively.
Equity Price Risk
In connection with the funds we raised in 2012,
2013 and 2016, we have issued a certain number of Investor and Placement Agent Warrants (see Item 5. “Operating and Financial
Review and Prospects—Warrants”). We recorded such Warrants as a liability at fair value and we adjust the carrying
value of the Warrants to their estimated fair value at each reporting date. The fair value increases (decreases) are recorded as
a financial income (loss) in our consolidated Statement of Income. We use a Black-Scholes option pricing model to adjust the fair
value of the Warrants. A 10% increase in our stock price from its December 31, 2016 closing price of $3.28 per ADR would result
in an increase of €1.1 million in the fair value of the Warrants with a corresponding financial loss in our Statement of Income.
See Note 23 of our consolidated financial statements.
Item 12. Description of Securities Other than Equity Securities
American Depositary Shares
Fees Payable to ADS Holders
The Bank of New York Mellon, as the Company’s
Depositary, currently collects its fees for the delivery and surrender of ADSs directly from investors depositing shares or surrendering
ADSs for the purpose of withdrawal or from intermediaries acting for them. With respect to the outstanding 2012, 2013 and 2016
warrants, fees for delivery of ADSs directly linked to a warrant exercise or the payment of quarterly interest shares are supported
by the Company.
The Depositary may collect fees for making distributions
to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the
fees. The Depositary may collect its annual fee for Depositary services by deductions from cash distributions or by directly billing
investors or by charging the book-entry system accounts of participants acting for them. The Depositary may generally refuse to
provide fee-attracting services until the fees for those services are paid.
Fees:
|
For:
|
|
|
|
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)
|
-
|
Issuance of ADSs, including issuances resulting from a distribution
of shares or rights or other property,
|
|
-
|
Cancellation of ADSs for the purpose of withdrawal,
including if the deposit agreement terminates.
|
|
|
|
|
|
|
$0.2 (or less) per ADS
|
-
|
Any cash distribution to ADS registered holders.
|
|
|
|
|
|
|
A fee equivalent to the fee that would be payable if securities distributed to you had
been shares and the shares had been deposited to issuance of ADSs
|
-
|
Distribution of securities distributed to
holders of deposited securities which are distributed by the Depositary to ADS registered holders.
|
|
|
|
|
|
|
Registration or transfer fees
|
-
|
Transfer and registration of shares on our share register to
or from the name of the Depositary or its agent when you deposit or withdraw shares
|
|
|
|
|
|
|
Expenses of the Depositary
|
-
|
Cable, telex and facsimile transmissions (when expressly provided
in the deposit agreement)
|
|
-
|
Converting foreign currency to
U.S. dollars
|
|
|
|
|
|
|
Taxes and other governmental charges the Depositary or the custodian have to pay on any
ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes
|
-
|
As necessary
|
|
|
|
|
|
|
Any charges incurred by the Depositary or its agents for servicing the deposited securities
|
-
|
As necessary
|
|
|
|
|
|
|
|
Fees Payable to the Company by the Depositary
From January 1, 2016 to March 17, 2017, the
following amounts were paid by the Depositary to the Company: $90,000.00 and $2,932.84 respectively for the administration of the
ADR program and for expenses linked to the assistance in printing, mailing and distributing materials and proxies for shareholders’
meetings.
The accompanying notes are an integral part of the consolidated financial
statements.
The accompanying notes are an integral part of the consolidated financial
statements.
The accompanying notes are an integral part of the consolidated financial
statements.
The accompanying notes are an integral part of the consolidated
financial statements.
1—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
1-1 Nature of operations
EDAP TMS S.A. and its subsidiaries (‘‘the
Company’’) are engaged in the development, production, marketing, distribution and maintenance of a portfolio of minimally-invasive
medical devices for the treatment of urological diseases. The Company currently produces devices for treating stones of the urinary
tract and localized prostate cancer. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe,
export sales to third-party distributors and agents, and export sales through subsidiaries based in Germany, Italy, the United
States and Asia.
Moreover, the Company develops a novel HIFU
treatment for liver cancer in cooperation with its long-term academic partner INSERM and leading cancer centers (the “HECAM”
project).
The Company purchases the majority of the components
used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the
supply of these components or other components was interrupted and these delays could be extended in certain situations where a
component substitution may require regulatory approval. Failure to obtain adequate supplies of these components in a timely manner
could have a material adverse effect on the Company’s business, financial position and results of operation.
1-2 Management estimates
The preparation of financial statements in conformity
with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates
and assumptions, such as business plans, stock price volatility, duration of standard warranty per market and price of maintenance
contract used to determine the amount of revenue to be differed. These estimates and assumptions affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
1-3 Consolidation
The accompanying consolidated financial statements
include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries, which include EDAP TMS France SAS, EDAP
Technomed Inc., Edap Technomed Sdn Bhd, Edap Technomed Italia S.R.L, EDAP Technomed Co. Ltd. and EDAP TMS Gmbh. Edap Technomed
Sdn Bhd was incorporated in early 1997. Edap Technomed Co. Ltd. was created in late 1996. EDAP TMS Gmbh was created in July 2006.
EDAP SA, a subsidiary incorporating HIFU activities merged all of its activity into EDAP TMS France SAS in 2008. All intercompany
transactions and balances are eliminated in consolidation.
1-4 Revenue recognition
Sales of goods:
For medical device sales with no significant
remaining vendor obligation, payments contingent upon customer financing, acceptance criteria that can be subjectively interpreted
by the customer, or tied to the use of the device, revenue is recognized when evidence of an arrangement exists, title to the
device passes (depending on terms, either upon shipment or delivery), and the customer has the intent and ability to pay in accordance
with contract payment terms that are fixed or determinable. For sales in which payment is contingent upon customer financing,
acceptance criteria can be subjectively interpreted by the customer, or payment depends on use of the device, revenue is recognized
when the contingency is resolved. The Company provides training and provides a minimum of one-year warranty upon installation.
The Company accrues for the warranty costs at the time of sale. Revenues related to disposables are recognized when goods are
delivered.
EDAP TMS S.A. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of euros unless otherwise noted, except per share data)
Sales of RPPs and leases:
Revenues related to the sale of HIFU treatments
invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the
treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line
basis.
Sales of spare parts and services:
Revenues related to spare parts are recognized
when goods are delivered. Maintenance contracts rarely exceed one year and are recognized on a straight line basis. Billings or
cash receipts in advance of services due under maintenance contracts are recorded as deferred revenue.
1-5 Shipping and handling costs
The Company recognizes revenue from the shipping
and handling of its products as a component of revenue. Shipping and handling costs are recorded as a component of cost of sales.
1-6 Cash equivalents and short term investments
Cash equivalents are cash investments which
are highly liquid and have initial maturities of 90 days or less.
Cash investments with a maturity higher than
90 days are considered as short-term investments.
1-7 Accounts Receivables
Accounts receivables are stated at cost net
of allowances for doubtful accounts. The Company makes judgments as to its ability to collect outstanding receivables and provides
allowances for the portion of receivables when collection becomes doubtful. Provision is made based upon a specific review of all
significant outstanding invoices. These estimates are based on our bad debt write-off experience, analysis of credit information,
specific identification of probable bad debt based on our collection efforts, aging of accounts receivables and other known factors.
Accounts receivables also include receivables factored for which the Company is supporting the collection risk.
1-8 Inventories
Inventories are valued at the lower of manufacturing
cost, which is principally comprised of components and labor costs, or market. Cost is determined on a first-in, first-out basis
for components and spare parts and by specific identification for finished goods (medical devices). The Company establishes reserves
for inventory estimated to be obsolete, unmarketable or slow moving, first based on a detailed comparison between quantity in inventory
and historical consumption and then based on case-by-case analysis of the difference between the cost of inventory and the related
estimated market value.
1-9 Property and equipment
Property and equipment is stated at historical
cost. Depreciation and amortization of property and equipment are calculated using the straight-line method over the estimated
useful life of the related assets, as follows:
Leasehold improvements
|
|
10 years or lease term if shorter
|
Equipment
|
|
3-10 years
|
Furniture, fixtures, fittings and other
|
|
2-10 years
|
Equipment includes industrial equipment and research equipment that
has alternative future uses. Equipment also includes devices that are manufactured by the Company and leased to customers through
operating leases related to Revenue-Per-Procedure transactions and devices subject to sale and leaseback transactions. This equipment
is depreciated over a period of seven years.
EDAP TMS S.A. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of euros unless otherwise noted, except per share data)
1-10 Long-lived assets
The Company reviews the carrying value of its
long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate
that the carrying amount of such assets may not be fully recoverable. Recoverability of long-lived assets is assessed by a comparison
of the carrying amount of the assets (or the Group of assets, including the asset in question, that represents the lowest level
of separately-identifiable cash flows) to the total estimated undiscounted cash flows expected to be generated by the asset or
group of assets. If the future net undiscounted cash flows is less than the carrying amount of the asset or group of assets, the
asset or group of assets is considered impaired and an expense is recognized equal to the amount required to reduce the carrying
amount of the asset or group of assets to its then fair value. Fair value is determined by discounting the cash flows expected
to be generated by the assets, when the quoted market prices are not available for the long-lived assets. Estimated future cash
flows are based on assumptions and are subject to risk and uncertainty.
1-11 Goodwill and intangible assets
Goodwill represents the excess of purchase price
over the fair value of identifiable net assets of businesses acquired. Goodwill is not amortized but instead tested annually for
impairment or more frequently when events or change in circumstances indicate that the assets might be impaired by comparing the
carrying value to the fair value of the reporting units to which it is assigned. Under ASC 350, “Goodwill and other intangible
assets”, the impairment test is performed in two steps. The first step compares the fair value of the reporting unit with
its carrying amount, including goodwill. If the fair value of the reporting unit is less than its carrying amount, a second step
is performed to measure the amount of impairment loss. The second step allocates the fair value of the reporting unit to the Company’s
tangible and intangible assets and liabilities. This derives an implied fair value for the reporting unit’s goodwill. If
the carrying amount of the reporting units’ goodwill exceeds the implied fair value of that goodwill, an impairment loss
is recognized equal to that excess. For the purpose of any impairment test, the Company relies upon projections of future undiscounted
cash flows and takes into account assumptions regarding the evolution of the market and its ability to successfully develop and
commercialize its products.
Changes in market conditions could have a major
impact on the valuation of these assets and could result in additional impairment losses.
Intangible assets consist primarily of purchased
patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation
of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method
over the shorter of the contractual or estimated useful life of the assets, as follows:
Patents
|
|
|
5 years
|
|
Licenses
|
|
|
5 years
|
|
Trade name and trademark
|
|
|
7 years
|
|
1-12
Treasury Stocks
Treasury stock purchases are accounted for at
cost. The sale of treasury stocks is accounted for using the first in first out method. Gains on the sale or retirement of treasury
stocks are accounted for as additional paid-in capital whereas losses on the sale or retirement of treasury stock are recorded
as additional paid-in capital to the extent that previous net gains from sale or retirement of treasury stocks are included therein;
otherwise the losses shall be recorded to accumulated benefit (deficit) account. Gains or losses from the sale or retirement of
treasury stock do not affect reported results of operations.
EDAP TMS S.A. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of euros unless otherwise noted, except per share data)
1-13
Warranty expenses
The Company provides customers with a warranty
for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period
may vary from 1 year to 2 years depending on the market. Actual warranty costs incurred are charged against the accrual when paid
and are classified in cost of sales in the statement of income. Warranty expense amounted to €319 thousand, €354 thousand
and €429 thousand for the years ended December 31, 2016, 2015 and 2014, respectively.
1-14
Income taxes
The Company accounts for income taxes in accordance
with ASC 740, ‘‘Accounting for Income Taxes’’ Under ASC 740, deferred tax assets and liabilities are determined
based on differences between the financial reporting and tax basis of assets and liabilities and are measured by applying enacted
tax rates and laws to taxable years in which such differences are expected to reverse. A valuation allowance is established if,
based on the weight of available evidence, it is more likely than not that some portion, or all of the deferred tax assets, will
not be realized. In accordance with ASC740, no provision has been made for income or withholding taxes on undistributed earnings
of foreign subsidiaries, such undistributed earnings being permanently reinvested.
As of January 1, 2007, the Company adopted FIN48
(now ASC 740) “Accounting for uncertainty in income tax”. Under ASC740, the measurement of a tax position that meets
the more-likely-that-not recognition threshold must take into consideration the amounts and probabilities of the outcomes that
could be realized upon ultimate settlement using the facts, circumstances and information available at the reporting date.
1-15 Research and development costs
Research and development costs are recorded as an expense in the
period in which they are incurred.
The French government provides tax credits to
companies for innovative research and development. This tax credit is calculated based on a percentage of eligible research and
development costs and it can be refundable in cash and is not contingent on future taxable income. As such, the Company considers
the research tax credits as a grant, offsetting operating expenses.
The research tax credit amounted to €511
thousand, €448 thousand and €518 thousand for the years ended December 31 2016, 2015 and 2014, respectively.
1-16 Advertising costs
Advertising costs are recorded as an expense
in the period in which they are incurred. Advertising costs amounted to €744 thousand, €461 thousand and €413 thousand
for the years ended December 31, 2016, 2015 and 2014, respectively.
EDAP TMS S.A. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of euros unless otherwise noted, except per share data)
1-17 Foreign currency translation and
transactions
Translation of the financial statements of
consolidated companies
The reporting currency of EDAP TMS S.A. for
all years presented is the euro (€). The functional currency of each subsidiary is its local currency. In accordance with
ASC 830, all accounts in the financial statements are translated into euro from the functional currency at exchange rate as follows:
|
•
|
assets
and liabilities are translated at year-end exchange rates;
|
|
•
|
shareholders’
equity is translated at historical exchange rates (as of the date of contribution);
|
|
•
|
statement
of income items are translated at average exchange rates for the year; and
|
|
•
|
translation
gains and losses are recorded in a separate component of shareholders’ equity.
|
Foreign currencies transactions
Transactions involving foreign currencies are
translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables
denominated in foreign currencies are translated at year-end exchange rates. The resulting unrealized exchange gains and losses
are carried to the statement of income.
1-18 Earnings per share
Basic earnings per share is computed by dividing
income available to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted
earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised
or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The
dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure
the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted
from U.S. dollars at the average exchange rate for the period.
1-19 Derivative instruments
ASC 815 requires the Company to recognize all
of its derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting
for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and
qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments
that are designated and qualify as hedging instruments, the Company must classify the hedging instrument, based upon the exposure
being hedged, as fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.
Gains and losses from derivative instruments
are recorded in the income statement.
1-20 Employee stock option plans
At December 31, 2016, the Company had four stock-based
employee compensation plans. The Company adopted ASC 718, “Share-Based Payment”, effective January 1, 2006. ASC 718
requires the recognition of fair value of stock compensation as an expense in the calculation of net income (loss).
On May 22, 2007, the shareholders of EDAP TMS
S.A. authorized the Board of Directors to grant up to 600,000 options to subscribe to 600,000 new Shares at a fixed price to be
set by the Board of Directors.
Conforming to this stock option plan, on October
29, 2007, the Board of Directors granted 504,088 options to subscribe to new Shares to certain employees of EDAP TMS. The exercise
price was fixed at €3.99 per share. Options were to begin vesting one year after the date of grant and all options were fully
vested as of October 29, 2011 (i.e., four years after the date of grant). Shares acquired pursuant to the options cannot be sold
prior to four years from the date of grant. The options expire on October 29, 2017 (i.e., ten years after the date of grant) or
when employment with the Company ceases, whichever occurs earlier. At December 31, 2007 the total fair value of the options granted
under this plan was €1,731 thousand. This non-cash financial charge has been recognized in the Company’s operating expenses
over a period of 48 months, between October 2007 and October 2011. There was no impact on 2014, 2015 and 2016 operating income.
Under this plan, 327,838 options are still in force on December 31, 2016.
EDAP TMS S.A. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of euros unless otherwise noted, except per share data)
Conforming to this stock option plan, on June
25, 2010, the Board of Directors granted the remaining 95,912 options to subscribe to new Shares to certain employees of EDAP TMS.
The exercise price was fixed at €1.88 per share. Options were to begin vesting one year after the date of grant and will be
fully vested as of June 25, 2014 (i.e., four years after the date of grant). Shares acquired pursuant to the options cannot be
sold prior to four years from the date of grant. The options expire on June 25, 2020 (i.e., ten years after the date of grant)
or when employment with the Company ceases, whichever occurs earlier. At June 25, 2010 the total fair value of the options granted
under this plan was €143 thousand. This non-cash financial charge will be recognized in the Company’s operating expenses
over a period of 48 months. The impact on operating income, in accordance with ASC 718, was €8 thousand on 2014 and there
was no impact on 2015 and 2016 operating income. Under this plan, 50,000 options are still in force on December 31, 2016.
On June 24, 2010, the shareholders authorized
the Board of Directors to grant up to 229,100 options to purchase pre-existing Shares at a fixed price to be set by the Board of
Directors. All of the Shares that may be purchased through the exercise of stock options are currently held as treasury stock.
Conforming to this stock option plan, on June 25, 2010, the Board of Directors granted 229,100 options to purchase existing Shares
to certain employees of EDAP TMS. The exercise price was fixed at €2.38 per share. Options were to begin vesting one year
after the date of grant and will be fully vested as of June 25, 2014 (i.e., four years after the date of grant). Shares acquired
pursuant to the options cannot be sold prior to four years from the date of grant. The options expire on June 25, 2020 (i.e., ten
years after the date of grant) or when employment with the Company ceases, whichever occurs earlier. At June 24, 2010 the total
fair value of the options granted under this plan was €328 thousand. This non-cash financial charge will be recognized in
the Company’s operating expenses over a period of 48 months. The impact on operating income, in accordance with ASC 718,
was €4 thousand on 2014 and there was no impact on 2015 and 2016 operating income. Under this plan, 127,100 options are still
in force on December 31, 2016.
On December 19, 2012, the shareholders authorized
the Board of Directors to grant up to 500,000 options to subscribe to 500,000 new shares at a fixed price to be set by the Board
of Directors. Conforming to this stock option plan, the Board of Directors granted 500,000 options to subscribe Shares to certain
employees of EDAP TMS on January 18, 2013. The exercise price was fixed at €1.91 per share. Options were to begin vesting
one year after the date of grant and all options will be fully vested as of January 18, 2017 (i.e., four years after the date of
grant). Shares acquired pursuant to the options cannot be sold prior to four years from the date of grant. The options expire on
January 18, 2023 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier.
At December 31, 2013 the total fair value of the options granted under this plan was €660 thousand. This non-cash financial
charge has been recognized in the Company’s operating expenses over a period of 48 months. The impact on operating income,
in accordance with ASC 718, was €128 thousand, €66 thousand and €29 thousand in 2014, 2015 and 2016, respectively.
Under this plan, 362,500 options are still in force on December 31, 2016.
On February 18, 2016, the shareholders authorized
the Board of Directors to grant up to 1,000,000 options to subscribe to 1,000,000 new shares at a fixed price to be set by the
Board of Directors. Conforming to this stock option plan, the Board of Directors granted 575,000 options to subscribe Shares to
certain employees of EDAP TMS on April 26, 2016. The exercise price was fixed at €3.22 per share. Options were to begin vesting
one year after the date of grant and all options will be fully vested as of April 26, 2020 (i.e., four years after the date of
grant). Shares acquired pursuant to the options cannot be sold prior to four years from the date of grant. The options expire on
April 26, 2026 (i.e., ten years after the date of grant) or when employment with the Company ceases, whichever occurs earlier.
At December 31, 2016 the total fair value of the options granted under this plan was €331 thousand. This non-cash financial
charge has been recognized in the Company’s operating expenses over a period of 48 months. The impact on operating income,
in accordance with ASC 718, was €331 thousand on 2016. Under this plan, 560,000 options are still in force on December 31,
2016.
EDAP TMS S.A. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of euros unless otherwise noted, except per share data)
The fair value of each stock option granted
during the year is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
|
|
Year Ended December 31,
|
|
|
|
2016
|
|
|
2015
(1)
|
|
|
2014
(1)
|
|
Weighted-average expected life (years)
|
|
|
6.25
|
|
|
|
—
|
|
|
|
—
|
|
Expected volatility rates
(2)
|
|
|
60,60
|
%
|
|
|
—
|
|
|
|
—
|
|
Expected dividend yield
|
|
|
0
|
%
|
|
|
—
|
|
|
|
—
|
|
Risk-free interest rate
|
|
|
0,01
|
%
|
|
|
—
|
|
|
|
—
|
|
Weighted-average exercise price (€)
|
|
|
3.22
|
|
|
|
—
|
|
|
|
—
|
|
Weighted-average fair value of options granted during the year (€)
|
|
|
1.67
|
|
|
|
—
|
|
|
|
—
|
|
(1) The Company did
not make any grants during the years ended December 31, 2015 and 2014.
(2) Historical volatility
calculated over 10 years.
1-21 Warrants
On March 28, 2012, pursuant to a securities
purchase agreement dated March 22, 2012, as amended, the Company issued new ordinary shares in the form of ADSs to selected institutional
investors in a registered direct placement (the “March 2012 Placement”) with warrants attached (the “March 2012
Investor Warrants”). The Company also issued warrants to the placement agent, Rodman & Renshaw LLC (the “March
2012 Placement Agent Warrants” and together with the March 2012 Investor Warrants, the “March 2012 Warrants”).
The Company has accounted for the March 2012 Warrants as a liability and reflected this analysis in the Company’s financial
statements filed for the year 2012.
The Company used the Black-Scholes pricing
model to value the March 2012 Warrants at inception, with subsequent changes in fair value recorded as a financial expense or income.
On May 28, 2013, pursuant to a securities purchase
agreement dated May 20, 2013, as amended, the Company issued 3,000,000 new ordinary shares in the form of ADSs to selected institutional
investors in a registered direct placement (the “May 2013 Placement”) with warrants attached (the “May 2013 Investor
Warrants”). The Company also issued warrants to the placement agent, H.C. Wainwright & Co., LLC (the “May 2013
Placement Agent Warrants” and together with the May 2013 Investor Warrants, the “May 2013 Warrants”). As the
May 2013 Warrants comprised the same structure and provisions than the March 2012 Warrants, including an exercise price determined
in U.S. dollars while the functional currency of the Company is the euro, the Company determined that the May 2013 Warrants should
be accounted for as a liability.
The Company used the Black-Scholes pricing
model to value the May 2013 Warrants at inception, with subsequent changes in fair value recorded as a financial expense or income.
On April 14, 2016, pursuant to a securities
purchase agreement dated April 7, 2016, as amended, the Company issued new ordinary shares in the form of ADSs to selected institutional
investors in a registered direct placement (the “April 2016 Placement”) with warrants attached (the “April 2016
Investor Warrants”). As the April 2016 Warrants comprised the same structure and provisions than the March 2012 and May 2013
Warrants, including an exercise price determined in U.S. dollars while the functional currency of the Company is the Euro, the
Company determined that the April 2016 Warrants should be accounted for as a liability.
The Company used the Black-Scholes pricing
model to value the April 2016 Warrants at inception, with subsequent changes in fair value recorded as a financial expense or income.
EDAP TMS S.A. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of euros unless otherwise noted, except per share data)
1-22 Leases and Sales and leaseback transactions
In accordance with ASC 840, Accounting for Leases,
the Company classifies all leases at the inception date as either a capital lease or an operating lease. A lease is a capital lease
if it meets any one of the following criteria; otherwise, it is an operating lease:
|
-
|
Ownership is transferred to the lessee by the end of the lease term;
|
|
-
|
The lease contains a bargain purchase option;
|
|
-
|
The lease term is at least 75% of the property’s estimated remaining economic life;
|
|
-
|
The present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the
leased property to the lessor at the inception date.
|
For sales type leases, the following two additional criteria are applied:
|
-
|
Collectability of the minimum lease payment is reasonably predictable;
|
|
-
|
No important uncertainties surround the amount of un-reimbursable costs yet to be incurred by the lessor under the lease.
|
The Company enters into sale and leaseback transactions
from time to time. In accordance with ASC 840, any profit or loss on the sale is deferred and amortized prospectively over the
term of the lease, in proportion to the leased asset if a capital lease, or in proportion to the related gross rental charged to
expense over the lease term, if an operating lease.
1-23 New accounting pronouncements
In July 2015, the FASB issued ASU 2015-14
Revenue from Contracts with Customers: Deferral of the Effective Date (ASU 2015-14) which deferred the effective date for ASU No.
2014-09, Revenue from Contracts with Customers (ASU 2014-09), by one year. ASU 2014-09 will supersede the revenue recognition requirements
in Revenue Recognition (Topic 605) and requires entities to recognize revenue in a way that depicts the transfer of promised goods
or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for
those goods or services. ASU 2014-09 is now effective for annual reporting periods beginning after December 15, 2017, including
interim periods within that reporting period, which for the Company is January 1, 2018. Early adoption is permitted only as of
annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The new standard
can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change
recognized at the date of the initial application in retained earnings. The Company reviewed the accounting pronouncement with
respect to its current accounting principles and does not expect a significant impact from implementation. The company anticipates
selecting the full retrospective method.
In November 2015, the FASB issued ASU No.
2015-17,
Balance Sheet Classification of Deferred Taxes
(ASU 2015-17), which requires that deferred tax liabilities and
assets be classified as noncurrent in a classified statement of financial position. ASU 2015 – 17 is effective for the Company
in its first quarter of fiscal 2017, with early application permitted and, upon adoption, may be applied either prospectively or
retrospectively. The Company will adopt the ASU 2015-17 for the year ended December 31, 2017.
In February 2016, the FASB issued ASU No.
2016-02,
Leases
(ASU 2016-02), which supersedes ASC 840 “
Leases
” and creates a new topic, ASC 842 "
Leases
."
This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including
operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures
surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those
fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach
for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements.
The Company is expecting that the impact of this update on its consolidated statements will mainly consist of leases for facilities
situated in France, Japan and in the U.S. as described in Note 12.2.
EDAP TMS S.A. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands of euros unless otherwise noted, except per share data)
In August 2014, the FASB issued ASC Update
No. 2014-15, Presentation of Financial Statements—Going Concern: Disclosure of Uncertainties about an Entity’s Ability
to Continue as a Going Concern (Subtopic 205-40). Update 2014-15 requires management to assess an entity’s ability to continue
as a going concern every reporting period, and provide certain disclosures if management has substantial doubt about the entities
ability to operate as a going concern, or an express statement if not, by incorporating and expanding upon certain principles that
are currently in U.S. auditing standards. Update 2014-15 is effective for the annual period ending after December 15, 2016, and
for annual periods and interim periods thereafter. The Company implemented ASU 2014-15 as of January 1, 2016.